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Barrett’s esophagus
Barrett’s esophagus (BE) is a condition caused by chronic gastro-esophageal 
and biliary reflux in which the squamous epithelium of the distal esophagus 
is replaced by columnar epithelium containing goblet cells [1]. BE can be 
recognized during endoscopy by red discoloration of the normally vale pink 
mucosa. Patients with BE have an increased risk to develop esophageal 
adenocarcinoma (EAC) with an estimated incidence of 0.1 to 0.4% per year [2, 
3, 4]. The progression from BE to EAC is a gradual process, in which intestinal 
metaplasia evolves via low-grade dysplasia (LGD), to high-grade dysplasia 
(HGD) and finally to EAC, a cancer with an overall 5-year survival of less than 
20% [5, 6]. Therefore current guidelines recommend endoscopic surveillance 
of BE patients to detect HGD or EAC at an early and potentially curable stage 
[7, 8].
BE surveillance
Nowadays, histological diagnosis of LGD is used for risk assessment of 
neoplastic progression in BE. Guidelines recommend endoscopic surveillance 
every 3 to 5 years in patients without dysplasia, and surveillance every 6 to 12 
months in patients with LGD [7, 8]. Endoscopic surveillance is standardized 
and at each endoscopy targeted biopsies from mucosal abnormalities as well 
as quadrant biopsies every 2 cm from the most distal to the most proximal 
part of the Barrett’s epithelium are taken to obtain histological diagnosis and 
grading of dysplasia. However, diagnosis of LGD has a low predictive value, 
owing to sample error and overlapping features with reactive changes as well 
as considerable inter- and intraobserver variation [9, 10, 11]. Identification of 
other biomarkers for neoplastic progression could improve risk stratification 
and hence the effectiveness of BE surveillance.
Biomarkers for BE surveillance
SOX2
Application of biomarkers in addition to histology may contribute to the 
identification of BE patients at risk for neoplastic progression. Many 
biomarkers have been investigated and immunohistochemical staining of p53 
appears to be the most promising so far [12]. However, only 40% of the BE 
patients with progression to HGD or EAC showed an aberrant p53 protein 
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expression using immunohistochemistry during surveillance, indicating that 
additional biomarkers are needed [12]. SOX2 is a high-mobility group box 
transcription factor, involved in the maintenance of pluripotency and self-
renewal in embryonic stem cells and regulates an array of genes involved in 
normal and malignant processes [13, 14, 15]. Recent studies in gastric cancer 
cells revealed a role of SOX2 in growth inhibition through cell-cycle arrest and 
induction of apoptosis, indicating cancer-suppressive functions [16]. Only one 
study reported SOX2 in human BE and observed that SOX2 was present in 
multilayered esophageal epithelium, but was downregulated in biopsy samples 
with intestinal metaplasia [17]. However, the role of SOX2 in the development 
of BE and its expression during the metaplasia-dysplasia-adenocarcinoma 
sequence in BE epithelium has not yet been investigated.
Cyclin A
Another potential biomarker is cyclin A, a protein that plays an important role 
in the G1-S transition of the cell cycle. Overexpression of cell-cycle related 
proteins, including cyclin A, has been linked to the metaplasia-dysplasia-
carcinoma sequence in BE and associated with an increased risk of neoplastic 
progression [18, 19, 20]. The results of previous studies evaluating the value 
of cyclin A expression for predicting neoplastic progression are conflicting. 
A small case-control study showed that cyclin A surface expression was 
significantly associated with an increased risk of neoplastic progression (OR 
7.6; 95% CI 1.6 to 37.0), whereas a more recent larger population-based study 
could not confirm this correlation and only found a trend towards an increased 
risk of progression, which eventually lost significance in a multivariate analysis 
(OR 1.32; 95% CI 0.66 to 2.66) [18, 19, 20]. However, validation of cyclin A in 
a large prospective cohort of BE patients is still missing. In addition, there is 
a lack of studies testing performance of multiple biomarker simultaneously in 
the same cohort of BE patients.
Cost-effectiveness and survival
Although BE surveillance seems reasonable and is incorporated in international 
guidelines, there is little scientific evidence that BE surveillance is actually 
beneficial in daily clinical practice. To date no randomized controlled trails 
have been performed and the value of BE surveillance is still under discussion. 
The relevant key questions in this discussion are: (I) is BE surveillance cost-
effective and (II) can BE surveillance reduce mortality due to EAC. Important 
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is that over the past decades there has been a major shift in treatment 
modalities for patients with neoplastic progression. Nowadays endoscopic 
treatment with endoscopic mucosal resection and radiofrequency ablation is 
frequently used, while in the previous century almost all patients underwent 
esophagectomy. Application of these new treatment modalities may improve 
the cost-effectiveness of BE surveillance and reduce mortality due to EAC.
Esophageal adenocarcinoma
Over the past decades, the incidence of EAC has increased in the western 
world by at least six-fold, making EAC the cancer with the most rapid rise in 
incidence [21]. Although neoadjuvant chemoradiotherapy (nCRT) followed by 
surgery has recently become standard of care for locally advanced esophageal 
cancers (EC) and achieves a 5-year overall survival benefit of 10-15% compared 
to surgery alone. The overall prognosis for most patients including those 
treated with curative intent is still dismal with a 5-year survival of 47% at most 
[6, 22]. However, response to nCRT and overall prognosis is highly variable 
in EAC patients. Surgical resection, immediately after nCRT is associated with 
significant morbidity and substantial impact on the quality of life [23, 24]. So 
if clinicians were able to accurately identify (near-) complete responders, these 
patients might be candidates to postpone or even omit surgical resection. In 
addition, patients without substantial pathological response do not seem to 
benefit from nCRT but experience unnecessary side-effects and curative surgery 
is delayed [25, 26]. Therefore, there is a need for informative biomarkers that 
determine the biological behavior of individual tumors and may contribute to 
predict response to nCRT and prognosis, to eventually improve individualized 
decision-making in these patients. The tumor suppressor gene p53 has been 
identified as an important molecular factor associated with tumor tolerance 
to chemotherapy and radiation in patients with EAC [27, 28, 29]. Other 
potential biomarkers are SOX2 and CD44, both linked to cancer stem cells 
(CSCs), a small population of cells, found to be more resistant to chemo- and 
radiotherapy in various malignant tumor types [30, 31]. Although the first 
studies have shown promising results, the protein expression of p53, SOX2 
and CD44 and the possible relation with response to nCRT in EAC has barely 
been investigated. Additionally, in previous literature the pattern of SOX2 
expression also has been associated with prognosis in various malignancies, 
including gastric adenocarcinoma [32, 33]. But little is known about the role 
of SOX2 in EAC in terms of prognostication.
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Outline of this thesis
The overall aim of this thesis is to evaluate whether the use of biomarkers 
can improve risk stratification in BE patients, as well as treatment and 
prognostication of EAC patients. In addition, the cost-effectiveness of BE 
surveillance and impact on survival was assessed.  To investigate this, the 
following studies were performed:
In chapter 2 the existing literature is systematically reviewed regarding 
the value of immunohistochemical biomarkers for predicting neoplastic 
progression in BE patients and a meta-analysis is performed for the biomarkers 
investigated multiple times in independent studies. In chapter 3 and 4 
we assessed the predictive value of the biomarkers SOX2 and cyclin A for 
cancer risk stratification in BE patients. In chapter 5 the cost-effectiveness 
of different surveillance intervals and treatment strategies is evaluated. In 
Chapter 6 the survival of BE patients diagnosed with HGD or EAC in a 
surveillance program is explored and compared to the survival of patients 
diagnosed with EAC in the general population. In chapter 7 and chapter 8 
the predictive value of the biomarkers p53, SOX2 and CD44 for response to 
nCRT, as well as the value of  SOX2 as prognostic marker in EAC patients is 
investigated. In chapter 9 and 10 the results of this thesis are discussed and 
summarized.
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Abstract
Introduction: The low incidence of esophageal adenocarcinoma (EAC) in 
Barrett’s esophagus (BE) patients reinforces the need for risk stratification 
tools to make BE surveillance more effective. Currently, none of the clinical 
and endoscopic criteria are able to accurately predict which BE patient will 
progress to EAC. Immunohistochemical (IHC) biomarkers are relatively easy 
applicable and may prove of additional value to predict neoplastic progression 
in BE. Therefore, this study aims to provide a systematic review and meta-
analyses of published studies on IHC biomarkers in Barrett’s esophagus. 
Methods: We searched MEDLINE, EMBASE, Web of Science, CENTRAL, 
Pubmed publisher, and Google scholar up to October 1st of 2015. All studies 
on IHC biomarkers in BE surveillance were included. 
Results: A total of 16 different IHC biomarkers have been studied in 31 
studies. These studies included 414 cases and 1695 controls from a screening 
population of more than 7.000 BE patients. A meta- analysis was performed 
for P53, aspergillus oryzae lectin (AOL), Cyclin A, and Cyclin D. Aberrant p53 
expression was significantly associated with an increased risk of neoplastic 
progression with an OR of 3.18 (95% CI 1.68 to 6.03). This association was 
confirmed for both non-dysplastic BE and BE with low grade dysplasia (LGD). 
Another promising biomarker to predict neoplastic progression was AOL, 
with an OR of 3.04 (95% CI 2.05 to 4.49). 
Conclusions: Use of p53 IHC staining will improve risk stratification in BE 
surveillance. Aberrant P53 expression in BE patients appeared to be associated 
with a significantly increased risk of neoplastic progression for both non-
dysplastic and dysplastic BE patients.
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Introduction
Development of EAC is related to Barrett’s esophagus (BE), a premalignant 
condition of the distal esophagus. In BE, the pre-existent squamous 
epithelium is replaced by columnar epithelium which develops under the 
influence of chronic acid reflux and frequently contains goblet cells [1, 2, 3]. 
The progression from BE to EAC is a gradual process, in which intestinal 
metaplasia (IM) evolves to low-grade dysplasia (LGD), high-grade dysplasia 
(HGD) and eventually EAC [4]. Therefore, current guidelines recommend 
endoscopic surveillance in BE patients to detect HGD or EAC at an early 
stage, with the aim to improve survival rates [5, 6]. Several studies have shown 
that patients diagnosed with EAC during BE surveillance have earlier staged 
tumors and better survival compared to those diagnosed after the onset of 
symptoms [7, 8, 9, 10]. 
The estimated incidence of EAC in patients with BE is reported to be between 
0.5 and 1% per year [11, 12, 13, 14]. However, more recent population-based 
studies and two meta-analyses have set this risk around 0.12% to 0.38% per 
year [15, 16, 17, 18]. This relatively low annual risk reinforces the need for risk 
stratification tools to make BE surveillance more effective. BE length, male 
gender, smoking, and LGD are known risk factors for progression to HGD 
and EAC [13, 15, 18, 19, 20]. Two large population studies confirmed that 
patients with LGD have an approximately five times higher risk of progression 
compared to patients with non-dysplastic BE [15, 18]. Thus, more intensive 
surveillance is recommended in BE patients with LGD [5, 6]. However, the 
histological diagnosis of LGD is subject to a considerable inter- and intra-
observer variation, because of sample error and overlap with features of non-
neoplastic regenerative changes [21, 22, 23, 24]. 
Because none of the current clinical and histologic criteria are able to accurately 
predict which patients are likely to progress to HGD or EAC, there is an 
increasing interest in (molecular) biomarkers. Many immunohistochemical 
(IHC) biomarkers have been studied in BE progression, mainly because they 
can be applied to standard histological samples. In clinical practice, IHC 
biomarkers are relatively easily applicable compared to other techniques. 
Currently, only p53 IHC is recommended in the guideline of the British 
Society of Gastroenterology to improve the diagnostic reproducibility of the 
histological diagnosis of LGD [5]. The use of IHC biomarkers as independent 
predictor of neoplastic progression is not yet performed in routine clinical 
care, neither for p53, nor for other IHC biomarkers. Therefore, this study aims 
proefschrift_def.indd   19 20/04/2017   20:02
20
Chapter 2
to provide a systematic review and meta-analyses of all IHC biomarkers as 
predictor of neoplastic progression in patients with BE.
Methods
Definitions
BE was defined as columnar lined esophagus (CLE). Neoplastic progression 
was defined as the development of HGD or EAC during follow up. Patients 
with neoplastic progression were classified as cases and patients without 
neoplastic progression as controls.
Data sources and Searches
Records were identified by searching the following electronic databases: 
1. EMBASE 1980 - 01-10-2015, 2. MEDLINE 1950 - 01-10-2015, 3. Web of 
Science until 01-10-2015, 4. CENTRAL 1994 - 01-10-2015, 5. Pubmed Publisher 
until 01-10-2015, 6. Google scholar until 01-10-2015. The search strategy was 
constructed by applying a sensitivity maximizing approach. A combination of 
MESH subject headings and text words were used related to IHC markers for 
progression in patients with BE. The search was confined to English language 
publications. Conference abstracts indexed in Embase from the years 2014 
and 2015 were included.
Study selection
Search results were combined and duplicates removed. Every article was 
screened on title avvnd abstract level for relevance by a single author (SvO 
or VJ). Articles were reviewed full text by the same two independent authors 
and included if they met the following criteria: (1) association between IHC 
biomarker expression on formalin fixed paraffin embedded material and risk 
of neoplastic progression was assessed; (2) a cohort or case-control study 
design; (3) patients with known or newly diagnosed BE with or without LGD 
at baseline; (4) patients defined as cases must have progressed to either HGD 
or EAC during follow-up; (5) mean follow-up of at least one year from the 
time of initial BE diagnosis. Studies were excluded if: (1) BE cohorts included 
patients with HGD at baseline; (2) endoscopic therapies affecting neoplastic 
progression were performed during follow-up (see figure 1).
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Figure 1. Flow chart of the study.
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Data extraction and quality assessment
For each included study two independent authors extracted data according 
to a standardized data extraction form and assessed the quality of the eligible 
studies. In case of disagreement consensus was reached by consulting a third 
author (MS). Concerning quality assessment, the items baseline histology, age, 
duration of follow-up, sex, length of BE segment, control staining(s), number 
of pathologists, their agreement, and blinding were extracted.
Data synthesis and analyses
Odds ratio’s (OR)s and 95% confidence intervals (CI)s were extracted or 
estimated from the data. If ORs could not be extracted directly from the text 
or the tables, ORs were calculated indirectly by using the numbers of cases 
and controls with a positive and negative IHC biomarker expression from text, 
tables, or figures. In the meta-analyses different studies using the same IHC 
biomarker were combined. An inverse variance random-effect model was used. 
If data on multiple definitions of aberrant staining were available, definitions 
were chosen to resemble those from other included studies for that IHC 
biomarker. Pooled estimates of effect were calculated and results investigated 
for statistical heterogeneity by visual inspection and the I-squared test (I2) 
= [(Q-df )/Q]*100% was used, where Q was the chi squared statistic and df 
was its degree of freedom). Small study effects such as publication bias were 
assessed using a funnel plot. 
Sensitivity analyses
Sensitivity analyses were performed in case of small sample size (if small 
study effects were present as observed in the funnel plot), if no adjustments 
were made for known predictors of progression, and if only an abstract was 
available. Additional analyses were performed to assess if an IHC biomarker 
can be used as a predictor of neoplastic progression, independent of the 
presence of dysplasia. Thereto, all studies including non-dysplastic BE, BE 
with LGD, or studies adjusted for histology type were summarized. 
Stringency of the definition for aberrant staining used and its 
interpretation
The stringency level of the definition for aberrant staining and its 
interpretation could lead to variation in the predictive ability of the IHC 
biomarker investigated. To investigate whether this effect might be present, 
the proportion of controls deemed positive was plotted against the OR of each 
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study.
Results
Included studies
1987 records were retrieved, after removal of duplicates. After excluding 1966 
records based on title and abstract, a total of 22 full text articles and four 
abstracts were assessed in detail (figure 1). Of these, 16 full text articles and 
two abstracts were included in this review [25, 26, 27, 28, 29, 30, 31, 32, 33, 
34, 35, 36, 37, 38, 39, 40, 41, 42, 43]. These articles contained a total of 31 
studies. 
Characteristics
A total of 31 studies were included, containing 2118 patients of which 417 cases, 
selected from a populations of more than 7.000 BE patients. The proportion 
of male patients ranged from 66% to 100%. Mean duration of follow-up varied 
from 11.3 months to 94.8 months. Most studies were retrospective case-control 
studies (n=28), and three prospective cohort studies One study defined BE as 
CLE without IM, other studies defined BE as CLE with IM (n=22), or gave no 
definition (n=8). Endpoint was EAC in five studies and either HGD or EAC in 
26 studies. 
Dilutions and definitions for aberrant staining used
For p53, the antibody DO-7 (Dako, Glostrup, Denmark) was used most frequently 
with a dilution ranging from 1:25 to 1:1000. The definition for aberrant IHC 
staining was heterogeneous. Very intense staining was considered aberrant by 
all studies (being independent of the concentration used). However, intensity 
of staining was not a prerequisite for considering a staining pattern aberrant 
in six studies. The three more recent studies also considered a total absence 
of staining as aberrant [32, 33, 36]. For aspergillus oryzae lectin (AOL), one 
study calculated the OR for aberrant AOL in 2 or 3 epithelial compartments 
versus 0 or 1 compartment [31]. Another study reported multiple ORs for 
aberrant AOL in 1, 2, or 3 versus 0 epithelial compartments [36]. The OR of 
aberrant AOL IHC in 2 or 3 versus 0 or 1 compartment was extracted from this 
second study and analyzed together with the data from the first study for the 
meta-analysis.
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Quality of studies
In 13 of the 31 studies there was at least a 10% difference in baseline histology 
between cases and controls. In these studies, around 31% of the cases had IND 
or LGD at baseline, versus 8% in the controls. In five studies an age difference 
at baseline of at least 5 years was found between cases and controls, in four of 
these studies the case group was older. In three studies 10% more males were 
included in the case groups, 93% males on average in the cases, versus 70% in 
controls. Information on length of the BE segment for both cases and controls 
was provided in nine studies. In cases a longer BE segment was present, on 
average 6 cm versus 5.2 cm in the controls. In 17 studies the total follow-up 
time differed by at least 10% between case and control groups. On average, 
follow up time was 48 months versus 58 months for cases versus controls, 
respectively. Five studies did provide adjusted outcome measures and for four 
studies adjusted ORs could be extracted and were included meta-analyses.
IHC staining was scored by one observer in 12 studies, by two observers in 12 
studies, and by three observers in two studies. Kappa values were mentioned 
in only seven studies, and 15 studies did not mention the use of any positive 
or negative controls in order to validate the staining process. Whether slides 
were assessed in a blinded manner was not mentioned in five studies.
Meta-analyses
Meta-analyses were performed for biomarkers studied more than once. This 
was possible for P53, AOL, Cyclin A, and Cyclin D, which were studied 12, 2, 
3, and 2 times respectively. The most frequent reasons for excluding articles 
were the absence of follow-up data and LGD being defined as neoplastic 
progression and end-point of the study (see figure 1). Biomarkers studied only 
once were MCM2, CD1a, β-catenin, hERG1, COX2, Ki67, HER2, Sialyl Lewis, 
Wheat germ, Lewis, AMACR, and SOX2.
P53
A total of 12 studies, containing 2023 patients, of which 372 cases, were included 
in the meta-analysis. One study gave multiple ORs for various expression 
levels of p53, but only intense overexpression of p53 staining was considered 
positive [31]. Individual patient data of one study were converted in order to 
extract an adjusted OR [32]. The overall OR for neoplastic progression was 
6.67 (95% CI 3.64 to 12.22) for patients with aberrant p53 expression (see 
table 1 and figure 2). Aberrant p53 expression detected in both non-dysplastic 
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BE and LGD patients was significantly associated with the development of 
HGD or EAC. Significant heterogeneity (I2=55%, P<0.01) was observed 
between the included studies. The 12 studies were plotted in a funnel plot 
showing small study effects. In order to reduce the influence of such effects a 
sensitivity analysis was performed, which excluded all studies with a standard 
error above 1. Based on this criterion, six studies were selected, containing 
1610 patients and 323 cases. The overall OR for neoplastic progression was 
4.40 (95% CI 2.30 to 8.40) in patients with an aberrant p53 expression (see 
table 1 and figure 3).
Table 1. summary of meta-analyses of studies investigating p53 IHC as an 
independent predictor of neoplastic progression.
Analysis Studies Cases Controls OR 95% CI I2
P53 (main) 12 372 1651 6.67 3.64-12.22 64%
P53 (excluded SE > 1) 6 323 1287 4.40 2.30-8.40 63%
P53 (also excluded unadjusted ORs) 4 278 1044 3.18 1.68-6.03 55%
P53 (also excluded abstracts) 3 138 905 3.78 1.65-8.68 52%
P53 (only ORs stratified for histology) 7 316 1221 4.13 2.36-7.21 41%
P53 (only non-dysplastic BE) 2 61 659 6.12 2.99-12.52 0%
P53 (only LGD) 4 37 145 8.64 3.62-20.62 0%
Figure 2. Forest plot of 12 studies investigating p53 as a predictor of progression.
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The use of a more stringent definition of aberrant staining may lead to loss of 
aberrant expression in cases, in controls, or in both. In order to investigate 
this, the proportion of controls deemed aberrant was plotted against the OR of 
each study. Further sensitivity analyses were performed excluding studies for 
which unadjusted ORs were used in the meta-analyses and studies presented 
as abstracts. These sensitivity analyses showed similar results with slightly 
lower point estimates (see table 1). For three studies both unadjusted and 
adjusted ORs were available, and all three adjusted ORs had a lower point 
estimate compared to the unadjusted ones, in line with the outcome of our 
meta-analysis.
Figure 3. Forest plot of the first sensitivity analysis of studies investigating p53 IHC 
as a predictor of progression. All studies with a SE above one were excluded in order 
to reduce the effect of small study effects.
For the analysis whether P53 can serve as a predictor of progression 
independently of histology, studies that did not adjust for histology at baseline 
were excluded. The overall OR for aberrant p53 IHC on neoplastic progression, 
after stratification for histology, was 4.13 (95% CI 2.36 to 7.21), (see table 1).
P53 in non-dysplastic Barrett
Two studies, with a total of 720 BE patients, of which 61 cases, were included 
for this analysis [29]. Individual patient data of one study [32] was re-analyzed 
to provide an OR for non-dysplastic BE patients only. The overall OR for 
neoplastic progression to HGD or EAC in non-dysplastic BE patients was 6.12 
(95% CI 2.99 to 12.52; I2=0%, P=0.93), (see table 1).
P53 in low grade dysplasia Barrett
For BE with LGD, four studies, with a total of 182 BE patients, of which 37 
cases, were included. One study [32] was re-analyzed to provide an OR for the 
LGD subgroup only. The overall OR for neoplastic progression to HGD or EAC 
was 8.64 (95% CI 3.62 to 20.62; I2=0%, P=0.91), see table 1).
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AOL
Two studies, containing 573 BE patients, of which 204 cases, were included 
in this meta-analysis. The overall OR for neoplastic progression in BE 
patients with an aberrant AOL staining in 2 or 3 compartments, versus 0 or 
1 compartments of the tissue was 3.04 (95% CI 2.05 to 4.49) (see table 2). 
Results of the two studies were consistent in their findings (I2=0%, P=0.85). 
Table 2. Summary of meta-analyses of studies investigating IHC biomarkers other 
than p53 as a predictor of neoplastic progression.
Analysis Studies Cases Controls OR 95% CI I2
AOL 2 204 369 3.04 2.04-4.49 0%
Cyclin A 3 235 415 1.54 0.62-3.79 71%
Cyclin B 2 46 212 1.87 0.17-20.63 87%
Cyclin A
Three studies, containing 650 patients, of which 235 cases, were included in 
this meta-analysis. The overall OR for neoplastic progression in BE patients 
with cyclin A positivity was 1.54 (95% CI 0.62 to 3.79). Results of the three 
studies were inconsistent in their findings (I2=71%, P=0.03).
Cyclin D
Two studies containing 258 patients, of which 46 cases, were included in this 
meta-analysis. The overall OR for neoplastic progression in BE patients with 
cyclin D positivity was 1.87 (95% CI 0.17 to 20.63) (see table 2). Results of the 
two studies were inconsistent in their findings (I2=87%, P=0.006).
Studies pertaining other IHC biomarkers
The following IHC biomarkers were investigated only once: AMACR, β-catenin, 
CD1a, COX2, hERG1, HER2, Ki67, Lewis, Mcm2, Sialyl Lewis, SOX2, and 
WGA. In the CD1a study CLE without IM was used as baseline histology [42]. 
When considering study size and point estimate, CD1a, SOX2, and AMACR 
appeared most promising (see table 2).
Discussion
This is the first systematic review and meta-analysis to assess if IHC 
biomarkers can be used as a risk stratification tool to predict neoplastic 
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progression in BE surveillance. Sixteen biomarkers have been investigated in 
this setting, of which four biomarkers have been investigated more than once. 
The meta-analysis showed that aberrant p53 expression was associated with 
a significantly increased risk of neoplastic progression. Moreover, aberrant 
p53 expression predicted neoplastic progression in both non-dysplastic BE 
patients and BE patients with LGD. Of the other three IHC biomarkers, AOL 
appeared to be most promising in predicting neoplastic progression, whereas 
Cyclin A and Cyclin D appeared to have limited value.
Current use of p53 IHC in BE patients differs in international guidelines. 
The guideline of the British Society of Gastroenterology recommends the 
addition of p53 IHC staining for the pathological assessment of BE to 
improve the diagnostic reproducibility of dysplasia [5]. While the American 
Gastroenterological Association guideline states that: “data supporting the 
use of biomarkers to confirm the histologic diagnosis of dysplasia must be 
considered preliminary [44]. No guideline has yet adopted the use of IHC 
biomarkers to predict neoplastic progression. Two large population based 
studies confirmed that patients with LGD have an approximately 5 times 
higher risk of neoplastic progression compared to patients without LGD [15, 
18]. Our meta-analysis is the first to show that BE patients with aberrant p53 
IHC have approximately the same increased cancer risk as patients with LGD, 
independent of presence of dysplasia.   
Although routine p53 IHC will incur higher cost than histological assessment 
alone, application of this marker has the potential to reduce the overall costs 
related to BE surveillance by improved risk stratification. The disparity in ORs 
of neoplastic progression found in the various studies may be explained by 
differences in staining methods, including antibodies used, antigen retrieval 
methods, definitions, and interpretations of aberrant staining used. Therefore, 
special consideration should be given to the protocol of staining and the 
definition and interpretation used for aberrant expression. Some studies did 
not consider loss of p53 staining aberrant, which might have contributed 
to the protocol being less predictive compared to other studies. By using a 
more stringent definition of aberrant expression, cases appeared to remain 
p53 aberrant, while controls were not considered as aberrant. Thus, the use of 
more stringent definitions and interpretations for aberrant staining will likely 
lead to an even higher predictive ability of p53 IHC. 
The strength of this paper is the focus on IHC biomarkers as a relatively easy 
applicable tool to improve risk stratification in BE surveillance. No previous 
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publications with this approach were identified. Additionally, we performed a 
broad search, and the extraction of ORs from text, tables and figures resulted 
in the inclusion of quite a large number of trials. The inclusion of abstracts 
results in an up to date overview of this field. Several limitations were present 
in the data set, such as the apparent presence of publication bias, differences 
in baseline comparability within studies, and various adjustments made for 
these baseline differences. Thereto, we performed sensitivity analyses of the 
p53 meta-analyses, these show that the point estimate of the OR decreased 
from 6.67 to 3.18 when we accounted for these limitations. Because aberrant 
p53 IHC co-occurs with LGD, separate analyses were performed in which we 
stratified for dysplastic and non-dysplastic patients. These analyses show that 
aberrant p53 expression is an independent prognostic factor for neoplastic 
progression. 
In conclusion, we show that sixteen IHC biomarkers in BE surveillance have 
been studied. Aberrant P53 expression is the most studied IHC biomarker 
and associated with a significantly increased risk to develop HGD or 
EAC, this association was independent of the presence of LGD. Consensus 
amongst pathologists concerning the appropriate staining method, definition, 
and interpretation of aberrant p53 expression is currently low, and more 
consensus is required. Other promising biomarkers such as AOL need further 
investigation.
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Abstract
Introduction: The value of Barrett’s esophagus (BE) surveillance based on 
histological diagnosis of low-grade dysplasia (LGD) remains debated given the 
lack of adequate risk stratification. The aim of this study was to evaluate the 
predictive value of SOX2 expression for neoplastic progression in BE patients.
Methods: We conducted a case-control study within a prospective cohort of 
720 BE patients. Patients with neoplastic progression, defined as development 
of high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), were 
classified as cases and patients without neoplastic progression as controls. 
SOX2 expression was determined by immunohistochemistry in more than 
12,000 biopsies from 635 patients; these results were combined with our 
previous p53 immunohistochemical data.
Results: Non-dysplastic BE showed homogeneous nuclear staining for 
SOX2, while SOX2 was progressively lost in dysplastic BE. Loss of SOX2 
was seen in only 2% of biopsy series without dysplasia, in contrast to 28% 
in LGD and 67% in HGD/EAC. Loss of SOX2 expression was associated with 
an increased risk of neoplastic progression in BE patients after adjusting for 
gender, age, BE length and esophagitis (adjusted relative risk 4.8; 95% CI 3.2 
to 7.0). The positive predictive value (PV) for neoplastic progression increased 
from 16% with LGD alone to 56% with concurrent loss of SOX2 and aberrant 
p53 expression. 
Conclusions: SOX2 expression is lost during transition from non-dysplastic 
BE to HGD/EAC and associated with an increased risk of neoplastic 
progression. The highest PV is achieved by concurrent loss of SOX2 and 
aberrant p53 expression in BE patients with LGD. The use of these markers has 
the potential to significantly improve risk stratification of Barrett surveillance.
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Introduction
Over the past decades, the incidence of esophageal adenocarcinoma (EAC) 
has increased rapidly in the Western world [1, 2]. In most cases development 
of EAC is related to Barrett’s esophagus (BE). BE is a premalignant condition 
in which the squamous epithelium of the distal esophagus is replaced by 
columnar epithelium containing goblet cells, under the influence of chronic 
esophageal acid exposure [3, 4, 5]. Patients with BE have an increased risk 
to develop EAC with an estimated incidence of 0.1% to 0.5% per year [6, 7, 
8]. The transition from BE to EAC is a gradual process, in which intestinal 
metaplasia evolves to low-grade dysplasia (LGD), high-grade dysplasia (HGD) 
and finally EAC [5, 9]. Current guidelines recommend endoscopic surveillance 
of BE patients to detect HGD or EAC at an early and potentially curable stage 
[10, 11]. However, the current endoscopic surveillance strategy based on 
histological diagnosis alone remains debated given the lack of discriminative 
power to stratify BE patients at high risk for neoplastic progression from those 
at low risk [12, 13].
Histological diagnosis of LGD is the only accepted predictor for neoplastic 
progression to date and more intensive surveillance is recommended in 
BE patients with LGD (yearly instead of every 3 years) [10, 14]. However, 
histological diagnosis of LGD has a low predictive value, owing to sample error 
and considerable interobserver variation [15, 16, 17]. The use of biomarkers in 
addition to histological assessment may improve risk stratification in BE patients 
and has the potential to improve cost-effectiveness of BE surveillance. Many 
biomarkers are under investigation and our group previously reported that 
aberrant p53 protein expression appears to be a highly informative predictor 
for neoplastic progression [18, 19, 20]. The British Society of Gastroenterology 
guidelines already recommend the addition of p53 immunochemistry to the 
histopathological assessment of BE to improve the diagnostic reproducibility 
of histological diagnosis of dysplasia [11]. Recent study by Weaver et al. showed 
that only TP53 mutations differentiated between never-dysplastic BE and 
malignant stages HGD and EAC, which underlines the role of p53 as potential 
biomarker [21]. However, only 40% of the BE patients with progression to 
HGD or EAC showed an aberrant P53 protein expression during surveillance, 
suggesting that additional biomarkers are needed [18].
Another potential biomarker is SOX2, a transcription factor involved in the 
maintenance of pluripotency and self-renewal in embryonic stem cells [22]. 
During embryonal development, SOX2 plays a pivotal role in the formation and 
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differentiation of esophageal and gastric epithelium [23]. In adult organism, 
SOX2 is expressed in many tissues including esophageal squamous epithelium 
as well as foveolar gastric epithelium. In the past, SOX2 was introduced mainly 
as a relevant oncogene; gene amplification and overexpression of SOX2 have 
been detected in squamous cancers of the lung and esophagus [24, 25, 26]. 
However, the role of SOX2 might be cell-dependent. Immunohistochemically, 
SOX2 protein was shown to be progressively downregulated in intestinal 
metaplasia and adjacent gastric cancer [27, 28]. Recent studies in gastric 
cancer cells revealed a role of SOX2 in growth inhibition through cell-cycle 
arrest and induction of apoptosis, indicating cancer-suppressive functions 
[29]. Furthermore, loss of SOX2 expression was detected in EAC in earlier 
studies and associated with poor survival [30, 31, 32]. However, the role of 
SOX2 in the development of BE and its expression during the metaplasia-
dysplasia-adenocarcinoma sequence in BE epithelium has not yet been 
investigated. 
Therefore, the aim of the present study was to evaluate SOX2 expression in 
a prospective BE cohort within different grades of dysplasia and to assess 
the value of SOX2 to predict neoplastic progression in patients with BE. In 
addition, the results obtained from this analysis were combined with our 
previously reported p53 immunohistochemical data.
Methods
Study design
We conducted a case-control study within a large ongoing prospective cohort 
of 720 consecutive BE patients. Patients were included between November 
2003 and December 2004 in three university medical centers and 12 regional 
hospitals throughout the Netherlands and received endoscopic surveillance 
according to the guidelines of the American College of Gastroenterology 
[10]. Inclusion criterion was known or newly diagnosed BE of at least 2 cm, 
histologically confirmed by the presence of intestinal metaplasia on initial 
biopsy. Patients with a history of HGD or esophageal cancer were excluded. All 
endoscopic procedures were performed by an experienced gastroenterologist, 
according to a standard protocol. An experienced gastroenterologist was 
defined as a gastroenterologist with at least several years of experience in 
endoscopic procedures and with an interest for BE. Prior to taking biopsies, 
endoscopic landmarks such as the diaphragm impression, gastroesophageal 
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junction and squamocolumnar junction were noted. The presence of 
esophagitis was graded according to the Los Angeles Classification, and 
abnormalities were reported [33]. At each endoscopy quadrant biopsies were 
taken every 2 cm from the most distal to the most proximal part of the Barrett’s 
epithelium, according to the Seattle protocol and targeted biopsies were taken 
from mucosal abnormalities [34]. Patients without dysplasia, based on a 
histological consensus diagnosis, underwent upper endoscopy with biopsy 
sampling every three years and patients with LGD every year.
Histology
Biopsy samples were fixed in 10% buffered formalin and embedded in paraffin, 
according to standard procedure. From each biopsy set, four-micrometer thick 
sections were cut and stained with haematoxylin-eosin. After examination of 
all biopsy samples, the highest degree of abnormality was reported for each 
endoscopy. Slides were assessed for the presence of BE and grade of dysplasia, 
first by a local pathologist and second by an expert pathologist. When the 
local pathologist and expert pathologist disagreed on the grade of dysplasia, 
a second expert pathologist evaluated the slides. Pathologists were blinded 
to each other’s diagnosis and a final diagnosis was made only if at least two 
pathologists agreed on the grade of dysplasia. If there was still disagreement, 
a panel of expert pathologists reviewed the slides and a final diagnosis was 
made based on consensus agreement. Given the equal surveillance strategy 
according the ACG guidelines, the biopsies (n=7) with the diagnosis of 
indefinite for dysplasia were included in the group of biopsies with LGD.
Patient selection
We collected paraffin material suitable for immunohistochemistry from all 720 
patients in our BE cohort. Paraffin material was not available in 85 patients, 
leaving 635 patients to be included in this study. Patients who developed 
HGD or EAC during follow-up were classified as cases and patients without 
neoplastic progression were classified as controls (Figure 1). In accordance 
with our previous p53 paper, the minimum time interval between the index 
biopsies and a diagnosis of HGD or EAC was nine months to prevent inclusion 
of prevalent cases.  A sensitivity analysis with a minimum time interval of 1 year 
was performed and had no impact on the results.  Immunohistochemistry was 
performed on the complete series of biopsies of all surveillance endoscopies 
of patients who developed any form of dysplasia i.e. LGD, HGD or EAC 
during follow-up. This included the total number of biopsies taken during 
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endoscopic surveillance at different levels of the Barrett segment, according 
to the Seattle protocol. In patients without any dysplasia during follow-up, 
immunohistochemistry was performed on biopsies of a random surveillance 
endoscopy.
Figure 1. Flowchart of patients included in the study. Patients with neoplastic 
progression were classified as cases and patients without neoplastic progression 
were classified as controls.
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Immunohistochemistry
For SOX2 immunohistochemistry, paraffin-embedded tissue sections 
were deparaffinized in xylene and rehydrated in graded alcohols. Antigen 
retrieval was enhanced by heating in Tris buffer and endogenous peroxidase 
activity was blocked by incubating the slides in a solution of 0.3% hydrogen 
peroxide in phosphate-buffered saline. Primary antibody (AF2018; R&D 
systems, Abingdon, United Kingdom: goat, polyclonal) with a dilution of 
1:400 was incubated overnight at 4 degrees Celsius. As secondary antibody, 
a biotinylated horse anti-goat IgG antibody was used (1:150; BA-950, Vector, 
United Kingdom). Visualization was achieved by using the horseradish 
peroxidase avidin-biotin complex (HRP-ABC) method and diaminobenzidine 
(DAB). Finally, the slides were counterstained with haematoxylin. A sample 
of embryonal carcinoma was used as positive control for each section [35]. 
Immunohistochemical staining for p53 was performed by using an automatic 
immunohistochemical staining machine, as previously described [18]. Briefly, 
sections were deparaffinized and heat-induced epitope retrieval was performed 
at 97 °C for 15 min. Endogenous peroxidase activity was blocked by incubating 
the slides in a solution of 3.0%  hydrogen peroxide in phosphate-buffered 
saline. The primary antibody (Clone DO-7, Dako, Glostrup, Denmark: mouse 
monoclonal) with a dilution of 1:25 was applied for 30 min. Visualization was 
achieved by using the Dako REAL EnVision system (peroxidase/DAB, Rabbit/
Mouse, Dako, Glostrup, Denmark).
Immunohistochemically stained slides were examined in tandem with the 
haematoxylin-eosin stained slides to determine SOX2 and p53 expression 
in areas with dysplasia. Nuclear SOX2 expression was scored on a binary 
two-point scale; positive or loss of expression. Positive expression included 
strong as well as weak nuclear SOX2 positivity and was interpreted as normal 
expression. As previously described, P53 expression was scored on a three-
point scale; normal expression, overexpression or loss of expression. Only 
intense nuclear staining for p53 was scored as overexpression. All stained 
slides were scored by two independent experienced investigators (KB and SO) 
who were blinded for long-term outcome. Loss of SOX2 expression in a cluster 
of glands, excluding BE glands containing many goblet cells (i.e., colon-like 
BE) was defined as aberrant SOX2 expression. Aberrant p53 expression was 
defined as either overexpression or complete loss of expression in at least 
one gland. In biopsy series with dysplasia, SOX2 and p53 expression was 
scored in the dysplastic areas.  After scoring all biopsies, the highest degree of 
proefschrift_def.indd   41 20/04/2017   20:02
42
Chapter 3
abnormality was reported for each endoscopy. When there was disagreement 
between the two investigators, slides were reviewed by both investigators 
simultaneously to reach a consensus diagnosis.
 
Figure 3. Representative examples of SOX2 and p53 immunohistochemistry 
in non-dysplastic Barrett’s epithelium (BE), LGD and HGD (A-I). (A-C) Non-
dysplastic BE with normal nuclear SOX2 (B) and normal p53 expression(C); (D-
F) BE with LGD, loss of SOX2 expression (E) and overexpression of p53 (F) in 
dysplastic epithelial cells; (G-I) BE with HGD, loss of SOX2 expression (H) and p53 
overexpression (I) in corresponding glands. Magnification 1:200 (A-I).
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Ethics
The study protocol was approved by the institutional review board of the 
Erasmus Medical Center, including those of all participating hospitals. Before 
the first endoscopy, written informed consent was obtained from all patients.
Statistical analysis
Characteristics of cases and controls were compared using Mann-Whitney-
Wilcoxon tests for continuous variables and χ2 tests for categorical variables. 
To compare SOX2 expression in biopsy series of cases and controls with 
different grade of dysplasia, the Mann-Whitney-Wilcoxon test and Kruskal-
Wallis test were used, thereby ignoring that multiple biopsy series could be 
from the same patient. Neoplastic progression was defined as the development 
of HGD or EAC after inclusion and follow-up time was defined as the time 
between two consecutive surveillance endoscopies. The value of SOX2 and 
p53 immunohistochemistry to predict neoplastic progression was estimated 
in loglinear regression models. The fact that immunohistochemistry was not 
performed on all biopsy series, data were split up by endoscopy. Loglinear 
models were used to calculate relative risks (RRs) and 95% Confidence 
Intervals (CIs) with the logarithm of follow-up time as offset variable. In 
multivariable models we adjusted for gender, age, BE length and esophagitis 
to estimate adjusted RRs. Interobserver agreement for SOX2 expression was 
determined by using Cohen kappa statistics. Kappa value of <0.21 reflects 
’poor’, 0.21 to 0.40 ‘fair’, 0.41 to 0.60 ‘moderate’, 0.61 to 0.8 ‘substantial’, 
and above 0.81 ‘very good’ [36]. Two sided p values <0.05 were considered 
statistical significant. Data were analyzed using SPSS software (V.22.0).
Results
Patient characteristics
We followed 635 patients with BE (73% men, median age of 60 years 
(interquartile range (IQR) 53-69)) for a median duration of 6.9 years (IQR 
5.1-7.5). Thirty-seven (6%) patients developed HGD and 14 (2%) patients 
developed EAC during follow-up. These 51 (8%) patients with neoplastic 
progression were classified as cases. The incidence rate of HGD and EAC 
together was 1.3 per 100 patients-years. The remaining 584 (92%) patients 
without neoplastic progression were classified as controls (Figure 1). Biopsy 
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series were defined as a total number of biopsies from one endoscopy. 
Histology, SOX2 and p53 protein expression were assessed in biopsy series 
of 1,486 endoscopies, 194 endoscopies were performed in cases and 1,292 in 
controls. The highest degree of abnormality was reported for each endoscopy 
after evaluation of all biopsies. In total more than 12,000 biopsies were 
reviewed. Except for a smaller number of follow-up endoscopies, a higher 
number of biopsies per endoscopy, longer Barrett length and more often 
diagnosed with LGD at baseline there were no significant differences between 
cases and controls (Table 1).
Table 1. Characteristics of cases and controls
Controls
n = 584
Cases
n = 51 p Value
Follow-up Median, years (IQR) 6.5 (5.2-7.2) 3.3 (1.9-5.3) <0.001
Endoscopies Median number (IQR) 4 (4-5) 3 (2-4) <0.001
Biopsies Median per endoscopy (IQR) 6 (4-9) 8 (6-12) 0.001
   Total Number 10.560 1837
Age Median, years (IQR) 60 (53-69) 65 (54-71) 0.145
Sex Male 424 (73%) 42 (82%) 0.131
Alcohol use Never 68 (12%) 6 (12%) 0.992
Former 53 (9%) 5 (10%)
Current 451 (79%) 40 (78%)
Smoking Never 190 (33%) 12 (24%) 0.312
Former 261 (46%) 25 (49%)
Current 121 (21%) 14 (27%)
Reflux symptoms Yes 176 (31%) 19 (37%) 0.326
Barrett diagnosis  ≤ 1999 237 (41%) 16 (33%) 0.401
2000-2002 199 (34%) 21 (39%)
2003-2004 143 (25%) 14 (30%)
Barrett length Median, cm (IQR) 4 (3-6) 5 (3-7) <0.001
Baseline histology Low-grade dysplasia 89 (15%) 24 (47%) <0.001
Esophagitis Yes 110 (19%) 14 (28%) 0.117
Patients with neoplastic progression were classified as cases and patients without neoplastic progression 
were classified as controls. 
Mann-Whitney U-test and chi-squares test were used to compare the characteristics of cases and controls 
IQR, interquartile range
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Histology
Histology was assessed in biopsies series of 1,486 endoscopies of both cases 
and controls. This included 1,094 (74%) biopsy series without dysplasia, 
341 (23%) with LGD, 37 (2%) with HGD and 14 (1%) with EAC. Presence of 
LGD was more common in biopsy series of cases (47%) than in biopsy series 
of controls (21%) and was associated with an increased risk of neoplastic 
progression with a RR of 4.3 (95% CI 3.0 to 6.0) and this association remained 
after adjusting for gender, age, BE length and esophagitis (adjusted RR 4.0; 
95% CI 2.8 to 5.7) (Table 2). In total, 227 (36%) patients were diagnosed with 
LGD during follow-up, of these patients only 37 (16%) eventually developed 
HGD or EAC. The sensitivity for predicting neoplastic progression was 47% 
with a specificity of 79%.
Table 2. Histology, p53 and SOX2 expression in biopsy series of cases and controls
Controls
n = 1292
Cases
n = 143 RR (95% CI) RRa (95% CI)
Histology
ND 1018 (79%) 76 (53%) Reference Reference
LGD 274 (21%) 67 (47%) 4.3 (3.0-6.0) 4.0 (2.8-5.7)
SOX2 expression
Normal SOX2 expression 1207 (93%) 107 (75%) Reference Reference
Aberrant SOX2 expression 85 (7%) 36 (25%) 5.2 (3.5-7.6) 4.8 (3.2-7.0)
P53 expression
Normal p53 expression 1119 (86%) 70 (49%) Reference Reference
Aberrant p53 expression 173 (14%) 73 (51%) 6.1 (4.3-8.4) 5.7 (4.1-8.0)
Histology and SOX2 expression
ND & normal SOX2 1000 (78%) 69 (48%) Reference Reference
LGD & normal SOX2 207 (16%) 38 (27%) 3.5 (2.4-5.2) 3.2 (2.1-4.8)
ND & aberrant SOX2 18 (1%) 7 (5%) 4.6 (1.8-10.2) 4.0 (1.8-8.8)
LGD & aberrant SOX2 67 (5%) 29 (20%) 8.0 (5.2-12.4) 7.6 (4.9-11.8)
Histology and p53 expression
ND & normal p53 930 (72%) 50 (35%) Reference Reference
LGD & normal p53 189 (15%) 20 (14%) 2.4 (0.9-5.8) 2.2 (0.8-5.0)
ND & aberrant p53 88 (7%) 26 (18%) 4.7 (2.9-7.7) 4.4 (2.7-7.1)
LGD & aberrant p53 85 (7%) 47 (33%) 11.0 (7.3-16.4) 10.4 (6.9-15.7)
Histology, p53 and SOX2 expression
ND, normal SOX2 & normal p53 918 (71%) 44 (31%) Reference Reference
LGD, normal SOX2 & normal p53 141 (11%) 13 (9%) 2.1 (0.6-4.9) 2.0 (0.5-4.5)
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Controls
n = 1292
Cases
n = 143 RR (95% CI) RRa (95% CI)
ND, aberrant SOX2 or aberrant p53 94 (7%) 31 (22%) 5.9 (3.8-9.4) 5.3 (3.3-8.3)
LGD, aberrant SOX2 or aberrant p53 114 (9%) 32 (22%) 8.0 (5.1-12.7) 7.3 (4.6-11.5)
ND, aberrant SOX2 & aberrant p53 6 (1%) 1 (1%) 2.9 (0.5-24.8) 2.8 (0.4-27.5)
LGD, aberrant SOX2 & aberrant p53 19 (1%) 22 (15%) 18.2 (10.7-30.5) 18.5  (11.1-31.2)
Number of aberrant markersb
0 918 (71%) 44 (31%) Reference Reference
1 235 (18%) 44 (31%) 4.3 (2.9-6.6) 3.9 (2.6-6.0)
2 120 (9%) 33 (23%) 7.7 (4.9-12.1) 7.0 (4.4-11.0)
3 19 (2%) 22 (15%) 18.2 (10.7-30.5) 18.5  (10.9-31.1)
The highest degree of abnormality was reported for each endoscopy after examining all biopsies. 
RR, relative risks; CI, confidence interval; ND, no dysplasia; LGD, low-grade dysplasia. 
a RR adjusted for gender, age, BE length and esophagitis. 
b Included aberrant markers were LGD, aberrant p53 expression and aberrant SOX2 expression.
SOX2 immunohistochemistry
Homogeneous nuclear SOX2 protein expression, classified as normal 
expression, was seen in all biopsies where squamous epithelium was present, 
as well as in most biopsies with non-dysplastic BE. In cases and controls 
together, normal SOX2 expression was seen in 1,333 (90%) biopsy series 
whereas loss of SOX2 expression, classified as aberrant SOX2 expression, 
was seen in 153 (10%) biopsy series. The interobserver agreement for SOX2 
expression was good with a kappa-value of 0.70 (95% CI 0.67 to 0.73). The 
observers disagreed on SOX2 expression in 106 (7%) biopsy series (Table 3). 
Interestingly, while loss of SOX2 expression was seen in 25 (2%) biopsy series 
without dysplasia, it was more frequent in dysplastic BE, including 96 (28%) 
biopsy series with LGD, 22 (63%) biopsy series with HGD and 10 (71%) biopsies 
with EAC (p<0.001) (Figure 2). In addition, loss of SOX2 expression was more 
common in biopsy series of cases (25%) than in biopsy series of controls (7%) 
and was associated with an increased risk of neoplastic progression with a 
RR of 5.2 (95% CI 3.5 to 7.6). This association remained after adjusting for 
gender, age, BE length and esophagitis with an adjusted RR of 4.8 (95% CI 3.2 
to 7.0) and was seen in biopsy series without dysplasia and biopsy series with 
LGD (Table 2). The sensitivity of aberrant SOX2 expression for predicting 
neoplastic progression was 25% with a specificity of 94%. In total, 73 (12%) 
patients were diagnosed with LGD and concurrent aberrant SOX2 expression 
during follow-up. Of these patients, 22 (30%) eventually developed HGD or 
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EAC.
Table 3. Interobserver agreement for SOX2 expression
SOX2 expression Positive expression Loss of expression K value
Positive expression 1253 (84%) 45 (3%) 0.70
Loss of expression 61 (4%) 127 (9%)
The highest degree of abnormality was reported for each endoscopy after examination of all biopsies.
Cohen K statistics were used to determine interobserver agreement. 
The observers disagreed on SOX2 expression in 106 (7%) of the biopsy series with balanced results 
between the two observers in final SOX2 score (55% observer 1 versus 45% observer 2).
Figure 2. Percentage of biopsy series with loss of SOX2 expression stratified by 
grade of dysplasia.     Loss of SOX2 expression
proefschrift_def.indd   47 20/04/2017   20:02
48
Chapter 3
Histology, SOX2 and p53 immunohistochemistry
Previous p53 stained slides were re-evaluated in this study.[18] Briefly, 
aberrant p53 expression was more common in biopsy series of cases (51%) 
than in biopsy series of controls (14%) and was associated with an increased 
risk of neoplastic progression with an adjusted RR of 5.7 (95% CI 4.1 to 
8.0) (Table 2). A total of 72 (11%) patients were diagnosed with LGD and 
concurrent aberrant p53 expression during follow-up. Of these patients, 26 
(36%) eventually developed HGD or EAC.
Histology and SOX2 expression were correlated with our previously published 
p53 immunohistochemical data (Figure 3 and Table 2). Non-dysplastic BE 
with both normal SOX2 and p53 expression was seen in 962 (67%) biopsy 
series. In contrast, non-dysplastic BE with aberrant SOX2 or p53 expression 
was detected in only 125 (9%) of the biopsy series of cases and controls. LGD 
with normal SOX2 and p53 expression was more common (11%) than LGD with 
presence of aberrant SOX2 or p53 expression (10%), as also more common 
than LGD with the presence of both aberrant SOX2 and p53 expression (3%). 
Aberrant expression of either SOX2 or p53 was more common in biopsy 
series of cases than in biopsy series of controls, in both, non-dysplastic BE 
(22% vs 7%) and in LGD (22% vs 9%). Also, concurrent aberrant SOX2 and 
p53 expression was more common in biopsy series of cases than in biopsy 
series of controls in LGD (15% vs 1%) but not in non-dysplastic BE (1% vs 1%). 
Aberrant SOX2 or p53 expression in non-dysplastic BE was associated with 
an increased risk of neoplastic progression with an adjusted RR of 5.3 (95% CI 
3.3 to 8.3), the risk was even higher with concurrent LGD (adjusted RR 7.3; 
95% CI 4.6 to 11.5), but aberrant expression of both SOX2 and p53 in BE with 
LGD was associated with the highest risk of neoplastic progression (adjusted 
RR 18.5; 95% CI 11.1 to 31.2). The risk to develop HGD or EAC in the individual 
BE patient increases with the number of aberrant markers, including LGD, 
aberrant SOX2 and p53 expression (Table 2).
During follow-up, 32 (5%) patients were diagnosed with aberrant SOX2 and 
concurrent aberrant p53 expression in BE with LGD. Of these patients, 18 
(56%) eventually developed HGD or EAC (positive predictive value of 56%). 
Calculated RR to predict neoplastic progression subdivided into cases with 
progression to HGD and cases with progression to EAC are presented in the 
supplementary data.
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Discussion
In this case-control study, we confirmed the independent value of SOX2 
immunohistochemistry to predict neoplastic progression in patients with BE 
when combined with our previously reported p53 immunohistochemical data. 
SOX2 expression was progressively lost in dysplastic BE and associated with 
an increased risk of neoplastic progression. The risk of neoplastic progression 
was the highest in patients with LGD and concurrent aberrant SOX2 and p53 
expression.
Surveillance of BE patients, especially of those with LGD is under significant 
debate. Several previous studies demonstrated repeatedly the value of LGD 
as a risk factor for neoplastic progression, although with a low predictive 
value [14, 16, 33, 34, 37]. In our study up to 36% of patients were diagnosed 
with LGD during surveillance, while only 16% of these patients eventually 
developed HGD or EAC. Ultimately, the predictive value was low, despite 
using a consensus diagnosis of dysplasia. The diagnosis of LGD in BE is 
challenging due to sampling error and considerable interobserver variation, 
mainly because features of dysplasia may overlap with features of non-
neoplastic regenerative changes [15, 17]. Even though the predictive value of 
LGD increases with consensus of multiple pathologists, still one-third of the 
BE patients are diagnosed with LGD during surveillance, while the 10-year 
cumulative incidence of neoplastic progression is only around 15% in this 
group [16, 37, 38]. This obviously has important implications for the cost-
effectiveness of a surveillance program [39].
SOX2 is a high-mobility group box transcription factor, involved in the 
maintenance of pluripotency and self-renewal in embryonic stem cells and 
regulates an array of genes involved in normal and malignant processes [22, 
40, 41]. Until now, only one publication reported on SOX2 in BE. Chen and 
coworkers studied SOX2 in rat and human BE and observed that SOX2 was 
present in multilayered esophageal epithelium, but was downregulated in 
biopsy samples with intestinal metaplasia in both species [42]. Our study is the 
first study to explore SOX2 expression in different grades of dysplasia in BE 
and to test its value to predict neoplastic progression. Because it was shown by 
us and others, that p53 is one of the most promising predictive experimental 
molecular markers so far, we also tested the combined value of SOX2 and p53 
within the same cohort [37, 43, 44, 45]. 
In the present study strong nuclear SOX2 expression was seen in all biopsies 
were squamous epithelium was present, as well as in most non-dysplastic BE. 
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Interestingly, expression of SOX2 was progressively lost in BE with neoplastic 
changes. The percentage of biopsy series with loss of SOX2 expression 
increased from 2% in BE samples without dysplasia to 71% in samples with 
EAC. Our results suggest that SOX2 may play a role along the metaplasia-
dysplasia-adenocarcinoma sequence in BE. Loss of SOX2 expression might 
reflect the loss of differentiation potential of metaplastic columnar epithelial 
cells. Previous studies reported loss of SOX2 expression in 65-87% of human 
samples with EAC, which corresponds to the results of our study [30, 31]. Loss 
of SOX2 expression was identified more frequently in cases than in controls 
and was associated with an increased risk of developing HGD or EAC. The 
positive predictive value for neoplastic progression increased from 16% with 
histological diagnosis of LGD alone to 30% with concurrent aberrant SOX2. P53 
as a single biomarker has more power to predict neoplastic progression than 
SOX2 alone, but the highest predictive value was achieved by the combination 
of histological diagnosis of LGD with concurrent loss of SOX2 and aberrant 
p53 expression amounting to a positive predictive value of 56%. This finding 
might have important and clinically relevant implications. A recent study from 
Phoa et al. showed that in patients with BE and a consensus diagnosis of LGD, 
treatment with radiofrequency ablation resulted in a reduced risk of neoplastic 
progression [46]. To date, we have limited ability to predict which patients 
with LGD and no visible mucosal irregularities are truly at risk to develop an 
esophageal malignancy. Assessment of SOX2 and p53 immunohistochemistry 
offers an added tool to select these high risk patients for either intensified 
surveillance or ablation of BE epithelium and may contribute to a more cost-
effective management.
In this study we have also shown good interobserver agreement for the 
assessment of SOX2 expression similar to the results on p53 expression, 
which indicates that both markers are clinically suitable markers to predict 
progression in BE [18]. The evaluation of SOX2 immunohistochemistry was 
simple and straightforward; surrounding squamous epithelium as well as BE 
without dysplasia with positive SOX2 expression, contrasts well to the areas 
of SOX2 loss. Although routine p53 and SOX2 immunohistochemistry incur 
higher costs than histology alone, application of this panel of biomarkers has 
the potential to reduce overall costs of BE surveillance. Patients at low-risk of 
neoplastic progression, i.e. the majority of LGD patients, might be followed up 
less intensively. However, cost-effectiveness analysis should be performed to 
examine the economic value of both, p53 and SOX2 immunohistochemistry in 
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BE surveillance, which is beyond the scope of this study.
Our study has several strengths. Patients were prospectively followed according 
to a stringent scheme during a long follow-up time and both clinical and 
pathological data were collected. Additionally, a standardized endoscopy and 
biopsy protocol was used. All slides were reviewed by at least two experienced 
observers to obtain a final diagnosis based on consensus. A limitation of the 
study is that we cannot exclude that patients presently classified as controls 
may develop HGD or EAC in the future. This may lead to underestimation 
of the value of SOX2 and p53 to predict neoplastic progression. Further 
validation of these markers in large, prospective studies is required to confirm 
our findings.
In conclusion, loss of SOX2 expression is associated with an increased risk of 
neoplastic progression in patients with BE. The combination of histological 
diagnosis of LGD, aberrant p53 and loss of SOX2 expression has the highest 
predictive value to identify BE patients at high risk to develop HGD or EAC 
(56%). Clinical application of these biomarkers in routine practice has the 
potential to improve cost-effectiveness of BE surveillance.
proefschrift_def.indd   51 20/04/2017   20:02
52
Chapter 3
References
1 Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus 
among white Americans by sex, stage, and age. J Natl Cancer Inst 2008;100:1184-7.
2 Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to 
rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 2012;23:3155-62.
3 Kastelein F, Spaander MC, Biermann K, Vucelic B, Kuipers EJ, Bruno MJ. Role of 
acid suppression in the development and progression of dysplasia in patients with Barrett’s 
esophagus. Dig Dis 2011;29:499-506.
4 Winters C, Jr., Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF, 3rd, 
et al. Barrett’s esophagus. A prevalent, occult complication of gastroesophageal reflux disease. 
Gastroenterology 1987;92:118-24.
5 American Gastroenterological A, Spechler SJ, Sharma P, Souza RF, Inadomi JM, 
Shaheen NJ. American Gastroenterological Association medical position statement on the 
management of Barrett’s esophagus. Gastroenterology 2011;140:1084-91.
6 de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers 
EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide 
cohort study. Gut 2010;59:1030-6.
7 Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal 
adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and 
meta-analysis. Clin Gastroenterol Hepatol 2010;8:235-44; quiz e32.
8 Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of 
Adenocarcinoma among Patients with Barrett’s Esophagus. New Engl J Med 2011;365:1375-83.
9 Buttar NS, Wang KK. Mechanisms of disease: Carcinogenesis in Barrett’s esophagus. 
Nat Clin Pract Gastroenterol Hepatol 2004;1:106-12.
10 Wang KK, Sampliner RE, Practice Parameters Committee of the American College of 
G. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. 
Am J Gastroenterol 2008;103:788-97.
11 Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society 
of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 
2014;63:7-42.
12 Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, 
et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. 
Gastroenterology 2005;129:1825-31.
13 Wang JS, Canto MI. Predicting Neoplastic Progression in Barrett’s Esophagus. Ann 
Gastroentol Hepatol 2010;1:1-10.
14 Sikkema M, Looman CW, Steyerberg EW, Kerkhof M, Kastelein F, van Dekken H, et al. 
Predictors for neoplastic progression in patients with Barrett’s Esophagus: a prospective cohort 
proefschrift_def.indd   52 20/04/2017   20:02
53
SOX2 in Barrett’s esophagus
3
study. Am J Gastroenterol 2011;106:1231-8.
15 Kerkhof M, van Dekken H, Steyerberg EW, Meijer GA, Mulder AH, de Bruine A, et 
al. Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between 
general and gastrointestinal pathologists. Histopathology 2007;50:920-7.
16 Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis 
of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am 
J Gastroenterol 2000;95:3383-7.
17 Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-
grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol 
2010;105:1523-30.
18 Kastelein F, Biermann K, Steyerberg EW, Verheij J, Kalisvaart M, Looijenga LH, et al. 
Aberrant p53 protein expression is associated with an increased risk of neoplastic progression 
in patients with Barrett’s oesophagus. Gut 2012.
19 Kastelein F, Biermann K, Steyerberg EW, Verheij J, Kalisvaart M, Looijenga LH, 
et al. Value of alpha-methylacyl-CoA racemase immunochemistry for predicting neoplastic 
progression in Barrett’s oesophagus. Histopathology 2013;63:630-9.
20 di Pietro M, Boerwinkel DF, Shariff MK, Liu X, Telakis E, Lao-Sirieix P, et al. The 
combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic 
tool for dysplasia in Barrett’s oesophagus. Gut 2015;64:49-56.
21 Weaver JM, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, et al. 
Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 
2014;46:837-43.
22 Liu K, Lin B, Zhao M, Yang X, Chen M, Gao A, et al. The multiple roles for Sox2 in stem 
cell maintenance and tumorigenesis. Cell Signal 2013;25:1264-71.
23 Que J, Okubo T, Goldenring JR, Nam KT, Kurotani R, Morrisey EE, et al. Multiple 
dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut 
endoderm. Development 2007;134:2521-31.
24 Wilbertz T, Wagner P, Petersen K, Stiedl AC, Scheble VJ, Maier S, et al. SOX2 gene 
amplification and protein overexpression are associated with better outcome in squamous cell 
lung cancer. Mod Pathol 2011;24:944-53.
25 Wang Q, He W, Lu C, Wang Z, Wang J, Giercksky KE, et al. Oct3/4 and Sox2 are 
significantly associated with an unfavorable clinical outcome in human esophageal squamous 
cell carcinoma. Anticancer Res 2009;29:1233-41.
26 Yang F, Gao Y, Geng J, Qu D, Han Q, Qi J, et al. Elevated expression of SOX2 and 
FGFR1 in correlation with poor prognosis in patients with small cell lung cancer. Int J Clin Exp 
Pathol 2013;6:2846-54.
27 Tsukamoto T, Inada K, Tanaka H, Mizoshita T, Mihara M, Ushijima T, et al. Down-
proefschrift_def.indd   53 20/04/2017   20:02
54
Chapter 3
regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox 
genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal-mixed to 
complete intestinal metaplasia. J Cancer Res Clin Oncol 2004;130:135-45.
28 Tsukamoto T, Mizoshita T, Mihara M, Tanaka H, Takenaka Y, Yamamura Y, et al. Sox2 
expression in human stomach adenocarcinomas with gastric and gastric-and-intestinal-mixed 
phenotypes. Histopathology 2005;46:649-58.
29 Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y. SOX2 is frequently downregulated in 
gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer 
2008;98:824-31.
30 DiMaio MA, Kwok S, Montgomery KD, Lowe AW, Pai RK. Immunohistochemical panel 
for distinguishing esophageal adenocarcinoma from squamous cell carcinoma: a combination 
of p63, cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows optimal subtyping. 
Hum Pathol 2012;43:1799-807.
31 Long KB, Hornick JL. SOX2 is highly expressed in squamous cell carcinomas of the 
gastrointestinal tract. Hum Pathol 2009;40:1768-73.
32 Honing J, Pavlov KV, Meijer C, Smit JK, Boersma-van Ek W, Karrenbeld A, et al. Loss 
of CD44 and SOX2 expression is correlated with a poor prognosis in esophageal adenocarcinoma 
patients. Ann Surg Oncol 2014;21 Suppl 4:S657-64.
33 DiBaise JK. The LA classification for esophagitis: a call for standardization. Am J 
Gastroenterol 1999;94:3403-4.
34 Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic 
biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s 
esophagus. Gastroenterology 1993;105:40-50.
35 de Jong J, Stoop H, Gillis AJ, van Gurp RJ, van de Geijn GJ, Boer M, et al. Differential 
expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical 
implications. J Pathol 2008;215:21-30.
36 Landis JR, Koch GG. The measurement of observer agreement for categorical data. 
Biometrics 1977;33:159-74.
37 Kaye PV, Haider SA, Ilyas M, James PD, Soomro I, Faisal W, et al. Barrett’s dysplasia 
and the Vienna classification: reproducibility, prediction of progression and impact of consensus 
reporting and p53 immunohistochemistry. Histopathology 2009;54:699-712.
38 Duits LC, Phoa KN, Curvers WL, Ten Kate FJ, Meijer GA, Seldenrijk CA, et al. Barrett’s 
oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological 
review by an expert pathology panel. Gut 2014.
39 Kastelein F, van Olphen S, Steyerberg EW, Sikkema M, Spaander MC, Looman CW, 
et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness 
analysis. Gut 2014.
proefschrift_def.indd   54 20/04/2017   20:02
55
SOX2 in Barrett’s esophagus
3
40 Wang JL, Rao S, Chu JL, Shen XH, Levasseur DN, Theunissen TW, et al. A protein 
interaction network for pluripotency of embryonic stem cells. Nature 2006;444:364-8.
41 Boiani M, Scholer HR. Regulatory networks in embryo-derived pluripotent stem cells. 
Nat Rev Mol Cell Bio 2005;6:872-84.
42 Chen XX, Qin R, Liu B, Ma Y, Su YH, Yang CS, et al. Multilayered epithelium in a rat 
model and human Barrett’s esophagus: Similar expression patterns of transcription factors and 
differentiation markers. Bmc Gastroenterol 2008;8.
43 Skacel M, Petras RE, Rybicki LA, Gramlich TL, Richter JE, Falk GW, et al. p53 
expression in low grade dysplasia in Barrett’s esophagus: Correlation with interobserver 
agreement and disease progression. American Journal of Gastroenterology 2002;97:2508-13.
44 Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PMH, Looman CWN, 
et al. Aneuploidy and Overexpression of Ki67 and p53 as Markers for Neoplastic Progression 
in Barrett’s Esophagus: A Case-Control Study. American Journal of Gastroenterology 
2009;104:2673-80.
45 Murray L, Sedo A, Scott M, McManus D, Sloan JM, Hardie LJ, et al. TP53 and 
progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population 
cohort. Gut 2006;55:1390-7.
46 Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, et al. 
Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and 
low-grade dysplasia: a randomized clinical trial. JAMA 2014;311:1209-17.
proefschrift_def.indd   55 20/04/2017   20:02
4proefschrift_def.indd   56 20/04/2017   20:02
Value of cyclin A immunohistochemistry for cancer 
risk-stratification in Barrett esophagus surveillance
S.H. van Olphen, F.J.C. ten Kate, M. Doukas, F. Kastelein, 
E.W. Steyerberg, J.A. Stoop, M.C.W. Spaander, L.H.J. 
Looijenga*, M.J. Bruno* and K. Biermann* on behalf of the 
ProBar-study group
*contributed equally to the work.
Medicine, 2016 Nov
proefschrift_def.indd   57 20/04/2017   20:02
58
Chapter 4
Abstract
Introduction: The value of endoscopic Barrett’s esophagus (BE) surveillance 
based on histological diagnosis of low-grade dysplasia (LGD) remains debated 
given the lack of adequate risk-stratification. The aim of this study was (I) to 
evaluate the predictive value of cyclin A expression and (II) to combine these 
results with our previously reported immunohistochemical p53, AMACR and 
SOX2 data, to identify a panel of biomarkers predicting neoplastic progression 
in BE.
Methods: We conducted a case-control study within a prospective cohort of 
720 BE patients. BE patients who progressed to high-grade dysplasia (HGD, 
n=37) or esophageal adenocarcinoma (EAC, n=13), defined as neoplastic 
progression, were classified as cases and patients without neoplastic 
progression were classified as controls (n=575). Cyclin A expression was 
determined by immunohistochemistry in all 625 patients; these results were 
combined with the histological diagnosis and our previous p53, AMACR and 
SOX2 data in loglinear regression models. Differences in discriminatory ability 
were quantified as changes in area under the ROC curve (AUC) for predicting 
neoplastic progression.
Results: Cyclin A surface positivity significantly increased throughout the 
metaplasia-dysplasia-carcinoma sequences and was seen in 10% (107/1050) 
of biopsy series without dysplasia, 33% (109/335) in LGD and 69% (34/50) 
in HGD/EAC. Positive cyclin A expression was associated with an increased 
risk of neoplastic progression (adjusted relative risk (RRa) 2.4; 95% CI 1.7 to 
3.4). Increases in AUC were substantial for P53 (+0.05), smaller for SOX2 
(+0.014), minor for Cyclin A (+0.003) and none for AMARC (0.00). 
Conclusions: Cyclin A immunopositivity was associated with an increased 
progression risk in BE patients. However, compared to p53 and SOX2, the 
incremental value of cyclin A was limited. The use of biomarkers has the 
potential to significantly improve risk-stratification in BE.
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Introduction
Barrett’s esophagus (BE) is a premalignant condition of the distal esophagus 
in which the normal squamous epithelium is replaced by columnar epithelium 
containing goblet cells, as a result of chronic   acid exposure [1, 2, 3]. Patients 
with BE have an increased risk to develop esophageal adenocarcinoma (EAC) 
with an estimated incidence of 0.2 to 0.5% per year [4, 5, 6, 7]. The transition 
from BE to EAC is a gradual process, in which intestinal metaplasia evolves 
via low-grade dysplasia (LGD), to high-grade dysplasia (HGD) and finally to 
EAC, a cancer with an overall 5-year survival of less than 20% [8, 9]. Current 
guidelines recommend endoscopic surveillance of BE patients to detect HGD 
or EAC at an early and potentially curable stage when endoscopic treatment is 
still feasible [10, 11]. However, the applied endoscopic surveillance strategy to 
date based on histological diagnosis alone remains debated given the overall 
low incidence of neoplastic progression, and the lack of discriminative power 
to stratify BE patients at high risk for neoplastic progression from those at low 
risk.
Histological diagnosis of LGD is nowadays used for the risk assessment of 
neoplastic progression in BE surveillance and more intensive follow-up is 
recommended in LGD patients (yearly instead of every 3 years) [10, 11, 12]. 
However, diagnosis of LGD has a low predictive value, owing to sample error 
and a considerable inter- and intraobserver variation [13, 14, 15]. The use of (a 
panel of) biomarkers in addition to histology may improve risk stratification 
in BE patients, and several immunohistochemical biomarkers are under 
investigation. Our group previously reported on the predictive value for 
neoplastic progression of p53, AMACR and SOX2 in a large prospective cohort 
of patients with BE [16, 17, 18]. 
Another potential biomarker is cyclin A, a protein that plays an important role 
in the G1-S transition of the cell cycle. Overexpression of cell-cycle related 
proteins, including cyclin A, has been linked to the metaplasia-dysplasia-
carcinoma sequence in BE and associated with an increased risk of neoplastic 
progression [19, 20, 21]. However, clinical validation of cyclin A in a large 
prospective cohort of BE patients is still missing. In addition, there is a lack 
of studies testing performance of multiple biomarker simultaneously in the 
same cohort of BE patient. 
The aim of the present study was (I) to assess the value of cyclin A 
immunohistochemistry to predict neoplastic progression in a large cohort 
of BE patients and (II) to combine the results obtained with our previously 
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reported p53, AMACR and SOX2 immunohistochemical data in the same 
prospective cohort, to identify a panel of biomarkers for predicting neoplastic 
progression in BE.
Methods
Study design
We conducted a case-control study nested within a large multi-center 
prospective cohort of 720 BE patients. All patients were included between 
November 2003 and December 2004 from three university medical 
centers and 12 regional hospitals throughout the Netherlands and received 
endoscopic surveillance according to the guidelines of the American 
College of Gastroenterology (ACG) [11]. Inclusion criterion was known or 
newly diagnosed BE of at least 2 cm according to the Prague C&M criteria, 
histologically confirmed by the presence of intestinal metaplasia on initial 
biopsies [22]. Patients with a history of HGD or esophageal malignancy 
were excluded. All endoscopic procedures were performed according to a 
standardized protocol, by an experienced gastroenterologist with at least 
several years of experience in endoscopic procedures and with interest for 
BE. Prior to taking biopsies, endoscopic landmarks such as the diaphragm 
impression, gastroesophageal junction and squamocolumnar junction were 
reported. The presence of esophagitis was graded according to the Los Angeles 
Classification, and abnormalities were noted, including nodules, ulcers and 
erosions [23]. At each endoscopic procedure targeted biopsies were taken from 
mucosal abnormalities and quadrant biopsies were taken every 2 cm from the 
most distal to the most proximal part of the Barrett segment, according to the 
Seattle protocol [24]. Patients without dysplasia in the biopsy samples, based 
on histological consensus diagnosis, underwent endoscopy surveillance with 
biopsy sampling every three year and patients with LGD every year.
Histology
According to standard procedure, all biopsy samples were fixed with buffered 
formalin and embedded in paraffin. From each biopsy set, 4-micrometer 
thick sections were cut and stained with haematoxylin-eosin to assess the 
presence of BE and grade of dysplasia. After assessment of all the biopsies, 
the highest degree of abnormality was reported for each endoscopy. Slides 
were graded first by a local pathologist and second by an expert academic 
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pathologist. In case of disagreement on the grade of dysplasia between the 
local pathologist and expert academic pathologist, the slides were reviewed 
by a second expert academic pathologist. Pathologists were blinded for each 
other’s diagnosis and a final diagnosis was made if at least two pathologists 
agreed on the grade of dysplasia. When there was still disagreement, a panel of 
expert pathologists reviewed the slides and a final diagnosis was made based 
on consensus agreement. Given the equal surveillance strategy according to 
the ACG guidelines, the biopsies (n=7) with the final diagnosis of indefinite 
for dysplasia were included in the group of biopsies with the diagnosis of LGD.
Patient selection
We collected formalin-fixed paraffin-embedded (FFPE) material suitable for 
immunohistochemistry from all 720 BE patients in our cohort. However, no 
material or not enough material was available in 95 patients, leaving 625 
patients to be included in this analysis. Patients with progression to HGD or 
EAC during follow-up were classified as cases and patients without neoplastic 
progression were classified as controls. In accordance with our previous 
analyses, the minimal time interval between the index endoscopy and 
diagnosis of HGD or EAC was nine months to prevent inclusion of prevalent 
cases. Immunohistochemistry was performed on the complete series of 
FFPE material of all surveillance endoscopies of patients who developed any 
form of dysplasia i.e. LGD, HGD or EAC during follow-up. This included the 
total number of biopsies taken during surveillance at different levels of the 
Barrett segment. In patients without any form of dysplasia during follow-up, 
immunohistochemistry was performed on biopsies of a random surveillance 
endoscopy.
Immunohistochemistry
For cyclin A immunohistochemistry, FFPE tissue sections were deparaffinized 
in xylene and rehydrated in graded alcohols. Antigen retrieval was done by 
heating in Tris buffer and endogenous peroxidase activity was blocked by 
incubating the slides in a solution of 0.3% hydrogen peroxide in phosphate-
buffered saline. Primary antibody (Leica, Novocastra, Newcastle upon 
Tyns, United Kingdom: monoclonal, mouse) with a dilution of 1:200 was 
incubated overnight at 4 degrees Celsius. Rabbit anti-mouse (1:150; E0413, 
Dako, Heverlee, Belgium) was used as secondary antibody. Visualization 
was achieved by using the horseradish peroxidase avidin-biotin complex 
(HRP-ABC) method and diaminobenzidine (DAB) substrate. Finally, slides 
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were counterstained with haematoxylin. A negative control was obtained by 
omission of the primary antibody. Positive nuclei in the proliferation zone of the 
BE epithelium were used as internal positive control. Immunohistochemical 
staining for p53, AMACR and SOX2 was performed as previously described 
[16, 17, 18].
Scoring of immunohistochemistry
Immunohistochemically stained slides were examined in tandem with the 
haematoxylin-eosin stained slides to determine cyclin A, and previously p53, 
AMACR and SOX2 expression in areas with dysplasia [16, 17, 18]. Nuclear 
cyclin A expression was scored on a two-point scale; negative or positive 
expression. The surface cells were counted up to a maximum of 600 cells to 
determine the percentage of cyclin A positive cells. Only surface cells with 
strong nuclear staining were considered as positive. The epithelial surface was 
defined as the columnar cells at the luminal side of the biopsy, as described 
previously [25]. Based on published data, a cut-off value of 1% or more was used 
for cyclin A positivity [21]. Cyclin A expression was scored in BE epithelium 
with the highest percentage of positive cyclin A cells and in biopsy series 
with dysplasia, cyclin A expression was scored in the dysplastic area. After 
scoring all biopsies, the highest degree of abnormality was reported for each 
surveillance endoscopy. All stained slides were scored by two independent 
expert investigators who were blinded for long-term outcome as well as each 
other’s results. When there was disagreement between the two investigators, 
slides were reviewed by an experienced academic pathologist (KB or MD) and 
final diagnosis was made if two investigators agreed on the extend of cyclin A 
expression. 
P53, AMACR and SOX2 expression was scored as previously described [16, 17, 
18]. Briefly, nuclear p53 and cytoplasmatic AMACR expression were scored on a 
three-point scale (p53; normal expression, overexpression or loss of expression 
and for AMACR; no expression, mild expression or strong expression). Only 
intense nuclear staining for p53 was scored as overexpression and aberrant 
p53 expression was defined as either overexpression or complete loss of 
expression in at least one gland. Nuclear SOX2 expression was scored on a 
two-point scale; positive or loss of expression. Positive expression included 
strong as well as weak nuclear SOX2 positivity and was interpreted as normal 
expression. Loss of SOX2 expression in a cluster of glands, excluding BE 
glands containing many goblet cells was defined as aberrant SOX2 expression.
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Ethics
The study protocol was approved by the institutional review board of the 
Erasmus University Medical Center, including those of all participating 
hospitals. Before the first endoscopy, written informed consent was obtained 
from all 720 BE patients.
Statistical analysis
Patient characteristics of cases and controls were compared using Mann-
Whitney U-tests for continuous variables and χ2 tests for categorical variables. 
To compare cyclin A expression in biopsy series of cases and controls with 
different grade of dysplasia, the Mann-Whitney U-tests test and Kruskal-Wallis 
test were used, thereby ignoring that multiple biopsy series could be from the 
same patient. Neoplastic progression was defined as the development of HGD 
or EAC at least 9 months after inclusion in the study, and follow-up time was 
defined as the time between two consecutive surveillance endoscopies. The 
value of cyclin A immunohistochemistry to predict neoplastic progression 
was estimated in loglinear regression models. Previous stained slides for p53, 
AMACR and SOX2 expression in the same cohort of BE patients were re-
evaluated in this study to explore the classification performance of different 
combinations of biomarkers for predicting neoplastic progression in BE. 
Because immunohistochemical staining was not performed on all biopsy 
series, data were split up by endoscopy (1,243 in 575 controls, 142 in 50 
cases). Loglinear models were used to calculate relative risks (RRs) and 95% 
Confidence Intervals (CIs) with the logarithm of follow-up time (time between 
two consecutive endoscopies) as offset variable. In multivariable analysis 
we adjusted for gender, age, BE length and esophagitis to estimate adjusted 
RRs and 95% CIs. For each of the biomarkers the sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV) was 
calculated. The areas under the Receiver Operating Characteristic (ROC) 
curves for neoplastic progression were calculated for the individual markers 
as well as for the comparison between a selection of models, in which the 
studied biomarkers were included or excluded. These included pathological 
diagnosis of grade of dysplasia alone, pathological diagnosis in combination 
with p53 and SOX2 immunohistochemistry and pathological diagnosis in 
combination with p53, SOX2 and cyclin A immunohistochemistry. The 
incremental value of each biomarker was calculated by the change in AUC 
after exclusion of the concerning biomarker in the ‘fully adjusted model’ 
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(model including histological diagnosis, cyclin A, p53, AMACR and SOX2 
immunohistochemistry) as described earlier 26.  Interobserver agreement for 
cyclin A expression was determined by Cohen kappa statistics. Kappa value of 
below 0.21 were considered ’poor’, 0.21 to 0.40 ‘fair’, 0.41 to 0.60 ‘moderate’, 
0.61 to 0.8 ‘substantial’, and above 0.81 ‘very good’27. Two sided p values 
of <0.05 were considered statistically significant. Data were analyzed using 
SPSS statistical software (V.21.0; IBM SPSS, Chicago, IL, USA).
Results
Patient characteristics
Six hundred and twenty-five patients with BE were included in this study (74% 
men, median age of 60 years (interquartile range (IQR) 53-69)) and followed 
for a median duration of 6.7 years (IQR 5.0-7.4). Thirty-seven (6%) patients 
developed HGD and 13 (2%) patients developed EAC during surveillance after 
a median follow-up of 3.2 years (IQR 1.9-5.3). These 50 (8%) BE patients 
with neoplastic progression were classified as cases and the remaining 575 
(92%) patients without neoplastic progression were classified as controls. 
Cyclin A expression was scored separately and subsequently correlated with 
histological diagnosis and expression of p53, AMACR and SOX2 in biopsy 
series of 1,432 endoscopies: 189 endoscopies were performed in 50 cases 
and 1,243 endoscopies in 575 controls. Biopsy series were defined as the total 
number of biopsies from one endoscopy and the highest degree of abnormality 
was reported for each surveillance endoscopy after evaluation of all biopsies 
taken at that respective endoscopy procedure.  Except for a smaller number 
of endoscopies, a higher number of biopsies per endoscopy, longer BE length 
and more frequent diagnosis of LGD at baseline there were no significant 
differences between the cases and controls (Table 1).
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Table 1. Baseline characteristics of cases and controls
Controls  
 n = 575 
Cases
n = 50 p Value
Follow-up Median, years (IQR) 6.5 (5.2-7.2) 3.2 (1.9-5.3) <0.001
Endoscopies Median number (IQR) 4 (4-5) 3 (2-4) <0.001
Biopsies available Median number per endoscopy 
(IQR)
6 (4-9) 9 (6-12) <0.001
Age Median, years (IQR) 60 (53-69) 65 (56-71 0.103
Sex Male 419 (73%) 41 (82%) 0.160
Alcohol use Never 66 (12%) 6 (12%) 0.981
Former 52 (9%) 5 (10%)
Current 445 (79%) 39 (78%)
Smoking Never 189 (34%) 12 (24%) 0.362
Former 256 (45%) 25 (50%)
Current 118 (21%) 13 (26%)
Reflux symptoms Yes 172 (30%) 19 (38%) 0.265
Barrett diagnosis  ≤ 1999 231 (41%) 16 (32%) 0.473
2000-2002 197 (34%) 19 (38%)
2003-2004 141 (25%) 15 (30%)
Barrett length Median, cm (IQR) 4 (3-6) 5 (4-7) 0.010
Baseline Low-grade dysplasia 88 (15%) 24 (48%) <0.001
Esophagitis Yes 109 (19%) 14 (30%) 0.104
IQR, Interquartile range. 
Patients with neoplastic progression were classified as cases and patients without neoplastic progression 
were classified as controls. 
Mann-Whitney U-test and chi-squares test were used to compare the characteristics of cases and controls.
Histology
Consensus histology assessments included, 1,050 (73%) biopsy series with 
non-dysplastic BE (NDBE), 335 (23%) with LGD, 34 (3%) with HGD and 
13 (1%) with EAC. The local pathologist and expert academic pathologist 
disagreed on grade of dysplasia in 421 (29%) biopsy series and these samples 
were reviewed by a second expert pathologist (kappa-value of 0.34; 95% CI 
0.32 to 0.36). In 22 (19%) biopsy series there was still disagreement and a 
second expert pathologist or a panel of expert pathologists reviewed the slides 
for a final diagnosis. The presence of LGD was more frequent in biopsy series 
of cases (47%) than in biopsy series of controls (22%) and was associated with 
an increased risk of neoplastic progression after adjusting for gender, age, 
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BE length and esophagitis (adjusted RR of 3.9; 95% CI 2.8 to 5.4), with an 
AUC of 0.62 (95% CI 0.58 to 0.68) (Table 2 and Figure 1). The sensitivity of 
histological diagnosis of LGD for predicting neoplastic progression was 47%, 
with a specificity of 78%. The PPV and NPV were respectively 20% and 93% 
(Table 3).
Table 2. Histology and cyclin A immunohistochemistry in biopsy series of cases and 
controls
Controls 
n = 1,243
Cases
n = 142
RR (95% CI) RRa (95% CI)
Histology
ND 975 (78%) 75 (53%) Reference Reference
LGD 268 (22%) 67 (47%) 4.2 (3.0 to 5.8) 3.9 (2.8 to 5.4)
Cyclin A expression
< 1% cyclin A positivity 1073 (86%) 96 (68%) Reference Reference
≥ 1% cyclin A positivity 170 (14%) 46 (32%) 2.7 (1.9 to 3.8) 2.4 (1.7 to 3.4)
Histology and cyclin A expression
ND and < 1% cyclin A positivity 883 (71%) 60 (42%) Reference Reference
LGD and < 1% cyclin A positivity 190 (15%) 36 (25%) 3.8 (2.5 to 5.8) 3.5 (2.3 to 5.3)
ND and ≥ 1% cyclin A positivity 92 (8%) 15 (11%) 2.0 (1.2 to 3.6) 1.7 (0.9 to 3.0)
LGD and ≥ 1% cyclin A positivity 78 (6%) 31 (22%) 6.4 (4.1 to 9.9) 5.8 (3.7 to 9.0)
 The highest degree of abnormality was reported for each endoscopy after examining all biopsies. 
RR, relative risk as calculated from a log-linear regression model; CI, confidence interval; ND, no 
dysplasia; LGD, low-grade dysplasia. 
a RR adjusted for gender, age, BE length and esophagitis.
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Figure 1. Receiver operating characteristic (ROC) comparing different biomarker 
models with the basic pathological diagnosis of grade of dysplasia. Area under the 
curve (AUC) for predicting neoplastic progression was calculated (pathological 
diagnosis grade of dysplasia AUC of 0.62 (95% CI 0.58 to 0.68), pathological 
diagnosis + p53 and SOX2 immunohistochemistry AUC of 0.72 (95% CI 0.67 to 
0.77) and pathological diagnosis + p53, SOX2 and cyclin A immunohistochemistry 
AUC of 0.72 (95% CI 0.67 to 0.77).
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Table 3. Performance of  each individual marker for predicting neoplastic 
progression
Biomarker Sensitivity Specificity PPV NPV AUC (95% CI)
Low-grade dysplasia 47% 78% 20% 93% 0.62 (0.58 to 0.68)
Cyclin A positivity 32% 86% 21% 92% 0.59 (0.54 to 0.64)
Aberrant p53 51% 87% 30% 94% 0.69 (0.64 to 0.74)
Strong AMACR 11% 96% 25% 90% 0.53 (0.48 to 0.59)
Loss of  SOX2 25% 93% 29% 92% 0.60 (0.55 to 0.65)
 PPV, positive predictive value; NPV, negative predictive value; AUC, area under the ROC curve; CI, 
confidence interval 
The highest degree of abnormality was reported for each endoscopy after examining all biopsies.
Cyclin A immunohistochemistry
A positive cyclin A expression was seen in 250/1,432 (17%) of the biopsy 
series. The interobserver agreement for cyclin A expression was moderate 
with a kappa-value of 0.46 (95% CI 0.43 to 0.49). The observers disagreed 
on cyclin A surface expression in 278 (19%) biopsy series (Table 4). Cyclin A 
surface positivity was seen in 107 (10%) biopsy series without dysplasia, and 
was more common in dysplastic BE, including 109 (33%) biopsy series with 
LGD, 26 (76%) biopsy series with HGD and eight (62%) with EAC (p<0.001). 
Positive cyclin A surface expression was more common in biopsy series of 
cases (32%) than in biopsy series of controls (14%), and it was associated with 
an increased risk of neoplastic progression with a RR of 2.7 (95% CI 1.9 to 
3.8). This association remained after adjusting for gender, age, BE length and 
esophagitis (adjusted RR 2.4; 95% CI 1.7 to 3.4) and was particularly seen 
in biopsy series with LGD (adjusted RR of 5.8; 95% CI 3.7 to 9.0) (Table 2). 
In per-biopsy analysis, cyclin A had an AUC of 0.59 (95% CI 0.54 to 0.64) 
for predicting neoplastic progression with a sensitivity of 32%, a specificity of 
86%, a PPV of 21% and a NPV of 92% (Table 3).
Table 4. Interobserver agreement for cyclin A expression
Cyclin A surface expression Cyclin A positivity < 1% Cyclin A positivity ≥ 1% K value
Cyclin A positivity < 1% 47% 93% 0.62 (0.58 to 0.68)
Cyclin A positivity≥ 1% 32% 92% 0.59 (0.54 to 0.64)
 The highest degree of abnormality was reported for each endoscopy after examination of all biopsies.
Cohen K statistics were used to determine interobserver agreement.
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P53, AMACR and SOX2 immunohistochemistry and incremental 
value of cyclin A
The pattern of p53, AMACR and SOX2 expression were studied previously and 
the data discussed elsewhere [16, 17, 18]. Aberrant p53 expression, as well as 
strong AMACR expression and aberrant SOX2 expression were more common 
in biopsy series of cases than in biopsy series of controls (p53; 51% vs. 13%, 
AMACR; 11% vs. 4%, SOX2; 25% vs. 7%) and were associated with an increased 
risk of neoplastic progression with adjusted RR of 5.6 (95% CI; 4.0 to 7.8) for 
aberrant p53 expression, 2.8 (95% CI; 1.6 to 4.8) for strong AMACR expression 
and 4.4 (95% CI; 3.0 to 6.5) for aberrant SOX2 expression, respectively. The 
highest risk of neoplastic progression was detected in patients with LGD and 
concurrent aberrant p53 expression (adjusted RR of 9.9; 95% CI 6.6 to 14.9). 
The addition of p53 immunohistochemistry improved the AUC compared to 
the histological diagnosis alone (from AUC 0.62 to AUC 0.70; 95% CI 0.66 to 
0.76).
Next, we combined the information on histology, cyclin A, p53, AMACR 
and SOX2 immunohistochemistry in a fully adjusted model for predicting 
neoplastic progression in BE (Table 5). Aberrant p53 expression showed the 
highest change in AUC (0.05), to a lesser extent aberrant SOX2 expression 
(0.014) and histological diagnosis of LGD (0.005). The biomarkers cyclin A 
and AMACR only showed a minimal drop or no drop in AUC after exclusion 
(cyclin A: 0.003 and AMACR: 0.0) (Table 5). Importantly, the addition of 
SOX2 slightly improved the AUC compared with the model including only 
histological diagnosis and p53 immunohistochemistry (from AUC 0.70 to 
AUC 0.72; 95% CI 0.67 to 0.77)(Figure 1).
Table 5. Fully adjusted model with histology, cyclin A, p53, AMACR and SOX2 
immunohistochemistry in biopsy series of cases and controls.
Variable RRa (95% CI) Change in AUCb
Low-grade dysplasia 1.8 (1.2 to 2.6) 0.005
Cyclin A positivity 1.4 (1.0 to 2.1) 0.003
Aberrant p53 expression 3.7 (2.6 to 5.4) 0.050
Strong AMACR expression 1.3 (0.8 to 2.3) 0.000
Loss of SOX2 expression 2.2 (1.4 to 3.4) 0.014
a RR adjusted for gender, age, BE length and esophagitis and all the other biomarkers 
b Calculated drop of AUC after exclusion of the concerning biomarker compared to AUC of the total model 
(AUC of 0.734; 95% CI 0.687 to 0.780)
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Discussion
In this large case-control study we evaluated the value of cyclin A expression 
for predicting neoplastic progression in patients with BE. These results 
were combined with our previously reported p53, AMACR and SOX2 
immunohistochemical data within the same cohort using AUC in ROC 
analysis, to explore the classification performance of different combinations 
of biomarkers. This modeling is a valuable tool for the overall judgment 
of the incremental value of the biomarkers studied but not intended as an 
exact analytic method [26]. Cyclin A surface positivity significantly increased 
throughout the metaplasia-dysplasia-carcinoma progression steps and was 
associated with an increased risk of neoplastic progression. However, the 
incremental value of cyclin A expression was limited compared to histological 
diagnosis of LGD, p53 and SOX2. 
Surveillance of BE patients is under significant debate given the lack of 
discriminative tools for adequate risk stratification. Additionally, with the 
introduction of minimally invasive endoscopic therapy and the evidence of 
cancer prevention by radiofrequency ablation in patients with LGD, there is 
an increasing need for accurate dysplasia detection during BE surveillance 
[28, 29]. Previous studies demonstrated repeatedly the value of LGD as a risk 
factor for neoplastic progression, albeit with a low predictive value due to 
sampling error and considerable interobserver variation [4, 6, 12, 13, 14, 15]. 
Even though the predictive value of LGD increases with consensus of multiple 
pathologists, approximately one-third of the patients with BE are diagnosed 
with LGD during surveillance, whereas the 5-year cumulative incidence of 
neoplastic progression is only between 5%-30% in this group [15, 30, 31]. 
Although the result of our study support the use of LGD diagnosed by expert 
GE pathologists, as indicator for increased risk of neoplastic progression, its 
sensitivity is only 47% and specificity 78%, despite using a consensus diagnosis 
of dysplasia. These results exemplify the interest in identifying molecular 
biomarkers to improve risk stratification and eventually cost-effectiveness of 
BE surveillance.
In the present study, cyclin A expression was confined to the base of the crypts 
in normal columnar gastrointestinal epithelium, as well as in most non-
dysplastic BE. With increasing grades of dysplasia the expression of cyclin A 
progressively shifted towards the surface epithelium. The percentage of biopsy 
series with a positive cyclin A surface expression increased from 10% in non-
dysplastic BE to 62% in biopsy series with EAC, which corresponds to previous 
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studies [20, 21]. A recent study identified cyclin A expression as one of a three-
biomarker panel which provides a more accurate and objective diagnosis of 
dysplasia in BE [20]. Our results confirmed the correlation between dysplasia 
and cyclin A expression and hence potential as diagnostic tool for dysplasia 
detection. 
Positive cyclin A surface expression was detected more frequently in cases 
than in controls, and was significantly associated with an increased risk of 
developing HGD or EAC (adjusted RR 2.4; 95% CI 1.7 to 3.4), particularly in 
dysplastic BE. The results of previous studies evaluating the value of cyclin 
A expression for predicting neoplastic progression are conflicting. A small 
case-control study showed that cyclin A surface expression was significantly 
associated with an increased risk of neoplastic progression (OR 7.6; 95% CI 
1.6 to 37.0), whereas a more recent larger population-based study could not 
confirm this correlation and only found a trend towards an increased risk of 
progression, which eventually lost significance in a multivariate analysis (OR 
1.32; 95% CI 0.66 to 2.66)[19, 21]. These conflicting results might be explained 
by a rather challenging interpretation of cyclin A immunohistochemistry. We 
found a moderate interobserver agreement with a kappa value of 0.46. This 
is low compared to the interobserver agreement of the other biomarkers p53 
and SOX2 (kappa values between 0.70 and 0.86) [17, 18, 32].
The biomarker with the greatest body of evidence remains aberrant p53 
expression (adjusted RR in fully adjusted model of 3.7 (95% CI 2.6 to 5.4), 
change in AUC 0.05) and to a lesser extent aberrant SOX2 expression (change 
in AUC 0.014). Cyclin A positivity showed only a minimal drop in AUC after 
exclusion (0.003). These findings might have important and clinically relevant 
implications. Assessment of p53 and SOX2 are promising to select high-
risk patients for either intensified surveillance or ablation therapy and may 
eventually contribute to a more cost-effective management. Although routine 
p53 and SOX2 staining and assessment incur higher costs than histology 
alone, application of this panel of biomarkers has the potential to reduce the 
overall costs related of Barrett surveillance. Patients at low-risk of neoplastic 
progression, i.e. the majority of the patients with LGD, might be followed-up 
less intensively with the potential to eventually discharge them. However, a 
more detailed cost-effectiveness analysis should be performed to evaluate the 
economic value of p53 and SOX2 immunohistochemistry, which is beyond the 
scope of this study.
Our study has several strengths. The large cohort of BE patients was 
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prospectively followed-up according to a stringent scheme during a long 
follow-up time, clinical, endoscopic and pathological data were collected. 
Additionally, a standardized endoscopy and biopsy protocol was used. All 
stained slides were assessed by at least two experienced observers blinded for 
clinical outcome and in case of disagreement an expert pathologist reviewed 
the slides for final diagnosis. Another major strength of this study was that 
we tested multiple biomarkers in the same cohort of BE patients so we could 
identify the smallest panel of biomarkers with the highest predictive value 
for neoplastic progression, and which can be performed on routine clinical 
collected FFPE tissue. 
Our study also has some limitations. Although immunohistochemistry is an 
established clinical examination method and easily applicable to standard 
clinical pathological laboratories, the scoring of the expression is a subjective 
assessment. It will require standardization of processing and scoring for 
reliable routine clinical application. In spite of this, our previous studies have 
shown good interobserver agreement for both p53 and SOX2 and they were 
relatively simple and straightforward to interpret [17, 18]. Further validation of 
this panel of biomarkers in large prospective studies is required to confirm our 
findings. Secondly, as all patients with BE, the patients considered as controls 
in this study still have the potential to progress to HGD or EAC during the 
future follow-up. However, since their median follow-up time was 6.5 years 
(which is more the twice the follow-up time of the cases), and the incidence of 
progression in only 2,6/1000 patients per year, the chance of progression in 
the controls is slim [6]. 
In conclusion, cyclin A surface expression was associated with an increased 
risk of neoplastic progression in BE patients, but its ability to predict neoplastic 
progression is limited compared to the biomarkers p53 and SOX2. The use 
of biomarkers has the potential to significantly improve risk-stratification in 
Barrett surveillance and hence the cost-effectiveness of Barrett surveillance 
programs.
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Abstract
Introduction: Surveillance is recommended for Barrett’s esophagus (BE) to 
detect early esophageal adenocarcinoma (EAC). The aim of this study was to 
evaluate the cost-effectiveness of surveillance.
Methods: We included 714 patients with long-segment BE in a multicenter 
prospective cohort study and used a multi-state-Markov model to calculate 
progression rates from no dysplasia (ND) to low-grade dysplasia (LGD), high-
grade dysplasia (HGD) and EAC. Progression rates were incorporated in a 
decision-analytic model, including costs and quality of life data. We evaluated 
different surveillance intervals for ND and LGD, endoscopic mucosal resection 
(EMR), radiofrequency ablation (RFA) and esophagectomy for HGD or early 
EAC and esophagectomy for advanced EAC. The incremental cost-effectiveness 
ratio (ICER) was calculated in costs per quality-adjusted life year (QALY). 
Results: The annual progression rate was 2% for ND to LGD, 4% for LGD 
to HGD or early EAC, and 25% for HGD or early EAC to advanced EAC. 
Surveillance every five or four years with RFA for HGD or early EAC and 
esophagectomy for advanced EAC had ICERs of €5.283 and €62.619 per QALY 
for ND. Surveillance every five to one year had ICERs of €4.922, €30.067, 
€32.531, €41.499, and €75.601 per QALY for LGD. EMR prior to RFA was 
slightly more expensive, but important for tumor staging.
Conclusions: Based on a Dutch healthcare perspective and assuming a 
willingness-to-pay threshold of €35.000 per QALY, surveillance with EMR 
and RFA for HGD or early EAC, and esophagectomy for advanced EAC is cost-
effective every 5-years for ND and every 3-years for LGD.
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Introduction
Barrett’s esophagus (BE) is a premalignant condition in which patients have 
an increased risk of developing esophageal adenocarcinoma (EAC) with an 
estimated incidence of 0.1 to 0.5% per year [1, 2, 3, 4]. The development of EAC 
in BE is a gradual process, in which metaplastic epithelium with no dysplasia 
(ND) evolves to low-grade dysplasia (LGD), high-grade dysplasia (HGD) and 
eventually EAC under the influence of chronic esophageal acid exposure [5]. 
Once a patient has developed EAC the prognosis is poor with a 5-year survival 
of less than 20% [6, 7]. Endoscopic surveillance is therefore recommended for 
BE to detect EAC at an early stage, when curative treatment is still feasible [8, 
9]. Histological diagnosis of dysplasia is the golden standard for predicting 
neoplastic progression in BE and is therefore used for defining surveillance 
intervals. Current guidelines recommend surveillance every three to five years 
in patients with ND, every six to twelve months in patients with LGD and every 
three months in patients with HGD (in absence of endoscopic therapy). Most 
patients with BE belong to the group with ND and have an overall low risk of 
neoplastic progression. The majority of patients with non-dysplastic BE will 
never develop HGD or EAC and die of causes not related to BE, which makes 
surveillance controversial in this patient group [10]. In patients with LGD the 
risk of neoplastic progression is increased, which makes surveillance more 
effective. However, histological diagnosis of LGD is subject to considerable 
intra- en interobserver variation which limits its predictive value [11, 12].
Over the past years there has been a major shift in the treatment of BE patients 
with the introduction of endoscopic treatment modalities such as endoscopic 
mucosal resection (EMR) and radiofrequency ablation (RFA). EMR is used to 
remove visible mucosal irregularities and has a role in tumor staging, while RFA 
is used to eradicate residual intestinal metaplasia. Although use of RFA alone 
is still controversial, some studies suggest that this might be just as effective 
[13, 14]. Nowadays endoscopic treatment with EMR and RFA is the preferred 
strategy for HGD and early EAC [8, 9]. Recently was suggested that RFA might 
also be suitable for patients without neoplastic progression, especially for 
those with confirmed LGD. However, it is difficult to make a reliable diagnosis 
of LGD and the risk of progression may vary greatly among these patients. 
Therefore no strict recommendations are made for patients with LGD [9]. 
Esophagectomy is still the mainstay for curative treatment of advanced EAC, 
but is nowadays complemented with neoadjuvant chemoradiotherapy [15]. 
Chemotherapy, esophageal stenting and brachytherapy have been added to 
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the palliative treatment of EAC [16].
One of the key questions in the discussion about BE surveillance is whether 
surveillance and (endoscopic) treatment is cost-effective. The cost-
effectiveness of BE surveillance has been investigated in previous studies, 
where transition rates to HGD and EAC were mostly based on pooled literature 
data [17, 18, 19, 20, 21, 22, 23, 24, 25, 26]. For a more accurate representation 
of the natural history of BE and its progression to EAC, true transition and 
misclassification rates can be calculated in a multi-state Markov (MSM) model 
using prospectively collected follow-up data from a large cohort of BE patients 
[27]. The aim of this study was to evaluate the cost-effectiveness of different 
surveillance intervals and treatment strategies for patients without dysplasia 
and LGD in long-segment BE, within a large multicenter prospective cohort 
study.
Methods
Study Design
We conducted a large multicenter prospective cohort study in three university 
medical centers and twelve regional hospitals throughout the Netherlands. 
Between November 2003 and December 2004, 714 consecutive patients 
were included presenting with known or newly diagnosed BE of at least two 
cm, without a history of HGD or EAC. The diagnosis was confirmed by the 
presence of intestinal metaplasia. Patients were followed according to the 
guidelines of the American College of Gastroenterology [9]. During follow-
up incident cases of HGD and EAC were identified. Patients who developed 
HGD or EAC were considered to have reached an endpoint and received 
appropriate treatment. At each follow-up endoscopy targeted biopsies were 
taken from mucosal abnormalities and four-quadrant biopsies were taken 
every two cm from the most distal to the most proximal part of the BE 
epithelium. Biopsies were first graded by a local pathologist and then by 
an expert pathologist for second opinion. After examining all biopsies, the 
highest degree of abnormality was reported for each endoscopy. When the 
local and expert pathologist disagreed on the grade of dysplasia, the slides 
were reviewed by a second expert pathologist. Pathologists were blinded to 
the diagnosis of each other and a final diagnosis was made only if at least two 
pathologists agreed on the grade of dysplasia. HGD and EAC limited to the 
mucosa (T1a) were considered as one category (HGD or early EAC), since both 
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are treated similarly. Carcinomas invading the submucosa (T1b), muscularis 
propria (T2), adventitia (T3) or adjacent structures (T4) were considered as 
another category (advanced EAC). 
Incidence, misclassification and transition rates
The incidence rates of LGD, HGD and EAC were calculated by dividing 
the number of incident cases by the total number of follow-up years. Since 
neoplastic progression is thought to be a gradual process, patients who 
developed HGD or EAC were supposed to have passed the stage of LGD. When 
LGD was not observed, the time till the development of LGD was estimated 
to be half of the follow-up time in patients who developed HGD or early EAC 
and one third of the follow-up time in patients who developed advanced EAC. 
Patients who developed advanced EAC were supposed to have passed the stage 
of HGD. When HGD was not observed, the time till the development of HGD 
was estimated to be two third of the follow-up time in patients with ND and 
half of the follow-up time in patients with LGD. Since histological diagnosis is 
subject to misclassification due to sampling error and interobserver variation, 
the histological diagnosis observed at each endoscopy may not represent the 
true histological diagnosis (or “true state”). The observed state is dependent 
on the true state as well as the misclassification rates (Figure 1). In a MSM 
model misclassification rates can be estimated based on observed follow-up 
data [27]. The assumption was made that advanced EAC was not observed in 
patients with true ND and that ND or LGD was not observed in patients with 
true advanced EAC. The misclassification rates were used to convert observed 
transition rates into true transition rates. Since patients who developed HGD 
or EAC were excluded from further follow-up, we were not able to observe 
the transition rate from HGD or early EAC to advanced EAC. Therefore we 
added one patient with HGD to our follow-up data who developed advanced 
EAC after four years of follow-up, based on observations in another Dutch BE 
cohort [28]. Although regression of dysplasia was observed in some patients, 
we assumed that true regression of dysplasia was not possible and that the 
observed regression was due to sampling error and observer variability.
Surveillance strategies
We evaluated the cost-effectiveness of sixteen different surveillance strategies. 
The first strategy consisted of upper endoscopy in case of symptoms such 
as dysphagia or severe pyrosis and esophagectomy with neoadjuvant 
chemoradiotherapy in patients with EAC (no surveillance). The other fifteen 
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strategies consisted of surveillance with different intervals (one to five years) 
for patients with ND or LGD and endoscopic or surgical intervention for 
patients with HGD or EAC. Treatment strategies for patients with HGD or 
early EAC consisted of RFA alone, EMR followed by RFA, or esophagectomy 
with neoadjuvant chemoradiotherapy. We assumed that complications 
occurred in 2.2% after EMR, 6.5% after RFA and 22.9% after esophagectomy 
and considered costs associated with additional treatment [29, 30, 31]. After 
endoscopic treatment with EMR or RFA we assumed that patients returned 
to ND and surveillance was resumed. We assumed that 5 to 10% of patients 
had early recurrence for which they received endoscopic treatment. After 
endoscopic treatment, patients remained at risk for neoplastic progression. 
Treatment of patients with advanced EAC consisted of esophagectomy with 
neoadjuvant chemoradiotherapy. Palliative treatment of EAC consisted of 
chemotherapy, esophageal stenting or brachytherapy and terminal care.
Figure 1. Multi-state Markov model 
BE, Barrett’s esophagus; LGD, low-grade dysplasia; HGD, high-grade dysplasia; 
EAC, esophageal adenocarcinoma
Costs and quality of life
The cost-effectiveness analysis was performed from a health care perspective. 
Direct medical true costs of endoscopic and surgical procedures, neoadjuvant 
and palliative treatment, and inpatient and outpatient care were obtained using 
the 2012 reimbursement rates per diagnosis and intervention as provided 
by the Dutch healthcare authority (NZa) [32]. Direct medical costs include 
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costs of medical procedures, equipment, overhead, personnel and honoraria 
of medical specialists. Hospitals get these costs reimbursed by the health 
insurance. Data on quality of life (utilities) associated with different health 
states were derived from the published literature and were used to convert 
absolute life-years of survival into quality-adjusted-life-years (QALYs) [33, 
34, 35]. Costs and utilities were discounted at an annual rate of 5%, which 
allows to compare our results to those of previous studies (Table 1).
Table 1. Variables included in cost-effectiveness analysis
Variables Base value Reference
Transition rates (per year)
ND to LGD 0.023 Own data
LGD to HGD/early EAC 0.043 Own data
HGD/early EAC to advanced EAC 0.250 (28)
Misclassification rates
True state Observed state
ND LGD
ND HGD/early EAC
LGD ND
LGD HGD/early EAC
LGD Advanced EAC
HGD/early EAC LGD
HGD/early EAC Advanced EAC
Advanced EAC HGD/early EAC
0.086
0.004
0.247
0.123
0.008
0.016
0.287
0.036
Own data
Own data
Own data
Own data
Own data
Own data
Own data
Own data
Probabilities
Probability of surgery 0.600 Cancer register
Probability of curative treatment 0.500 Cancer register
Probability of dying from surgery 0.018 (49)
Probability of complications from surgery 0.229 (29)
Probability of complications from endoscopy 0.001 (50)
Probability of complications from EMR 0.022 (31)
Probability of complications from RFA 0.065 (30)
Costs
Cost of endoscopy € 629 NZa
Cost of endoscopy with complication € 1677 NZa
Cost of EMR € 1925 Expert opinion
Cost of EMR with complication € 3425 Expert opinion
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Variables Base value Reference
Cost of RFA € 6210 Expert opinion
Cost of RFA with complication € 8710 Expert opinion
Cost of staging adenocarcinoma € 2499 NZa
Cost of esophagectomy € 17.887 NZa
Cost of esophagectomy with complication € 38.930 NZa
Cost of postoperative follow-up, per year € 948 NZa
Cost of neoadjuvant chemoradiation € 8792 NZa
Cost of palliative chemotherapy € 3867 NZa
Cost of palliative stenting € 1215 NZa
Cost of brachytherapy € 3004 NZa
Cost of terminal care, per year € 32565 (22)
Quality of life
Quality of life after HGD diagnosis 0.84 (33, 35)
Quality of life after EAC diagnosis 0.66 (33, 35)
Quality of life after endoscopic treatment (short term) 0.93 (33, 35)
Quality of life after esophagectomy (short term) 0.86 (34)
Quality of life after esophagectomy (long term) 0.90 (34)
Duration of short term morbidity
After endoscopic treatment 3 days (30)
After esophagectomy 4 weeks (34)
Discount rate 0.05 (22)
ND, no dysplasia; LGD, low-grade dysplasia; HGD, high-grade dysplasia; EAC, esophageal 
adenocarcinoma; EMR, endoscopic mucosal resection; RFA, radiofrequency ablation; NZa, Dutch 
healthcare authority
Ethics
The study protocol was approved by the Institutional Review Boards of the 
Erasmus University Medical Center, as well as those of all participating 
hospitals. Before the first endoscopy, written informed consent was obtained.
Cost-effectiveness analysis
For the analysis we used a modification of a previously published decision-
analytic Markov model, which was constructed in Windows Decision Maker 
(Beta test version 2010) [22]. In this computer model a BE cohort was simulated 
with as base case a 55-years old male BE patient with ND or LGD. The natural 
history of the BE cohort was modelled to examine the costs of no surveillance 
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and its effects on quality of life. Subsequently, the effect of multiple surveillance 
strategies was evaluated with various surveillance intervals for patients with 
ND or LGD and endoscopic or surgical interventions for patients with HGD 
or EAC. Simulation of the BE cohort started with baseline endoscopy and was 
continued with cycles of 3 months until death. True progression rates from 
ND to LGD, HGD, and advanced EAC were estimated in a MSM model based 
on the progression and misclassification rates observed in our cohort. Death 
from other causes than EAC was possible in any state and was modelled as a 
time-dependent variable with the risk increasing with age. 
Statistical analysis
Primary outcome of the study was the incremental cost-effectiveness ratio 
(ICER) of each surveillance strategy. The ICER is defined as the difference 
in cost between two surveillance strategies, divided by the change in QALY’s. 
Whether a strategy is cost-effective depends on the willingness-to-pay 
threshold, which is highly variable among countries. In the Netherlands a 
willingness-to-pay threshold is used of € 20.000 to € 80.000, depending on 
the severity of the condition [36]. In the United States of America and the 
United Kingdom a willingness-to-pay threshold of € 35.000 is used [37, 38]. In 
one-way sensitivity analyses we evaluated the effect of halving or doubling all 
individual input variables, while keeping the other input variables unchanged. 
In addition we performed analyses using a discount rate of 3% and using 
transition rates of 200%, 50% and 25% of the calculated values.
Results
Patient characteristics
Seven hundred fourteen patients (73% male, median age 61 years) with 
a median BE length of 4 centimeters were included and followed during 
surveillance with a median duration of 6 years and a total of 3992 person-
years of follow-up. Most patients (74%) were already known with BE before 
inclusion in the study for a median duration of 5 years (Table 2).
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Table 2. Characteristics of patients included in the Barrett’s esophagus cohort
Cohort 
n = 714
Follow-up Median, years (IQR) 6.1 (4.4-7.0)
Total, person-years 3992
Age Median, years (IQR) 61 (53-69)
Gender Male 520 (73%)
Female 194 (27%)
BE diagnosis < Inclusion 529 (74%)
≥ Inclusion 185 (26%)
BE length Median, cm (IQR) 4 (2-6)
Baseline esophagitis No 642 (90%)
Yes 72 (10%)
Baseline histology No dysplasia 606 (85%)
Low-grade dysplasia 108 (15%)
Mucosal abnormalities No 694 (97%)
Yes 20 (3%)
IQR, interquartile range; BE, Barrett’s esophagus
Incidence and transition rates
At baseline, 606 (85%) patients had ND and 108 (15%) LGD. In patients with 
ND the observed incidence of LGD was 6% per year. In patients with LGD 
the observed annual incidence was 13% for progression to HGD or early EAC 
and 57% for regression to ND. During follow-up 46 (6%) patients developed 
HGD or early EAC and 4 (1%) patients developed advanced EAC with an 
annual incidence of 1.2% (95% CI 0.9-1.6) for HGD or early E.1% (95% CI 0.0-
0.3) for advanced EAC, which was stable over time and similar for patients 
with incident and prevalent BE. (Table 3). After neoplastic progression, 33 
patients were treated with EMR. In 75% of cases the histological diagnosis 
was confirmed in the EMR specimen, in 20% the histological diagnosis was 
downgraded and in 5% upgraded after evaluation of the EMR specimen.
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Table 3. Observed annual incidence rates in patients with Barrett’s esophagus
Transition Observed
Cases 
Interpolated
Total
Follow-up 
in years
Incidence rate with 
95% CI
ND to LGD 180 27 207 3640 5.7% (4.9-6.5)
LGD to HGD/early EAC 18 28 46 350 13.1% (9.6-17.5)
LGD to ND 198 - 198 350 56.6% (49.0-65.0)
ND/LGD to HGD/early EAC 42 4 46 3990 1.2% (0.9-1.6)
ND/LGD to advanced EAC 4 - 4 3992 0.1% (0.0-0.3)
CI, confidence interval; ND, no dysplasia; LGD, low-grade dysplasia; HGD, high-grade dysplasia; EAC, 
esophageal adenocarcinoma
The true annual transition rate was estimated to be 2.3% for ND to LGD, 4.3% 
for LGD to HGD or early EAC, and 25% for HGD or early EAC to advanced 
EAC. The true incidence rate of HGD or EAC was estimated to be 0.1% per 
year in ND and 4.9% per year in LGD.
Surveillance in patients with no dysplasia
In patients with ND, the costs of no surveillance were € 5.695 for 12.62 
discounted QALYs. Surveillance every five years with RFA for HGD or early 
EAC and esophagectomy for advanced EAC resulted in an increase in life 
expectancy by 0.25 QALYs and an increase in costs by €1.324, representing 
an ICER of €5.283 per QALY. Surveillance every four years resulted in an 
additional increase in life expectancy by 0.02 QALYs and an additional increase 
in costs by €802, representing an ICER of €62.619 per QALY. Strategies with 
surveillance intervals shorter than four years provided substantial higher 
costs with similar or less QALYs gained (Table 4).
Strategies using EMR prior to RFA had similar effects on QALYs compared to 
strategies using RFA alone, but were slightly more expensive. Strategies using 
esophagectomy were much more expensive with less QALYs gained. However, 
use of RFA alone is still controversial and EMR contributed significantly to 
tumor staging, which may justify the slightly higher costs. In summary, when 
assuming a willingness-to-pay threshold of €35.000 per QALY, surveillance 
every five years with EMR followed by RFA or RFA alone for HGD or early 
EAC and esophagectomy with neoadjuvant chemoradiotherapy for advanced 
EAC is a cost-effective strategy for long-segment BE with ND. When assuming 
a willingness-to-pay threshold of €80.000 per QALY, surveillance every four 
years is cost-effective (Figure 2).
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Surveillance in patients with low-grade dysplasia
In patients with LGD, the costs of no surveillance were € 21.806 for 10.95 
discounted QALYs. Surveillance every five years with RFA for HGD or early 
EAC and esophagectomy for advanced EAC resulted in an increase in life 
expectancy by 0.96 QALYs and an increase in costs by €4.756, representing an 
ICER of €4.922 per QALY. Surveillance every one to four years resulted in an 
additional increase in life expectancy, but at increasing costs (Table 4). EMR 
followed by RFA for patients with HGD or early EAC had similar effects on 
QALYs compared to strategies using RFA alone, but costs were slightly higher. 
Esophagectomy was much more expensive with less QALYs gained. When 
assuming a willingness-to-pay threshold of €35.000 per QALY, surveillance 
every three years with EMR followed by RFA or RFA alone for HGD or early 
EAC and esophagectomy with neoadjuvant chemoradiotherapy for advanced 
EAC is a cost-effective strategy for long-segment BE with LGD. When assuming 
a willingness-to-pay threshold of €80.000 per QALY, surveillance every year 
is cost-effective.
Table 4. Cost-effectiveness of different surveillance intervals and treatment 
strategies in patients with Barrett’s esophagus.
No dysplasia
Strategy Costs QALYs ICER
No surveillance € 5.695 12.62
Surveillance every 5 years with RFA € 7.019 12.87 € 5.283
Surveillance every 5 years with EMR followed by RFA € 7.247 12.87 x
Surveillance every 5 years with esophagectomy € 13.965 12.64 x
Surveillance every 4 years with RFA € 7.821 12.89 € 62.619
Surveillance every 4 years with EMR followed by RFA € 8.086 12.89 x
Surveillance every 4 years with esophagectomy € 15.229 12.63 x
Surveillance every 3 years with RFA € 9.005 12.90 € 105.755
Surveillance every 3 years with EMR followed by RFA € 9.277 12.90 x
Surveillance every 3 years with esophagectomy € 16.890 12.61 x
Surveillance every 2 years with RFA € 10.984 12.90 € 324.420
Surveillance every 2 years with EMR followed by RFA € 11.286 12.90 x
Surveillance every 2 years with esophagectomy € 19.325 12.59 x
Surveillance every year with RFA € 15.074 12.89 x
Surveillance every year with EMR followed by RFA € 15.421 12.89 x
Surveillance every year with esophagectomy € 23.686 12.54 x
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Low-grade dysplasia
Strategy Costs QALYs ICER
No surveillance € 21.806 10.95
Surveillance every 5 years with RFA € 26.562 11.91 € 4.922
Surveillance every 5 years with EMR followed by RFA € 28.245 11.91 x
Surveillance every 5 years with esophagectomy € 50.909 11.33 x
Surveillance every 4 years with RFA € 28.964 11.99 € 30.067
Surveillance every 4 years with EMR followed by RFA € 30.856 11.99 x
Surveillance every 4 years with esophagectomy € 51.835 11.34 x
Surveillance every 3 years with RFA € 32.071 12.09 € 32.531
Surveillance every 3 years with EMR followed by RFA € 34.238 12.09 x
Surveillance every 3 years with esophagectomy € 52.851 11.34 x
Surveillance every 2 years with RFA € 36.242 12.19 € 41.499
Surveillance every 2 years with EMR followed by RFA € 38.779 12.19 x
Surveillance every 2 years with esophagectomy € 53.960 11.34 x
Surveillance every year with RFA € 42.086 12.27 € 75.601
Surveillance every year with EMR followed by RFA € 45.133 12.27 x
Surveillance every year with esophagectomy € 55.159 11.34 x
QALYs, quality-adjusted-life-years; ICER, incremental cost-effectiveness ratio ;RFA, radiofrequency 
ablation; EMR, endoscopic mucosal resection; x, strategy dominated by alternative
Sensitivity analysis
The most critical variables in the cost-effectiveness analysis were the true 
progression rates. When progression rates were doubled, surveillance every 
two years was cost-effective for long-segment BE with ND and every year 
for LGD with ICERs of €27.073 and €17.973 per QALY (Table 5). When 
progression rates were halved, surveillance every five years was cost-effective 
for both ND and LGD with ICERs of €29.802 and €7.631 per QALY. When 
progression rates were only 25% of the calculated values, surveillance was 
only cost-effective for LGD, with intervals of 5 years and an ICER of 11.753 per 
QALY. Changes in costs and quality of life data had less impact on the cost-
effectiveness of surveillance. When using a discount rate of 3% instead of 5%, 
results were similar.
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Figure 2. Costs and quality-adjusted life years (QALYs) associated with different 
surveillance strategies in patients with no dysplasia (A) or low-grade dysplasia 
(B).    No surveillance,     Surveillance with radiofrequency ablation for high-grade 
dysplasia (HGD) or early esophageal adenocarcinoma (EAC) and esophagectomy for 
advanced EAC,     Surveillance with esophagectomy for HGD or EAC
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Discussion
In this large prospective study, we evaluated the cost-effectiveness of 
different surveillance intervals and treatment strategies in patients with 
long-segment BE. Assuming a willingness-to-pay threshold of € 35.000 per 
QALY, endoscopic surveillance is cost-effective with intervals of 5 years, EMR 
followed by RFA for HGD or early EAC, and esophagectomy with neoadjuvant 
chemoradiotherapy for advanced EAC in patients with non-dysplastic BE. 
Surveillance every three years is cost-effective for patients with LGD. For 
patients with ND, the results of our study correspond to recommendations 
made in current guidelines [8, 9]. For patients with LGD however, surveillance 
is recommended with intervals of six to twelve months, while according to our 
study intervals should be at least three years in order to be cost-effective. When 
histology is used as the only predictor for neoplastic progression, surveillance 
intervals should be prolonged to three years in patients with LGD to be cost-
effective. However, with prolongation of the surveillance intervals, the risk of 
interval carcinomas may increase. Identification of additional risk factors may 
improve risk-stratification and thereby the cost-effectiveness of surveillance 
with short intervals.
Previous studies investigating the cost-effectiveness of BE surveillance have 
shown highly variable results, mainly due to different assumptions about 
progression rates and quality of life associated with different health states. 
Surveillance was reported to be cost-effective in four studies with surveillance 
intervals ranging from two to five years [20, 21, 23, 24]. However, in four other 
studies surveillance was not cost-effective with sometimes even higher costs 
and less quality of life than without surveillance [17, 19, 22, 26].
Over the past years there has been a major shift in the treatment BE patients 
with the introduction of endoscopic treatment strategies. We therefore 
included EMR and RFA in this cost-effectiveness analysis [8, 9]. An advantage 
of EMR is that it not only removes mucosal abnormalities suspect for 
dysplasia, but also allows for evaluation of tissue invasion [39, 40]. RFA is 
used in addition to EMR for complete eradication of BE, but may also be used 
as a single treatment modality [30, 41]. Previous studies have shown that RFA 
is effective in eradicating HGD, early EAC and complete segments of BE with 
low complication rates [30, 41, 42, 43]. The current study shows that RFA is 
also cost-effective, which corresponds to the results of previous studies [17, 18, 
19, 20, 21, 22, 23, 24, 25, 26]. Some recent studies suggested that RFA might 
also be cost-effective in patients with confirmed LGD [43, 44]. However, it is 
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hard to make a reliable diagnosis of LGD which limits its feasibility. Therefore 
we did not include RFA as a treatment strategy for LGD. Use of EMR in 
addition to RFA was associated with similar effects on quality of life, but was 
slightly more expensive. As a result, strategies using EMR followed by RFA 
were dominated by strategies using RFA alone. In two recent retrospective 
studies was shown that use of EMR before RFA had no additional benefit, 
which suggests that RFA alone might be a suitable treatment for patients with 
HGD or early EAC.[13, 14] However, use of RFA alone is still controversial and 
although use of additional EMR might be slightly more expensive, it allows 
for evaluation of tissue invasion and is therefore useful for tumor staging. 
The current study shows that in 25% of patients histological diagnosis was 
changed after evaluation of the EMR specimens and in some patients another 
treatment strategy was preferred based on these results. We therefore believe 
there is an additional role for EMR prior to RFA, which also corresponds to 
recommendations in current guidelines [8, 9].
The cost-effectiveness of a surveillance strategy not only depends on the costs 
and effects on quality of life, but also on the willingness-to-pay threshold [22]. 
We considered a willingness-to-pay threshold between €20.000 to €80.000 
per QALY with special emphasis on the threshold of €35.000 per QALY, 
which is used in the United Kingdom and the United States of America [36, 
37, 38]. The most critical variables in the cost-effectiveness analysis were the 
true progression rates. We used advanced statistical techniques to estimate 
these rates from prospectively collected follow-up data. The incidence rate of 
EAC was estimated at 0.1% per year which corresponds to the results of recent 
population-based studies, which confirms that our model is a good reflection of 
the natural history of neoplastic progression in BE [2]. For patients with LGD, 
the incidence rate of EAC was estimated at 4.9% per year. Previous studies have 
shown highly variable results for LGD with incidence rates of 0-26% and 1.7% 
in a recent meta-analysis [45]. The estimated progression rate in the current 
study was higher than in the meta-analysis which can be explained by the fact 
that we only included patients with long-segment BE, that LGD diagnosis was 
made only when at least two pathologists agreed on the diagnosis and that 
patients were under strict surveillance. When progression rates were halved, 
surveillance every five years was cost-effective for both ND and LGD. When 
progression rates were 25% of the calculated values, surveillance was only 
cost-effective for LGD. Changes in other variables such as costs and quality of 
life data had less impact on outcome.
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One of the strengths of this study is that the transition rates were estimated 
based on follow-up data from our own large prospective BE cohort instead of 
using pooled literature data. Transition rates based on pooled literature data 
are likely to overestimate the true incidence rate of neoplastic progression 
due to publication and selection bias. Transition rates based on large 
epidemiological studies are likely to underestimate the true incidence rate of 
neoplastic progression since these patients are not necessarily under strict 
surveillance, which is of major importance to detect HGD or early EAC.  With 
the use of our own follow-up data, we obtained a more accurate representation 
of the natural history of BE and its progression to EAC. In addition, patients 
with EAC were stratified according to TNM stage. As a result endoscopic 
intervention could be applied to patients with HGD as well as patients with 
early EAC. Furthermore, we incorporated new treatment strategies such as 
EMR and RFA for HGD or early EAC, neoadjuvant chemoradiotherapy for 
patients who underwent esophagectomy, and chemotherapy, esophageal 
stenting and brachytherapy for palliative treatment.
Our study also has some limitations. Although progression rates were estimated 
based on prospective follow-up data, the number of patients who developed 
HGD or EAC was relatively low which limits the accuracy of the estimate. 
When longer follow-up becomes available, a more reliable estimate can be 
made. Secondly, we were not able to observe the transition from HGD or early 
EAC to advanced EAC since these patients were excluded from further follow-
up and received appropriate treatment. Instead we used data from another 
Dutch BE cohort. Thirdly, we only included patients with BE of at least two 
centimeters and therefore our results cannot be applied universally to all BE 
patients. Since long-segment BE is associated with a higher risk of neoplastic 
progression we believe that our cohort is representative for the clinically 
relevant population with patients with long-segment BE, which are the patients 
who are most likely to benefit from surveillance. Finally, we did not include any 
other risk factors than histology. To date histological diagnosis of dysplasia is 
the only accepted predictor for neoplastic progression and therefore used for 
defining surveillance intervals. Other potential risk factors are insufficiently 
validated in large studies and are therefore not yet ready for use. However, 
when new risk factors become available they can be used to identify patients at 
high risk for neoplastic progression. By targeting surveillance to those at high 
risk the cost-effectiveness of surveillance can be improved. In previous studies 
we have already shown promising results of chemoprevention with proton 
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pump inhibitors, nonsteroidal anti-inflammatory drugs and statins and use of 
biomarkers such as p53 [46, 47, 48]. When new risk factors become available 
our model needs to be updated for a more personalized surveillance strategy.
In conclusion this study shows that surveillance every five years with EMR 
followed by RFA for HGD or early EAC and esophagectomy with neoadjuvant 
chemoradiotherapy for advanced EAC is a cost-effective strategy in patients 
with long-segment BE without dysplasia, assuming a willingness-to-pay 
threshold of € 35.000 per QALY. In patients with LGD surveillance every three 
years with EMR followed by RFA for HGD or early EAC and esophagectomy 
with neoadjuvant chemoradiotherapy for advanced EAC is cost-effective. In 
the future new risk factors or biomarkers may identify patients at high risk 
for neoplastic progression and thereby improve the cost-effectiveness of BE 
surveillance.
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Abstract
Introduction: Endoscopic surveillance for Barrett’s esophagus (BE) is under 
discussion given the overall low incidence of neoplastic progression and lack 
of evidence that it prevents advanced esophageal adenocarcinoma (EAC). The 
aim of this study was to evaluate the impact of endoscopic BE surveillance on 
tumor stage and survival of patients with neoplastic progression.
Methods: 783 patients with BE of at least two centimeter were included in 
a multicenter prospective cohort and followed during surveillance according 
to the ACG guidelines. Cases of high-grade dysplasia (HGD) and EAC were 
identified during follow-up. EAC staging was performed according to the 7th 
UICC-AJCC classification. Survival data were collected and cross-checked 
using death and municipal registries. Data from EAC patients in the general 
population were obtained from the Dutch cancer registry. We compared 
survival of BE patients with neoplastic progression during surveillance to 
those of patients without neoplastic progression and patients with EAC in the 
general population.
Results: 53 BE patients developed HGD or EAC during surveillance. Thirty-
five (66%) were classified as stage 0, 14 (26%) as stage 1, and 4 (8%) as 
stage 2. EAC was diagnosed at an earlier stage during BE surveillance than 
in the general population (P<0.001). Survival of BE patients with neoplastic 
progression was not significantly worse than those of patients without 
neoplastic progression and similar to survival of patients with stage 0 or 1 
EAC in the general population.
Conclusions: EAC is detected at an earlier stage during BE surveillance than 
in the general population with good survival rates.
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Introduction
Barrett’s esophagus (BE) is a premalignant condition in which patients have 
an increased risk of developing esophageal adenocarcinoma (EAC) with an 
estimated incidence of 0.1 to 0.5% per year [1, 2, 3, 4]. The development of EAC 
in BE is a gradual process, in which metaplastic epithelium without dysplasia 
evolves to low-grade dysplasia (LGD), high-grade dysplasia (HGD) and 
eventually EAC under the influence of esophageal acid exposure [5, 6]. Once 
a patient has developed EAC the prognosis is poor with a 5-year survival of 
less than 20% [7, 8, 9]. Endoscopic BE surveillance is therefore recommended 
to detect EAC at an early stage, when curative treatment is still feasible [10, 
11]. Current guidelines recommend endoscopic surveillance every three to five 
years in patients with non-dysplastic BE, every six to twelve months in patients 
with LGD and (endoscopic) treatment in patients with established HGD or 
EAC [11, 12]. A major drawback of endoscopic surveillance is that it is an 
invasive and expensive procedure which is subject to interobserver variation, 
sampling error and variation in protocols. However, endoscopic surveillance 
is the only screening test available for BE. Over the past years there has been 
a major shift in the treatment of BE patients with neoplastic progression 
with the introduction of endoscopic mucosal resection (EMR) and ablation 
techniques such as radiofrequency ablation (RFA), photodynamic therapy 
(PDT) and argon plasma coagulation (APC) [13]. Endoscopic treatment is 
effective, less burdensome, associated with low morbidity and mortality rates, 
and may improve survival [14]. Although esophagectomy is still the mainstay 
for advanced EAC, esophagectomy is nowadays complemented by neoadjuvant 
chemotherapy or chemoradiotherapy [15]. Chemotherapy, esophageal stenting 
and brachytherapy have been added to the palliative treatment of EAC [16].
Recently, the value of endoscopic BE surveillance has been under discussion 
given the overall low incidence of neoplastic progression and lack of evidence 
that endoscopic surveillance reduces the risk of advanced EAC and improves 
survival [17, 18, 19]. These key questions have been evaluated in case-control 
studies, population-based studies and small prospective cohort studies with 
conflicting results.[13, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 
33] Although most studies suggest that endoscopic surveillance enables the 
detection of early EAC with good survival, some other studies reported no 
effect on mortality [19]. Furthermore in most studies patients were included 
independent of BE length. However the risk of neoplastic progression is much 
lower in patients with short BE [34, 35]. The aim of the present study was to 
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evaluate the impact of endoscopic surveillance of patients with BE of at least 
two centimeters according to current guidelines, on tumor stage and survival 
of patients with EAC.
Methods
Study Design
We conducted a large multicenter prospective cohort study in three academic 
and twelve regional hospitals throughout the Netherlands. Between November 
2003 and December 2004, 783 consecutive patients were included with known 
or newly diagnosed BE with a maximum length of at least two centimeters 
according to the Prague C&M criteria [36]. The endoscopic diagnosis was 
confirmed by the presence of intestinal metaplasia and patients with HGD 
or EAC in the past or at the index endoscopy were excluded. Endoscopic 
surveillance was performed according to guidelines of the American College of 
Gastroenterology [11]. Patients without dysplasia underwent upper endoscopy 
with biopsy sampling every three years and patients with LGD every year. All 
endoscopic procedures were performed by experienced gastroenterologists, 
according to a standardized protocol. At each endoscopy targeted biopsies 
were taken from mucosal abnormalities and quadrant biopsies were taken 
every two cm from the most distal to the most proximal part of the BE 
epithelium, according to the Seattle protocol [37]. Most patients are still under 
surveillance.
Histology
Biopsy specimens were fixed with buffered formalin and embedded in paraffin, 
according to standard procedures. From each biopsy set four micrometer 
thick sections were cut and stained with haematoxylin-eosin to assess the 
presence of BE and define the grade of dysplasia. After examining all biopsies, 
the highest degree of abnormality was reported for each endoscopy. Slides 
were first graded by a local pathologist and then by an expert pathologist 
for second opinion. When the local and expert pathologists disagreed on the 
grade of dysplasia, the slides were reviewed by a second expert pathologist. 
Pathologists were blinded to the diagnosis of each other and a final diagnosis 
was made only if at least two pathologists agreed on the grade of dysplasia. If 
there was disagreement, a panel of expert pathologists reviewed the slides and 
a final diagnosis was made based on consensus agreement.
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Neoplastic progression
Neoplastic progression was defined as the development of HGD or EAC 
after inclusion in the study. The diagnosis was made only if at least two 
pathologists, including an expert pathologist, agreed on the presence of HGD 
or EAC. Patients with neoplastic progression were treated according to the 
guidelines of the American College of Gastroenterology. Patients with HGD 
received intensive endoscopic surveillance or were treated as early EAC with 
EMR, ablation techniques, or a combination of both depending on local 
expertise. Patients with advanced EAC received esophagectomy with or 
without neoadjuvant chemoradiotherapy [11]. EAC staging was performed 
according to the 7th UICC-AJCC classification. The stage of the primary 
tumor was based on histological assessment of biopsies, EMR specimens or 
resection specimens, whichever was available. The highest tumor stage was 
reported for each patient. After endoscopic or surgical treatment surveillance 
was resumed. During follow-up occurrence of complications, recurrence and 
metastasis was recorded.
Survival
Survival data were collected from all patients included in the study. Since 
surveillance intervals were up to three years and some patients dropped out of 
surveillance, survival was cross-checked using death registries and municipal 
administrations. When a patient was deceased, the cause of death was obtained 
from the attending gastroenterologist or general practitioner. Survival data 
from patients with EAC in the Netherlands, independent of cause of death and 
stratified by age, gender, stage, and year of diagnosis, were obtained from the 
Dutch cancer registry over the same time period [7]. Data on cause of death 
in the general population, stratified by age, gender and year of death, were 
obtained from the Dutch central statistical office [38].
Ethics
The study protocol was approved by the Institutional Review Boards of the 
Erasmus University Medical Center, as well as those of all participating 
hospitals. Before the first endoscopy, written informed consent was obtained 
from all patients.
Statistical analysis
The incidence rate of neoplastic progression was calculated by dividing the 
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number of patients with HGD or EAC by the total person-years of follow-up. 
Chi-squared tests were used to compare EAC stage at diagnosis in BE patients 
undergoing surveillance and patients with EAC in the general population. 
Survival of BE patients with and without neoplastic progression during 
surveillance was compared in Cox proportional-hazards models adjusted 
for age and gender, whereby neoplastic progression was modelled as a time-
dependent variable. Follow-up time was defined as the time from inclusion 
in the study to death or 1 January 2014, whichever came first. When no 
information was available from death or municipal registries, follow-up time 
was defined as the time from inclusion in the study to the last surveillance 
endoscopy. Cox-regression models were used to calculate hazard ratios (HR) 
and 95% confidence intervals (CI). In addition, survival of patients with 
different EAC stages in the general population was evaluated and compared 
to survival of patients with neoplastic progression during BE surveillance. To 
adjust for lead time bias, which is the time between the detection of preclinical 
EAC during surveillance and the moment EAC becomes symptomatic, we 
estimated the sojourn time for EAC from the difference in mean age at EAC 
diagnosis between BE patients undergoing surveillance and patients with EAC 
in the general population. To adjust for length time bias, which refers to the 
detection of less aggressive EAC during surveillance, we performed sensitivity 
analyses in which we only included patients with EAC. The 5-year cumulative 
survival was estimated using survival tables and Kaplan-Meier curves. In 
addition, we evaluated cause of death in BE patients and in individuals with 
similar age and gender in the general population. Two sided P-values <0.05 
were considered to be statistically significant. Data were analysed using SPSS 
Statistics (version 20.0, Chicago, Illinois, USA).
Results
Patient characteristics
Seven hundred eighty-three patients (73% male, median age 61 years) were 
included and followed during surveillance with a median duration of 7 years 
(interquartile range (IQR) 4-8 years) and a total 4556 person-years of follow-
up (Table 1). The majority of patients (72%) was already known with BE 
before inclusion in the study. At baseline, patients had a median BE length of 
4 cm (IQR 2-6 cm), 78 (10%) patients were diagnosed with esophagitis and 117 
(15%) with LGD.
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Table 1. Characteristics of patients with Barrett’s esophagus and patients with 
esophageal adenocarcinoma in the general population
Cohort
n = 783
HGD or EAC
n = 53
EAC general population
n = 8855
Age median years (IQR) 61 (53-70) 68 (59-74) 68 (60-77)
mean (SD) 61 (12) 66 (10) 68 (12)
Male gender number 573 (73%) 44 (83%) 7164 (81%)
Follow-up median years (IQR) 7 (4-8) 5 (2-7) 1 (0-2)
HGD, high-grade dysplasia; EAC, esophageal adenocarcinoma
Neoplastic progression
After a median follow-up of 3 years 53 patients (83% male, median age 68 
years) developed HGD or EAC with an incidence rate of 1.2 per 100 person-
years (IQR 0.9-1.5), which was stable over time (Figure 1). The incidence rate 
was 0.3 per 100 person-years (IQR 0.2-0.6) for EAC (all stages) and 0.1 per 
100 person-years (IQR 0.02-0.2) for advanced EAC (at least stage 2). Thirty-
five patients (66%) developed HGD, 12 (22%) T1a EAC, 2 (4%) T1b EAC, 2 
(4%) T2 EAC, and 2 (4%) T3 EAC. In 2 patients with T2 EAC, metastases were 
found in regional lymph nodes (N1). In none of the other patients lymph node 
metastases were found (N0). At the time of diagnosis, there was no evidence 
of distant metastases in any of the patients (M0). Thirty-five patients (66%) 
were classified as stage 0 disease, 14 (26%) as stage 1, and 4 (8%) as stage 2. 
EAC stage at diagnosis did not significantly change over time. Three patients 
(75%) with stage 2 EAC were previously diagnosed with LGD, for which they 
received annual surveillance. The remaining patient was never diagnosed with 
dysplasia and received surveillance every three years. Two patients (50%) 
with LGD at inclusion were diagnosed with stage 2 EAC at the first follow-up 
endoscopy one year later.
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Figure 1. Cumulative incidence of neoplastic progression during Barrett 
surveillance.      HGD and EAC, ∙∙∙ HGD,     EAC (all stages), ∙∙∙ advanced EAC (≥ 
stage 2)
In the Netherlands, 8855 patients (81% male, median age 68 years) were 
diagnosed with EAC between 2004 and 2012 according to data of the Dutch 
cancer registry [7]. One percent of patients was classified as stage 0 disease, 
14% as stage 1, 16% as stage 2, 23% as stage 3, and 46% as stage 4. EAC was 
diagnosed in a significantly earlier stage during BE surveillance than in the 
general population (P<0.001) (Figure 2).
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Figure 2. Stage of esophageal adenocarcinoma at the time of diagnosis in BE 
patients undergoing surveillance (   ) and in the general Dutch population (   ) 
(p<0.001)
Treatment
During surveillance 10 patients were diagnosed with focal HGD without 
mucosal abnormalities for which they received intensive surveillance. 
Although the initial diagnosis of HGD was confirmed by expert pathologists, 
in none of these patients HGD was confirmed during further follow-up. 
Therefore it was chosen to refrain from endoscopic treatment and follow a 
policy of watchful waiting. The remaining 25 patients with HGD received 
endoscopic treatment. Two patients were treated with PDT, 11 with EMR, 
7 with EMR followed by PDT, and 5 with EMR followed by RFA. One 
patient developed a stenosis after EMR for which dilatation was performed 
and 1 patient had a perforation for which a stent was placed. Five patients 
had recurrence of HGD or early EAC during follow-up for which they 
were treated successfully with EMR and RFA. Of the 12 patients with T1a 
EAC 2 were treated with EMR, 7 with EMR followed by PDT and 2 with 
EMR followed by RFA. One patient died prior to treatment, 1 patient 
developed a stenosis for which dilatation was performed and 2 patients had 
recurrence for which they were treated successfully with EMR and RFA. The 
remaining 6 patients with T1b, T2 or T3 EAC were treated with transhiatal 
esophagectomy, which in 2 patients was complemented by neoadjuvant 
chemoradiotherapy. Two patients developed postoperative anastomotic 
leakage. One patient died due to postoperative complications and two 
patients due to advanced EAC after a median follow-up of 2 years (Figure 3).
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Figure 3. Treatment of patients with neoplastic progression detected during 
surveillance. 
* 1 patient died prior to treatment of a cause not related to Barrett’s esophagus, all 
patients with local recurrence were successfully treated with EMR and RFA 
HGD, high-grade dysplasia; EAC, esophageal adenocarcinoma; PDT, photodynamic 
therapy; EMR, endoscopic mucosal resection; RFA, radiofrequency ablation; THE, 
transhiatal esophagectomy.
Survival
Of all 53 patients with neoplastic progression during surveillance, 12 patients 
(23%) (83% male, median age 73 years) died after a median follow-up of 2 
years (IQR 1-4 years). The all cause 5-year survival of patients with neoplastic 
progression during surveillance was 74% (95% CI 60-87%) and was similar for 
patients in academic and regional hospitals. The 5-year survival was 80% for 
patients with stage 0 disease (n=35), 68% for stage 1 (n=14), and 33% for stage 
2 (n=4). Of the remaining 730 BE patients in the cohort, 100 patients (14%) 
(76% male, median age 78 years) died after a median follow-up of 7 years (IQR 
3-8 years). The all cause 5-years survival of BE patients without neoplastic 
progression was 94% (95% CI 92-96%). Of the 8855 patients with EAC in the 
general population, 6352 patients (72%) (81% male, median age 71 years) died 
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after a median follow-up of 7 months (IQR 3-15 months). The all cause 5-year 
survival of patients with EAC in the Netherlands was 17% (95% CI 16-18%). 
The 5-year survival was 62% for patients with stage 0, 65% for stage 1, 30% for 
stage 2, 14% for stage 3, and 3% for stage 4 (Figure 4). 
The overall survival of BE patients with neoplastic progression during 
surveillance was only slightly (and not statistically significant) worse than 
those of BE patients without neoplastic progression during surveillance (HR 
1.8, 95% CI 0.9-3.3), and similar to those of patients with stage 0 or stage 1 
EAC in the general population (HR 0.8, 95% CI 0.3-1.8 and HR 0.7, 95% CI 
0.4-1.2 respectively).
Figure 4. Cumulative survival of Barrett’s esophagus (BE) patients with neoplastic 
progression during surveillance and patients with different stages of esophageal 
adenocarcinoma (EAC) in the general population.     BE with neoplastic progression 
during surveillance, ∙∙∙ EAC stage 0 
      EAC stage 1, ∙∙∙ EAC stage 2,      EAC stage 3, ∙∙∙ EAC stage 4
Lead and length time bias
To adjust for lead time bias we estimated the sojourn time for EAC based on the 
difference in mean age at EAC diagnosis in BE patients undergoing surveillance 
and patients from the general population (2.2 years). After adjusting for lead 
time bias, the all cause 5-year survival of patients with neoplastic progression 
during BE surveillance was 72% and the overall survival was still similar to 
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those of patients with stage 0 or stage 1 EAC in the general population (HR 0.8, 
95% CI 0.4-1.7 and HR 0.9, 95% CI 0.5-1.6 respectively). To adjust for length 
time bias we performed separate analyses for BE patients with at least stage 1 
EAC. The all cause 5-year survival of patients with EAC during BE surveillance 
was 62% and the overall survival was still similar to those of patients with 
stage 0 or stage 1 EAC in the general population (HR 0.9, 95% CI 0.3-2.4 and 
HR 0.9, 95% CI 0.4-2.1 respectively).
Cause of death
Of the 783 BE patients, 112 patients (14%) died after a median follow-up of 6 
years. The majority of patients died due to malignancies (36%) or cardiovascular 
diseases (29%). Four percent of patients died due to EAC after a median 
follow-up of 2 years. Of all 53 BE patients with neoplastic progression during 
surveillance, 12 patients (23%) died after a median follow-up of 2 years. Two 
patients (17%) died due to cardiovascular diseases, 4 (33%) due to pulmonary 
diseases, and 6 (50%) due to malignancies, among which 3 (25%) due to EAC 
(Table 2). The cause of death for BE patients in our cohort was comparable 
to those of individuals with similar age and gender in the general population.
Table 2. Cause of death in patients with Barrett’s esophagus and the general 
population
Cohort
n = 783
HGD or EAC
n = 53
General Dutch 
population*
Deceased 112 (14%) 12 (23%)
Cardiovascular diseases 32 (29%) 2 (17%) 29 %
Malignant neoplasms 40 (36%) 6 (50%) 36%
  Esophageal cancer 4 (4%) 3 (25%) 2%
Pulmonary diseases 7 (6%) 4 (33%) 10%
(Un)intentional injuries 5 (4%) - 4%
Neuropsychiatric disorders 6 (5%) - 3%
Other 22 (20%) - 18%
HGD, high-grade dysplasia; EAC, esophageal adenocarcinoma  
* Individuals with similar age and gender in the same period
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Discussion
The results of this large multicenter prospective cohort study suggest that 
EAC is detected at an earlier stage during surveillance than in the general 
population, independent of age, gender and year of diagnosis, and that 
endoscopic treatment leads to good survival.
Surveillance is a process of periodic testing in patients at high risk for a certain 
disease. Key elements in the effectiveness of surveillance are whether disease 
is detected at an early and curable stage and whether survival is improved. In 
the present study we showed that EAC was detected at a significantly earlier 
stage during endoscopic BE surveillance than in the general population. Of 
all patients with neoplastic progression during BE surveillance, 92% was 
diagnosed with early EAC (stage 0 or 1), compared to 15% in the general 
population. These results are in line with those of previous retrospective and 
small prospective studies, which reported early EAC in 60-95% of BE patients 
with neoplastic progression during surveillance and 10-40% of patients 
with EAC in the general population [19, 21, 23, 25, 26, 27, 29, 32]. In two 
previous studies surveillance failed to detect early EAC [7, 11]. One of the 
major shortcomings of those studies was that patients were not under strict 
surveillance, which is crucial for the detection of HGD or early EAC. 
In contrast to most previous studies, patients with early EAC in the present 
study received endoscopic treatment instead of esophagectomy, according 
to current guidelines. Since the majority of patients was diagnosed with 
early EAC, most patients were treated endoscopically and only 12% needed 
esophagectomy. After endoscopic treatment 6 (17%) patients had complications 
and 7 (19%) had recurrence of HGD or EAC for which they received additional 
endoscopic treatment. None of the patients with early EAC died due to EAC 
or its treatment. 
The overall 5-year survival was 74% in patients with EAC during BE surveillance 
and 17% in patients with EAC in the general population. Although it is difficult 
to compare survival of both groups due to different types of bias, including lead 
and length time bias, this large difference seems clinically relevant. The results 
correspond to those of previous retrospective and small prospective studies, 
which report an overall 5-year survival of 65-100% in patients with EAC during 
surveillance and 0-30% in patients with symptomatic EAC [6, 10, 15, 17, 18, 
21, 25, 38, 39]. The majority of patients undergoing BE surveillance died due 
to cardiovascular diseases or malignancies and only 4% due to EAC, which 
was comparable to cause of death in individuals with similar age and gender 
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in the general population. One in four patients with EAC during surveillance 
died due to EAC or its treatment. Unfortunately, no information was available 
on cause of death in patients with EAC in the general population. Since the 
cause of death in patients undergoing BE surveillance was comparable to 
those of individuals in the general population, it is likely that excess mortality 
in patients with EAC in the general population is caused by EAC itself or its 
treatment. This idea is supported by data from the Surveillance, Epidemiology, 
and End Results (SEER) database, which shows that approximately half of 
patients with EAC in the United States of America, dies due to EAC or its 
treatment [40]. 
The present study shows that EAC is detected at an early stage during BE 
surveillance, but the cost-effectiveness of BE surveillance is still controversial. 
Several recent studies among which one of our own study group, have shown 
that BE surveillance may be cost-effective with intervals of five years for 
patients with non-dysplastic BE and three years for LGD [41, 42]. Although 
surveillance intervals were shorter in the current study, a minority of patients 
still developed advanced EAC. With prolongation of surveillance intervals, the 
risk of interval carcinomas will increase thereby limiting the protective effect. 
To improve the cost-effectiveness of endoscopic BE surveillance identification 
of additional risk factors is needed [39, 43, 44]. Another possibility to improve 
cost-effectiveness would be a less invasive screening test. 
Our study has several strengths including the large sample size and long 
prospective follow-up. Consecutive BE patients were included presenting at 
the endoscopy unit of three academic and twelve regional hospitals throughout 
the Netherlands, resulting in a cohort that should be representative for the 
Dutch BE population. This is also supported by the annual incidence rate of 
EAC during follow-up of 0.3%, which corresponds to incidence rates reported 
in previous studies [1, 3, 4]. There were strict criteria for BE diagnosis and 
inclusion in the study, such as a BE length of at least two cm, presence of 
intestinal metaplasia in biopsies, and no presence or history of HGD or EAC. 
In addition, there was a stringent follow-up scheme and a standardized 
endoscopy and biopsy protocol. All biopsies were reviewed by at least two 
pathologists to obtain a diagnosis based on consensus. Surveillance and 
treatment of patients with neoplastic progression was performed according 
to current guidelines, which include endoscopic treatment modalities and 
neoadjuvant chemoradiotherapy for advanced EAC. Survival data were 
collected prospectively and were cross-checked using death registries and 
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municipal administrations.
Our study also has some limitations. Studies evaluating the effect of surveillance 
may be subject to lead and length time bias [45]. When improved survival 
is based on earlier detection during surveillance rather than postponement 
of death this is called lead time bias. Length time bias refers to the fact that 
surveillance enables the detection of less aggressive disease with a mild 
course and thereby better survival. Thus even in the absence of a true effect 
of surveillance it may improve survival due to lead and length time bias. Lead 
time bias is unlikely to affect the results of our study since improved survival 
was seen until ten years after diagnosis, while the median survival of patients 
with symptomatic EAC was only eleven months. To consider lead and length 
time bias as much as possible we performed additional analyses in which we 
estimated the sojourn time for EAC based on difference in mean age at EAC 
diagnosis and excluded patients with HGD, which had no major effect on the 
results. 
Unfortunately we were unable to adjust for differentiation grade, since this 
information was not available for the majority of patients with EAC in the 
general population.  
Despite our efforts to consider different types of bias as much as possible, 
we cannot excluded uncontrolled confounding. A randomized controlled trial 
would be the ideal way to investigate the effect of endoscopic BE surveillance 
on survival. Although not impossible, it would be difficult to perform such 
a trial since only a small proportion of patients with EAC is previously 
known with BE. An alternative would be to perform an observational study 
including both BE patients undergoing surveillance and BE patients not under 
surveillance. Unfortunately, all patients participating in our prospective study 
received endoscopic surveillance and as a result we were only able to compare 
our data to those of patients with EAC in the general population.  
We compared the pathological stage and survival of patients with neoplastic 
progression during BE surveillance to those of patients with EAC in the general 
population based on data from the Dutch cancer registry. Since patients are 
included in this registry based on a clinical or pathological diagnosis of cancer, 
there is underreporting of HGD. However, since most patients were diagnosed 
with advanced EAC we assume this is not a major source for bias. 
During surveillance 10 BE patients were diagnosed with focal HGD without 
mucosal abnormalities and although this diagnosis was confirmed by 
expert pathologists, in none of these patients HGD was confirmed during 
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further follow-up. An important question is whether this is the result of 
misclassification or is a reflection of the natural history of focal HGD, since 
this may result in overtreatment of patients with focal HGD. 
Unfortunately, the Dutch cancer registry provides no information on previous 
participation in surveillance. It is therefore possible that some patients 
in the control group had previous surveillance, which may result in an 
underestimation of the surveillance effect. In addition the register provides 
no information on cause of death in patients with EAC. 
Finally, we only included patients with BE of at least two cm in the study and 
therefore our results cannot be applied universally to all BE patients. Since 
longer BE length is associated with a higher risk of neoplastic progression we 
believe that our cohort is representative for the patients who are most likely to 
benefit from surveillance. 
In conclusion, this study suggests that regular endoscopic surveillance of 
BE patients enables the detection of EAC at an early and curable stage when 
endoscopic treatment is still feasible and leads to good survival. The results 
of this study therefore support current guidelines recommending endoscopic 
surveillance in patients with BE.
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Abstract
Introduction: Neoadjuvant chemoradiotherapy (nCRT) followed by 
surgery has become standard of care for esophageal adenocarcinoma (EAC). 
However, the response to nCRT is highly variable among patients. The aim 
of this study was to investigate the association between p53, SOX2 and CD44 
protein expression and tumor response, and to validate potential predictive 
biomarker(s) in an independent cohort.
Methods: EAC patients who underwent nCRT plus surgery, between January 
2003 and December 2014 at the Erasmus University Medical Center, were 
included and divided into a primary(n=77) and validation cohort(n=70). 
P53, SOX2 and CD44 expression was detected by immunohistochemistry in 
pretreatment tumor biopsies and scored independently by two investigators. 
Response to nCRT was assessed based on tumor regression grade (TRG) in 
the resection specimen.
Results: Forty-one(53%) patients in the primary cohort and 33(47%) patients 
in the validation cohort showed major response (TRG1 or TRG2) in the 
resection specimen. Aberrant p53 and absence of SOX2 were associated with 
major response in the primary cohort; adjusted odds ratio(OR) 6.3 (95%CI 
1.3–30.1) and adjusted OR 4.1 (95%CI 1.4–12.4), respectively. The same was 
true for the validation cohort (p53: adjusted OR 8.6; 95%CI 0.93-80.9 and 
SOX2: adjusted OR 6.1; 95%CI 1.6-23.4). The highest probability of a major 
response was seen in patients with concurrent aberrant p53 and absence of 
SOX2 expression, with an OR of 6.7 (95%CI: 2.1-21.4) and 6.2 (95%CI: 1.8-
21.2) in the primary and validation cohort.
Conclusions: Pattern of p53 and particularly SOX2 protein expression in 
EAC predicts response to nCRT. These biomarkers may help to individualize 
treatment in EAC patients.
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Introduction
Over the past decades, the incidence of esophageal adenocarcinoma (EAC) 
has increased rapidly in the United States and Western Europe [1, 2]. The 
5-year overall survival after surgery rarely exceeds 40% and early recurrence is 
common [2, 3]. Neoadjuvant chemoradiotherapy (nCRT) followed by surgery 
has recently become standard of care for locally advanced esophageal cancers 
(EC) and achieves a 5-year overall survival benefit of 10-15% compared to 
surgery alone [4, 5]. 
However, response to nCRT is variable, even among patients with a similar 
disease stage. In the Dutch CROSS trial nearly 25% of the patients with an EAC 
in the multimodality arm showed a pathological complete response (pCR; i.e. 
no viable tumor cells) and another 36% of the patients showed a near-complete 
response (1%-10% residual tumor cells) in the resection specimen [4]. Surgical 
resection, immediately after nCRT, is still considered the cornerstone of 
intentionally curative treatment for EC, although associated with significant 
morbidity and substantial impact on the quality of life [6, 7]. If clinicians were 
able to accurately identify (near-)complete responders, prior to surgery, these 
patients might be candidates to postpone or even omit surgical resection. 
In addition, patients without substantial pathological response do not seem 
to benefit from nCRT but experience unnecessary side-effects and curative 
surgery is delayed [8, 9].
Several studies have tried to assess the response to nCRT using conventional 
endoscopy with biopsy sampling, endoscopic ultrasonography (EUS), 
computed tomography (CT) and positron emission tomography (PET), but 
results have been mainly disappointing [10, 11, 12, 13]. Use of predictive 
biomarkers could improve the ability to predict tumor response and may 
facilitate individualization of treatment.
The tumor suppressor gene p53 has been identified as an important molecular 
factor associated with tumor tolerance to chemotherapy and radiation in patients 
with EC [14, 15, 16]. However, there is no general consensus on the predictive 
value of p53 status for therapy response. Other potential biomarkers are SOX2 
and CD44, both linked to cancer stem cells (CSCs), a small population of cells, 
found to be more resistant to chemo- and radiotherapy in various malignant 
tumor types [17, 18]. SOX2 is a transcription factor, related to CSCs and 
embryonic stem cells, involved in formation and differentiation of esophageal 
and gastric epithelium [19, 20]. SOX2 expression has been associated with 
both chemo- and radiotherapy resistance in several malignancies, including 
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breast cancer and oral squamous cell cancer [21, 22, 23]. CD44 is a membrane 
glycoprotein involved in cell adhesion and associated with CSCs in gastric and 
colon cancer [24, 25]. High CD44 expression has been suggested as possible 
marker of CSCs in EC and may play a role in radiotherapy resistance [26]. 
Their expression and possible relation with response to nCRT in EAC has 
barely been investigated. Based on these promising previous publications and 
our experience with staining and scoring of the selected biomarkers the aim of 
our study was (I) to investigate the association between p53, SOX2 and CD44 
protein expression in pretreatment tumor biopsies and extent of pathological 
tumor response in the resection specimen of patients with EAC treated with 
nCRT and (II) to validate potential predictive biomarker(s) for therapy 
response in an independent cohort of EAC patients treated with nCRT.
Methods
Patients and clinical staging
All consecutive patients with histologically proven EAC who received at least 
80% nCRT according to the CROSS regimen followed by esophagectomy, 
between January 2002 and December 2014 at the Erasmus University Medical 
Center were eligible for inclusion in the study. Sufficient and representative 
material of the pretreatment tumor biopsies and resection specimen had to 
be available. The total cohort of patients who met the selection criteria was 
divided into a primary and validation cohort based on surgical date (primary 
cohort surgical date between January 2002 and September 2009, and 
validation cohort between October 2009 and December 2014). Pretreatment 
clinical TNM (cTNM) staging included upper gastrointestinal endoscopy 
with biopsies; EUS (with fine needle aspiration (FNA) when indicated); CT 
of the neck, chest and abdomen; and external ultrasonography of the neck 
with FNA in case of suspected lymph nodes. In patients with a high suspicion 
of metastatic disease a PET-CT was done as well. Tumors were (re-)staged 
according the 7th UICC-AJCC TNM staging manual [27].
Neoadjuvant treatment and surgery
All patients received nCRT according to the CROSS regimen which consisted 
of carboplatin (targeted area under the curve = 2) and paclitaxel (50 mg/
m2) administered by intravenous infusion on day 1, 8, 15, 22 and 29 with 
concurrent external beam radiation with a total dose of 41.4 Gy, given in 23 
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fractions of 1.8 Gy, 5 fractions a week [4]. Esophagectomy was scheduled 4 to 
6 weeks after completion of nCRT. For tumors of the intrathoracic esophagus 
and for junctional tumors with positive lymph nodes at or above the carina, a 
transthoracic resection with a two-field lymph node dissection was performed. 
For tumors involving the gastro-esophageal junction, a transhiatal resection 
was the preferred technique. A lymphadenectomy of the nodes along the celiac 
axis and its branches was performed in both approaches.
Assessment of treatment response
All pretreatment tumor biopsies and resection specimens (entire primary 
tumor and all resected lymph nodes) were evaluated by a standardized 
protocol [28]. Pathological T-stage and N-stage were classified according to 
the UICC TNM Cancer Staging , 7th edition [29].
In addition, different aspects of tumor response were measured, pathological 
tumor downstaging and overall tumor regression grade (TRG). For the 
assessment of the pathological tumor and node downstaging, the initial tumor 
area, before nCRT, was estimated based on the extent of regressional changes 
(e.g., fibrosis, keratin pearls, mucous lakes and/or foreign body cell reactions) 
and on the residual tumor cells in the resection specimen, as has been 
described previously [30, 31]. These measurements were expressed as prepT 
and prepN, reflecting the assumed original depth of the primary tumor and 
the assumed number of originally involved lymph nodes, respectively. PrepT 
and prepN were compared with the eventual pathological ypT and ypN stage 
in the resection specimen after nCRT. In case of N-downstaging, patients with 
N0 stage before and after nCRT were excluded. 
The TRG was evaluated using the modified Mandard scoring system [32]. The 
extent of tumor regression was subdivided in four categories; TRG1: no viable 
tumor cells; TRG 2: between 1% and 10%; TRG 3: between 11% and 50%; TRG 
4: more than 50% residual tumor cells. Patients with TRG 1 or TRG 2 response 
were classified as major responders (i.e., ≤ 10% of tumor cells remaining), 
whereas patients with TRG 3 or TRG 4 response were classified as minor 
responders (i.e., > 10% of tumor cells remaining) [33, 34].
Immunohistochemistry
Sections of 5 mm thickness from paraffin blocks of the complete series 
of pretreatment tumor biopsies of all included patients were used. 
Immunohistochemical staining for p53 was performed as a single batch 
as previously described, using the primary antibody (Clone DO-7, Dako, 
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Glostrup, Denmark: mouse monoclonal) with a dilution of 1:25 [35]. For SOX2 
and CD44 immunohistochemistry, paraffin-embedded tissue sections were 
deparaffinized in xylene and rehydrated in graded alcohols. Antigen retrieval 
was enhanced by heating in Tris buffer and endogenous peroxidase activity 
was blocked by incubating the slides in a solution of 0.3% hydrogen peroxide 
in phosphate-buffered saline. Primary antibodies, SOX2 (AF2018, dilution 
1:800, R&D systems, Abingdon, United Kingdom: goat, polyclonal) and CD44 
(clone IM7, dilution 1:1000, BD Biosciences) were applied for 22 hours at 4 
degrees Celsius. As for p53, the same batch of SOX2 and CD44 antibodies were 
used for all included slides. As secondary antibody, a biotinylated horse anti-
goat IgG antibody (1:150; BA-950, Vector, Peterborough, United Kingdom) and 
rabbit anti-rat IgG antibody (1:150; BA-4000, Vector, Peterborough, United 
kingdom) were used. Visualization was achieved by using the horseradish 
peroxidase avidin-biotin complex (HRP-ABC) method and diaminobenzidine 
(DAB). Finally, the slides were counterstained with haematoxylin. A sample of 
testicular embryonal carcinoma was used as positive control for SOX2 and a 
sample of tonsil with squamous epithelium for CD44 [36, 37]. 
Scoring of immunohistochemistry
Immunohistochemically stained slides were examined in tandem with 
the haematoxylin-eosin stained slides to determine p53, SOX2 and CD44 
expression in tumor cells. P53 expression was scored on a three-point scale; 
normal expression, overexpression or loss of expression [35, 38]. Only intense 
nuclear staining for p53 was scored as overexpression (see Figure 1 for a 
representative example). Weak nuclear positivity in tumor cells, comparable 
to the expression in non-neoplastic squamous epithelium was interpreted 
as normal and complete loss of nuclear p53 staining was defined as negative 
expression. Aberrant p53 expression was defined as either overexpression or 
complete loss of expression in >50% of the tumor cells: this cut-off was chosen 
based on previous literature and our experience in assessment of p53 staining 
[35, 39]. Nuclear SOX2 and membranous CD44 expression was scored on a 
two-point scale; positive or absence of expression. As previously described in 
esophageal tissue and germ cell malignancies, strong as well as weak nuclear 
staining, but not cytoplasmatic SOX2 expression was interpret as positive 
(see Figure 1 for a representative example) [36, 38]. The most optimal cut-off 
values for SOX2 and CD44 immunohistochemical scoring to predict therapy 
response were calculated by ROC-curve analysis in the primary cohort, using 
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the area under the curve (AUC) as the performance measure. Based on these 
ROC-curve analyses, aberrant SOX2 expression was defined as absence of 
SOX2 expression in >50% of the tumor cells, whereas positive CD44 expression 
was defined as membranous CD44 expression of at least one tumor cell. All 
stained slides were scored independently by two investigators (KB and SvO) 
who were blinded for clinical outcome. In case of disagreement between the 
two investigators, slides were reviewed by both investigators simultaneously 
to reach a consensus diagnosis.
Figure 1. Representative immunohistochemical stained slides of SOX2 negative 
nuclear expression (A), SOX2 positive nuclear expression (insert), loss of p53 
expression (B) and p53 overexpression (insert) in esophageal adenocarcinoma tissue 
(A-B). Magnification 1:100 A-B, magnification 1:200 inserts.
Ethics
This study was performed on microscopy slides and tissue as used and obtained 
during regular patient diagnostics. The Ethics council of the Erasmus Medical 
Center approves research conducted on diagnostic tissue, without special 
permission. Therefore, no additional ethical approval was required.
Statistical analysis
To evaluate the associations with TRG response and TN-downstaging, clinical, 
pathological and biomarker data were compared using Kruskal-Wallis tests 
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for continuous variables and Pearson chi-square tests or Fisher exact test 
for categorical variables. TRG major response was defined as TRG1 or TRG2 
response in the resection specimen (≤ 10% of tumor cells remaining) whereas 
TRG minor response was defined as TRG3 or TRG 4 response (> 10% of 
tumor cells remaining). The value of p53 and SOX2 immunohistochemistry 
to predict TRG major response was estimated in logistic regression models. In 
multivariable models we adjusted for age, gender, tumor grade, pretreatment 
clinical T-stage and pretreatment clinical N-stage to estimate adjusted odds 
ratios (ORs) and 95% Confidence Intervals (CIs). Interobserver agreement for 
p53 and SOX2 protein expression was determined using Cohen K statistics. 
Two sided P values of <0.05 were considered statistically significant. Data 
were analyzed using SPSS statistical software (V.21.0; SPSS, Chicago, IL, 
USA).
Results
Patients and histopathological characteristics
In total, 258 patients with EAC who received at least 80% nCRT were eligible 
for inclusion in the study. Of these, 26 patients did not undergo resection 
and in 85 additional patients not enough representative pretreatment tumor 
biopsies and/or resection specimen tissue was available, leaving 147 to be 
included in the study. These 147 patients who met all the selection criteria 
were subdivided into a primary (n=77) and validation cohort (n=70) (see 
Table 1 for characteristics). Median age at diagnosis was 64 years (IQR 57-70), 
predominantly male (88%). Clinical staging revealed most often cT3 (77%), 
cN+ (69%) also pathological staging revealed most often prepT3 (86%) and 
prepN+ (57%). Median time between nCRT and subsequent surgical resection 
was 50 days (IQR 39 – 65 days). The overall distribution of TRG response 
was TRG1 = 32 (22%), TRG2 = 42 (29%), TRG3 = 43 (29%) and TRG4 = 30 
(20%). Aberrant p53 expression and absence of SOX2 expression was seen 
in 85% (125/147) and 59% (87/147), respectively. Interobserver agreement 
for both markers was good with a kappa-value of 0.79 (95% CI: 0.74-0.83) 
for p53 expression and a kappa-value of 0.73 (95% CI: 0.67-0.78) for SOX2 
expression. Expression of CD44 was only stained and scored in the primary 
cohort, in which 50 patients (65%) showed a positive CD44 expression (Table 
1).
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Table 1. Baseline and histopathological characteristics of primary and validation 
cohort
Variable
Total
n = 147
Primary cohort
n = 77
Validation 
cohort
n = 70
P value
Age
  Median, years (IQR) 64 (57 - 70) 61 (55 - 70) 64 (58 - 69) 0.392
Gender
  Woman 18 (12%) 10 (13%) 8 (11%) 0.773
  Men 129 (88%) 67 (87%) 62 (89%)
Median time between nCRT and 
surgery, days (IQR)
50 (39 - 65) 50 (34 - 62) 50 (40 - 70) 0.212
Grade of differentiation
  Well 10 (7%) 8 (10%) 2 (3%) 0.104
   Moderate 83 (56%) 45 (59%) 38 (54%)
  Poor 54 (37%) 24 (31%) 30 (43%)
cT-stagea
  cT1 5 (3%) 3 (4%) 2 (3%) 0.253
  cT2 29 (20%) 19 (25%) 10 (14%)
  cT3 113 (77%) 55 (71%) 58 (83%)
cN-stagea
  cN0 46 (31%) 28 (36%) 18 (26%) 0.163
  cN1 55 (37%) 31 (40%) 24 (34%)
  cN2 42 (29%) 16 (21%) 26 (37%)
  cN3 4 (3%) 2 (3%) 2 (3%)
PrepT-stageb
  prepT1/T2 21 (14%) 9 (12%) 12 (17%) 0.327
  prepT3 125 (86%) 68 (88%) 57 (83%)
prepN-stageb
  prepN0 62 (42%) 37 (48%) 25 (36%) 0.342
  prepN1 62 (42%) 29 (38%) 33 (48%)
  prepN2/N3 22 (15%) 11 (14%) 11 (16%)
ypT-stagec
  ypT0 36 (24%) 17 (22%) 19 (27%) 0.095
  ypT1 22 (15%) 17 (22%) 5 (7%)
  ypT2 28 (19%) 12 (16%) 16 (23%)
  ypT3 60 (41%) 30 (39%) 30 (43%)
  ypT4a 1 (1%) 1 (1%) 0 (0%)
ypN-stagec
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Variable
Total
n = 147
Primary cohort
n = 77
Validation 
cohort
n = 70
P value
  yNo 95 (65%) 57 (74%) 38 (55%) 0.012
  yN+ 52 (35%) 20 (26%) 32 (45%)
Median number of lymph nodes 
resected (IQR)
15 (11-21) 13 (10-19) 17 (13-22) <0.001
Total number tumor positive 
lymph nodes resected 
146 48 98
Radicalityd
  R0 135 (92%) 73 (95%) 62 (89%) 0.168
  R1 12 8%) 4 (5%) 8 (11%)
TRGe
  TRG 1 32 (22%) 15 (19%) 17 (24%) 0.532
  TRG 2 42 (29%) 26 (34%) 16 (23%)
  TRG 3 43 (29%) 21 (27%) 22 (31%)
  TRG 4 30 (20%) 15 (20%) 15 (22%)
P53 expression
  Normal 22 (15%) 13 (17%) 9 (13%) 0.111
  P53 overexpression 88 (60%) 40 (52%) 48 (69%)
  Loss of expression 37 (25%) 24 (31%) 13 (18%)
SOX2 expression
  Positive 60 (41%) 33 (43%) 27 (39%) 0.597
  Absence of expression 87 (59%) 44 (57%) 43 (61%)
CD44 expression
  Positive 50 (65%) 50 (65%) - -
  Absence of expression 21 (27%) 21 (27%) -
Missing 6 (8%) 6 (8%) -
Kruskall-Wallis test and Pearson chi-square test or Fisher exact test were used to compare the 
characteristics of primary and validation cohort. 
a Pretreatment T and N-stages as defined by endoscopic ultrasonography 
b Preoperative T and N-stage estimated based on the extent of regressional changes (eg, fibrosis, keratin 
pearls, mucous lakes and/or foreign body cell reactions) and on the residual tumor cells in the resection 
specimen. 
c Pathological T and N-stage in the resection specimen after neoadjuvante chemoradiotherapy according 
to UICC TNM Cancer Staging, 7th edition. 
d R0 was defined as a tumor-free resection margin ≥1 mm. R1 was defined as a macroscopically radical 
resection, with a microscopically tumor-free resection margin of < 1 mm. 
e Tumor regression grade (TRG) was defined as; TRG1: no residual tumor cells found; TRG2: 1-10% 
residual tumor cells; TRG3: 11-50% residual tumor cells; TRG4: >50% residual tumor cells. 
Abbreviation: IQR, interquartile range
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TRG response
Primary cohort
Forty-one (53%) of the 77 patients had a major pathological response (TRG 
1-2) in the resection specimen after nCRT, whereas 36 (47%) patients had a 
minor response (TRG 3-4). Aberrant p53 expression and absence of SOX2 
expression were more common in samples of patients with a major response 
than in patients with a minor response (p53; 93% vs 72%, p value 0.017 and 
SOX2; 71% vs 42%, p value 0.010) (Table 2). Aberrant p53 expression was 
significantly associated with a major response with an OR of 4.9 (95% CI: 
1.2–19.4; p value 0.025), even after adjusting for age, gender, tumor grade, 
pretreatment clinical T-stage and pretreatment clinical N-stage (adjusted OR 
of 6.3; 95% CI: 1.3–30.1; p value 0.02). Also, absence of SOX2 expression was 
significantly associated with major response with an OR 3.4 (95% CI: 1.3-8.7; 
p value 0.011) and adjusted OR of 4.1 (95% CI: 1.4–12.4; p value 0.012) (Table 
3).
In addition, the combination of both biomarkers showed that aberrant p53 with 
concurrent absence of SOX2 expression was seen in 26 (63%) patients with a 
major response but in only 9 (25%) patients with a minor response (Table 2). 
Aberrant expression of both biomarkers increased the probability of a major 
response in the individual patient (adjusted OR of 6.7; 95% CI: 2.1–21.4; p 
value 0.001) with a sensitivity of 63%, specificity of 75%, positive predictive 
value (PPV) of 74% and a negative predictive value (NPV) of 64% (Tables 3 
and 4). Evaluation of CD44 expression in the pretreatment tumor biopsies 
showed only a trend of increased possibility in case of absence of expression 
(p value 0.112). None of the included clinicopathological characteristics were 
statistically significantly associated with TRG response (Table 2).
proefschrift_def.indd   133 20/04/2017   20:02
134
Chapter 7
Ta
bl
e 
2.
 C
lin
ic
op
at
ho
lo
gi
ca
l c
ha
ra
ct
er
is
tic
s a
nd
 b
io
m
ar
ke
r e
xp
re
ss
io
n 
ac
co
rd
in
g 
to
 T
R
G
 re
sp
on
se
TR
G
 r
es
po
ns
e 
pr
im
ar
y 
co
ho
rt
TR
G
 r
es
po
ns
e 
va
lid
at
io
n 
co
ho
rt
V
ar
ia
bl
e
M
aj
or
 n
 =
 4
1
M
in
or
 n
 =
 3
6
P 
V
al
ue
M
aj
or
 n
 =
 3
3
M
in
or
 n
 =
 3
7
P 
V
al
ue
A
ge
M
ed
ia
n
, y
ea
rs
 (
IQ
R
)
62
 (
56
-6
9)
60
 (
55
-7
1)
0
.9
67
65
 (
58
-7
0
)
64
 (
57
-6
9)
0
.4
69
 
G
en
de
r
W
om
an
6 
(1
5%
)
4 
(1
1%
)
0
.7
42
5 
(1
5%
)
3 
(8
%
)
0
.4
62
M
en
35
 (
8
5%
)
32
 (
8
9%
)
28
 (
8
5%
)
34
 (
92
%
)
M
ed
ia
n 
ti
m
e 
be
tw
ee
n 
nC
R
T 
an
d 
su
rg
er
y,
 d
ay
s 
(I
Q
R
)
50
 (
34
-6
1)
51
 (
41
-6
6)
0
.4
0
5 
54
 (
42
-6
7)
49
 (
39
-7
3)
0
.6
13
Tu
m
or
 g
ra
de
W
el
l-
di
ff
6 
(1
4%
)
2 
(6
%
)
0
.3
92
1 
(3
%
)
1 
(3
%
)
0
.3
69
M
od
er
at
el
y-
di
ff
22
 (
54
%
)
23
 (
64
%
)
15
 (
46
%
)
23
 (
62
%
)
P
oo
rl
y-
di
ff
13
 (
32
%
)
11
 (
30
%
)
17
 (
51
%
)
13
 (
35
%
)
cT
-s
ta
ge
 a ,
 b
cT
1
2 
(5
%
)
1 
(3
%
)
0
.7
72
2 
(6
%
)
0
 (
0
%
)
0
.2
93
cT
2
9 
(2
2%
)
10
 (
28
%
)
4 
(1
2%
)
6 
(1
6%
)
cT
3
30
 (
73
%
)
25
 (
69
%
)
27
 (
8
2%
)
31
 (
8
4%
)
cN
 s
ta
ge
a
cN
0
15
 (
37
%
)
13
 (
36
%
)
0
.9
47
8
 (
24
%
)
10
 (
27
%
)
0
.9
30
cN
1
17
 (
41
%
)
14
 (
39
%
)
12
 (
36
%
)
12
 (
32
%
)
cN
2/
3
9 
(2
2%
)
9 
(2
5%
)
13
 (
39
%
)
15
 (
41
%
)
Pr
ep
T-
st
ag
ec
pr
ep
T
1/
T
2
7 
(1
7%
)
2 
(6
%
)
0
.1
62
8
 (
24
%
)
4 
(1
1%
)
0
.1
51
pr
ep
T3
34
 (
8
3%
)
34
 (
94
%
)
25
 (
76
%
)
32
 (
8
9%
)
Pr
ep
N
-s
ta
ge
 c
pr
ep
N
0
20
 (
49
%
)
17
 (
47
%
)
0
.4
48
15
 (
46
%
)
10
 (
28
%
)
0
.2
94
pr
ep
N
1
17
 (
41
%
)
12
 (
33
%
)
14
 (
42
%
)
19
 (
53
%
)
proefschrift_def.indd   134 20/04/2017   20:02
135
p53 and SOX2 expression in esophageal adenocarcinoma
7
TR
G
 r
es
po
ns
e 
pr
im
ar
y 
co
ho
rt
TR
G
 r
es
po
ns
e 
va
lid
at
io
n 
co
ho
rt
V
ar
ia
bl
e
M
aj
or
 n
 =
 4
1
M
in
or
 n
 =
 3
6
P 
V
al
ue
M
aj
or
 n
 =
 3
3
M
in
or
 n
 =
 3
7
P 
V
al
ue
pr
ep
N
2/
3
4 
(1
0
%
)
7 
(2
0
%
)
4 
(1
2%
)
19
 (
53
%
)
P5
3 
ex
pr
es
si
on
N
or
m
al
3 
(7
%
)
10
 (
28
%
)
0
.0
17
1 
(3
%
)
8
 (
22
%
)
0
.0
20
Ab
er
ra
nt
 e
xp
re
ss
io
nd
38
 (
93
%
)
26
 (
72
%
)
32
 (
97
%
)
29
 (
78
%
)
SO
X
2 
ex
pr
es
si
on
Po
si
tiv
e
12
 (
29
%
)
21
 (
58
%
)
0
.0
17
8
 (
24
%
)
19
 (
51
%
)
0
.0
20
Ab
se
nc
e 
of
 e
xp
re
ss
io
n
29
 (
71
%
)
15
 (
42
%
)
25
 (
76
%
)
18
 (
48
%
)
C
D
44
 e
xp
re
ss
io
n
Po
si
tiv
e
23
 (
56
%
)
27
 (
75
%
)
0
.1
12
-
-
-
Ab
se
nc
e 
of
 e
xp
re
ss
io
n
14
 (
34
%
)
7 
(1
9%
)
-
-
M
is
si
ng
4 
(1
0
%
)
2 
(6
%
)
-
-
N
um
be
r 
of
 a
be
rr
an
t 
bi
om
ar
ke
rs
e
0
 o
r 
1 
ab
er
ra
n
t b
io
m
ar
ke
r
15
 (
37
%
)
27
 (
75
%
)
<
0
.0
0
1
9 
(2
7%
)
22
 (
60
%
)
0
.0
0
9
2 
ab
er
ra
nt
 b
io
m
ar
ke
rs
26
 (
63
%
)
9 
(2
5%
)
24
 (
73
%
)
15
 (
40
%
)
K
ru
sk
al
l-
W
al
lis
 te
st
 a
n
d 
P
ea
rs
on
 c
hi
-s
qu
ar
e 
te
st
 o
r 
F
is
he
r 
ex
ac
t t
es
t w
er
e 
us
ed
 to
 c
om
pa
re
 th
e 
ch
ar
ac
te
ri
st
ic
s 
of
 p
at
ie
n
ts
 w
it
h 
m
aj
or
 r
es
po
n
se
 a
n
d 
pa
tie
nt
s w
ith
 m
in
or
 re
sp
on
se
. 
a  P
re
tr
ea
tm
en
t T
 a
n
d 
N
-s
ta
ge
s 
as
 d
efi
n
ed
 b
y 
en
do
sc
op
ic
 u
lt
ra
so
n
og
ra
ph
y 
b  W
he
n
 w
e 
 lo
ok
 a
t t
he
 a
ss
oc
ia
ti
on
 b
et
w
ee
n
 c
T
-s
ta
ge
 a
n
d 
co
m
pl
et
e 
pa
th
ol
og
ic
al
 r
es
po
n
se
 (
T
R
G
1)
 v
er
su
s 
al
l p
at
ie
n
ts
 w
it
h 
a 
T
R
G
 2
-3
-4
 r
es
po
n
se
 a
 
si
gn
ifi
ca
n
t a
ss
oc
ia
ti
on
 w
as
 o
bs
er
ve
d 
(p
 v
al
ue
 0
.0
3)
. 
c  P
re
op
er
at
iv
e 
T
 a
n
d 
N
-s
ta
ge
 e
st
im
at
ed
 b
as
ed
 o
n
 th
e 
ex
te
n
t o
f r
eg
re
ss
io
n
al
 c
ha
n
ge
s 
(e
g,
 fi
br
os
is
, k
er
at
in
 p
ea
rl
s,
 m
uc
ou
s 
la
ke
s 
an
d/
or
 fo
re
ig
n
 b
od
y 
ce
ll 
re
ac
ti
on
s)
 a
n
d 
on
 th
e 
re
si
du
al
 tu
m
or
 c
el
ls
 in
 th
e 
re
se
ct
io
n
 s
pe
ci
m
en
. 
d  A
be
rr
an
t p
53
 e
xp
re
ss
io
n
 w
as
 d
efi
n
ed
 a
s 
ei
th
er
 o
ve
re
xp
re
ss
io
n
 o
r 
co
m
pl
et
e 
lo
ss
 o
f e
xp
re
ss
io
n
. 
e  A
be
rr
an
t b
io
m
ar
ke
r e
xp
re
ss
io
n 
in
cl
ud
ed
 a
be
rr
an
t p
53
 e
xp
re
ss
io
n 
an
d 
ab
se
nc
e 
of
 S
O
X
2 
ex
pr
es
si
on
 
A
bb
re
vi
at
io
n
s:
 T
R
G
, T
um
or
 R
eg
re
ss
io
n
 G
ra
de
; I
Q
R
, i
n
te
rq
ua
rt
ile
 r
an
ge
.
proefschrift_def.indd   135 20/04/2017   20:02
136
Chapter 7
Ta
bl
e 
3.
 R
es
ul
ts
 o
f u
ni
- a
nd
 m
ul
tiv
ar
ia
te
 lo
gi
st
ic
 re
gr
es
si
on
 a
na
ly
si
s o
f b
io
m
ar
ke
r e
xp
re
ss
io
n 
to
 p
re
di
ct
 T
R
G
 m
aj
or
 
re
sp
on
se
 in
 p
ri
m
ar
y 
an
d 
va
lid
at
io
n 
co
ho
rt
.
Pr
im
ar
y 
co
ho
rt
V
al
id
at
io
n 
co
ho
rt
U
ni
va
ri
at
e 
an
al
ys
is
M
ul
ti
va
ri
at
e 
an
al
ys
is
a
U
ni
va
ri
at
e 
an
al
ys
is
M
ul
ti
va
ri
at
e 
an
al
ys
is
a
V
ar
ia
bl
e
O
R
95
%
 C
I
P 
V
al
ue
O
R
95
%
 C
I
P 
V
al
ue
O
R
95
%
 C
I
P 
V
al
ue
O
R
95
%
 C
I
P 
V
al
ue
P5
3 
ex
pr
es
si
on
N
or
m
al
1.
0
1.
0
1.
0
1.
0
Ab
er
ra
nt
 e
xp
re
ss
io
nb
4.
9
1.
2 
- 1
9
0
.0
25
6.
3
1.
3 
- 
30
0
.0
20
8.
8
1.
0
4 
- 
75
0
.0
46
8
.6
0
.9
3 
- 
8
1
0
.0
58
SO
X
2 
ex
pr
es
si
on
Po
si
tiv
e
1.
0
1.
0
1.
0
1.
0
Ab
se
nc
e 
of
 e
xp
re
ss
io
n
3.
4
1.
3 
- 8
.7
0
.0
11
4.
1
1.
4 
- 
12
0
.0
12
3.
3
1.
2 
- 9
.2
0
.0
22
6.
1
1.
6 
- 
23
0
.0
0
8
N
um
be
r 
of
 a
be
rr
an
t 
bi
om
ar
ke
rs
c
0
 o
r 
1 
bi
om
ar
ke
r
1.
0
1.
0
1.
0
1.
0
2 
 b
io
m
ar
ke
rs
5.
2
1.
9 
- 
14
0
.0
0
1
6.
7
2.
1 -
 2
1
0
.0
0
1
3.
9
1.
4 
- 
11
0
.0
0
8
6.
2
1.
8 
- 2
1
0
.0
0
4
a  A
dj
us
te
d 
fo
r a
ge
, g
en
de
r, 
tu
m
or
 g
ra
de
, p
re
tr
ea
tm
en
t c
lin
ic
al
 T
-s
ta
ge
 a
nd
 p
re
tr
ea
tm
en
t c
lin
ic
al
 N
-s
ta
ge
  
b  A
be
rr
an
t p
53
 e
xp
re
ss
io
n
 w
as
 d
efi
n
ed
 a
s 
ei
th
er
 o
ve
re
xp
re
ss
io
n
 o
r 
co
m
pl
et
e 
lo
ss
 o
f e
xp
re
ss
io
n
 
c  A
be
rr
an
t b
io
m
ar
ke
r e
xp
re
ss
io
n 
in
cl
ud
ed
 a
be
rr
an
t p
53
 e
xp
re
ss
io
n 
an
d 
ab
se
nc
e 
of
 S
O
X
2 
ex
pr
es
si
on
. 
L
og
is
ti
c 
re
gr
es
si
on
 m
od
el
s 
w
er
e 
us
ed
 to
 c
al
cu
la
te
 o
dd
s 
ra
ti
os
 (
O
R
s)
 a
n
d 
co
n
fid
en
ce
 in
te
rv
al
s 
(C
Is
) 
fo
r 
pr
ob
ab
ili
ty
 o
f a
 m
aj
or
 r
es
po
n
se
 a
ft
er
 n
C
R
T
proefschrift_def.indd   136 20/04/2017   20:02
137
p53 and SOX2 expression in esophageal adenocarcinoma
7
Ta
bl
e 
4.
 R
es
ul
ts
 o
f p
53
 a
nd
 S
O
X
2 
ex
pr
es
si
on
 a
s t
es
t f
or
 p
re
di
ct
in
g 
m
aj
or
 T
R
G
 re
sp
on
se
 in
 E
AC
 p
at
ie
nt
s t
re
at
ed
 w
ith
 
ne
oa
dj
uv
an
t c
he
m
or
ad
io
th
er
ap
y. S
en
si
ti
vi
ty
 (%
)
S
p
ec
ifi
ci
ty
 (
%
)
PP
V
 (%
)
N
PV
 (%
)
E
ffi
ci
en
cy
 o
f 
th
e 
te
st
 (
%
)
Pr
im
ar
y 
co
ho
rt
Ab
er
ra
nt
 p
53
 e
xp
re
ss
io
na
93
%
28
%
59
%
77
%
62
.0
Ab
se
nc
e 
of
 S
O
X
2 
ex
pr
es
si
on
71
%
58
%
66
%
64
%
64
.9
2 
ab
er
ra
nt
 b
io
m
ar
ke
rs
b
63
%
75
%
74
%
64
%
68
.8
V
al
id
at
io
n 
co
ho
rt
A
be
rr
an
t p
53
 e
xp
re
ss
io
n
*
97
%
22
%
52
%
8
9%
57
.0
Ab
se
nc
e 
of
 S
O
X
2 
ex
pr
es
si
on
76
%
51
%
58
%
70
%
62
.9
2 
ab
er
ra
nt
 b
io
m
ar
ke
rs
b
73
%
60
%
62
%
71
%
65
.7
T
he
 e
ffi
ci
en
cy
 o
f t
he
 te
st
 is
 c
al
cu
la
te
d 
as
 (
tr
ue
 p
os
it
iv
e 
+
 tr
ue
 n
eg
at
iv
e 
) 
/ 
n
um
be
r 
of
 s
am
pl
es
 x
 1
0
0
. 
Ab
br
ev
ia
tio
ns
: P
PV
, p
os
iti
ve
 p
re
di
ct
iv
e 
va
lu
e;
 N
PV
, n
eg
at
iv
e 
pr
ed
ic
tiv
e 
va
lu
e;
 T
R
G
, T
um
or
 R
eg
re
ss
io
n 
G
ra
de
; E
AC
, e
so
ph
ag
ea
l a
de
no
ca
rc
in
om
a.
 
a  A
be
rr
an
t p
53
 e
xp
re
ss
io
n
 w
as
 d
efi
n
ed
 a
s 
ei
th
er
 o
ve
re
xp
re
ss
io
n
 o
r 
co
m
pl
et
e 
lo
ss
 o
f e
xp
re
ss
io
n
  
b  A
be
rr
an
t b
io
m
ar
ke
r e
xp
re
ss
io
n 
in
cl
ud
ed
 a
be
rr
an
t p
53
 e
xp
re
ss
io
n 
an
d 
ab
se
nc
e 
of
 S
O
X
2 
ex
pr
es
si
on
.
proefschrift_def.indd   137 20/04/2017   20:02
138
Chapter 7
Validation cohort
CD44 expression showed no significant association with therapy response 
in the primary cohort and therefore further validation of this biomarker 
was discontinued. In contrast, validation of the predictive biomarkers p53 
and SOX2 was performed in an independent cohort of 70 EAC patients of 
which 33 patients (47%) showed a major pathological response (TRG 1-2) 
and 37 patients (53%) a minor response (TRG 3-4). Aberrant p53 expression 
as individual marker showed borderline significance for predicting therapy 
response after adjusting for age, gender, tumor grade, pretreatment clinical 
T-stage and pretreatment clinical N-stage (adjusted OR of 8.6; 95% CI: 0.93-
80.9, p value 0.058) (Table 3). 
Similarly to the results in the primary cohort, absence of SOX2 expression 
in the pretreatment tumor biopsies was again significantly associated with 
major response, with an adjusted OR of 6.1 (95% CI: 1.6-23.4; p value 0.008). 
Aberrant expression of both biomarkers was associated with a slightly higher 
probability of a major response with an adjusted OR of 6.2 (95% CI: 1.8-
21.2; p value 0.004) as shown in Table 3. The sensitivity of aberrant p53 with 
concurrent absence of SOX2 expression for predicting a major response was 
73%, with a specificity of 60%, PPV of 62% and NPV of 71% (Table 4). 
Pathological T- and N-downstaging
Based on the comparison between initial pretreatment pathological tumor 
staging and evaluation of the residual tumor cells after nCRT, 42 (55%) 
patients showed pathological T-downstaging and 25 (32%) patients showed 
pathological N-downstaging in the primary cohort versus 36 (53%) patients 
with T-downstaging and only 18 (26%) patients with N-downstaging in the 
validation cohort (Table 5). There was no significant correlation between 
pathological T- or N-downstaging and p53 expression in both the primary 
and validation cohort. However, in the validation cohort absence of SOX2 was 
more common in patients with pathological T-downstaging than in patients 
without pathological T-downstaging (80% versus 42%) after nCRT (p value 
of 0.001).
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Table 5. Clinicopathological characteristics and biomarker expression according to 
pathological TN-downstaging.
Primary cohort
Pathological T-downstaging Pathological N-downstaginga
Variable
Yes
n = 42
No
n = 35
P Value
Yes
n = 25
No
n = 16
P Value
Age
  Median, years (IQR) 62 (55 - 68) 62 (55 - 71) 0.910 59 (55 - 71) 59 (55 - 65) 0.843
Gender
  Woman 6 (14%) 4 (11%) 0.748 3 (12%) 4 (25%) 0.401
  Men 36 (86%) 31 (89%) 22 (88%) 12 (75%)
Tumor grade
  Well-diff 6 (14%) 2 (6%) 0.355 2 (8%) 1 (6%) 0.747
  Moderately-diff 22 (52%) 23 (66%) 15 (60%) 8 (50%)
  poorly-diff 14 (34%) 10 (28%) 8 (32%) 7 (44%)
P53 expression
  Normal 4 (10%) 9 (26%) 0.059 4 (16%) 4 (25%) 0.689
  Aberrant expressionb 38 (90%) 26 (74%) 21 (84%) 12 (75%)
SOX2 expression
  Positive 17 (40%) 16 (46%) 0.644 12 (48%) 9 (56%) 0.606
  Absence of expression 25 (60%) 19 (54%) 13 (52%) 7 (44%)
Validation cohort
Pathological T-downstaging Pathological N-downstaginga
Variable
Yes
n = 36
No
n = 33
P Value
Yes
n = 18
No
n = 26
P Value
Age
  Median, years (IQR) 66 (58 - 71) 64 (58 - 68) 0.307 67 (57 - 73) 64 (58 - 70) 0.304
Gender
  Woman 3 (8%) 5 (15%) 0.466 1 (6%) 3 (11%) 0.634
  Men 33 (92%) 28 (85%) 17 (94%) 23 (89%)
Tumor grade
  Well-diff 2 (6%) 0 (0%) 0.272 0 (0%) 1 (4%) 0.701
  Moderately-diff 21 (58%) 17 (52%) 10 (56%) 14 (54%)
  poorly-diff 13 (36%) 16 (48%) 8 (44%) 11 (42%)
P53 expression
  Normal 4 (11%) 5 (15%) 0.728 3 (17%) 5 (19%) 0.100
  Aberrant expressionb 32 (89%) 28 (85%) 15 (83%) 21 (81%)
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Validation cohort
Pathological T-downstaging Pathological N-downstaginga
Variable
Yes
n = 36
No
n = 33
P Value
Yes
n = 18
No
n = 26
P Value
SOX2 expression
  Positive 7 (20%) 19 (58%) 0.001 6 (33%) 11 (42%) 0.548
  Absence of expression 29 (80%) 14 (42%) 12 (67%) 15 (58%)
For the assessment of pathological TN-downstaging prepT and prepN (estimated based on the extent 
of regressional changes and the residual tumor cells in the resection specimen) were compared with the 
eventual pathological ypT and ypN stage after nCRT 
a Excluding patients with stage N0 before and after neoadjuvant chemoradiotherapy (including primary 
cohort n = 41 and validation cohort n = 44 patients) 
b Aberrant p53 expression was defined as either overexpression or complete loss of expression 
Abbreviation: IQR, interquartile range
Correlation between biomarker expression and 
clinicopathological characteristics
Tumor grade was the only clinicopathological characteristic which was 
significantly correlated with p53 and SOX2; presence of SOX2 expression 
was associated with a higher tumor grade in analyses of all the pretreatment 
biopsies (p value of 0.006).
Discussion
The response to nCRT is highly variable among patients with EAC. In our 
study 50% of the patients showed a major response (TRG1-2) in the resection 
specimen after nCRT, which is in line with previous publications [4, 40]. The 
currently available restaging modalities as CT, EUS and PET-CT have limited 
capacity to assess therapy response prior to surgery [11, 12, 41]. Additionally, 
a significant proportion of patients do not seem to benefit from neoadjuvant 
treatment and experience unnecessary side-effects with delayed surgical 
resection [8, 9]. Therefore, there is a need for informative biomarkers that 
determine the biological behavior of individual tumors and may contribute to 
predict individual patient response to nCRT.
Absence of SOX2 expression was seen in 59% of pretreatment tumor biopsies 
and proved to be an independent predictor for major pathological response 
in the primary and validation cohort (adjusted OR 4.1 and 6.1, respectively). 
Only one small study has previously evaluated the value of SOX2 expression 
for predicting response to nCRT in patients with EC, but no association 
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was observed [23]. This may be explained by investigation of both EAC and 
esophageal squamous cell carcinoma (ESCC), differences in assessing therapy 
response, as well as different interpretation of immunohistochemical staining 
(cytoplasmatic SOX2 was considered negative in our study). In line with our 
results, SOX2 expression has been associated with therapy response in several 
other cancer types. Ovarian and prostate cancer tissue showed a correlation 
between SOX2 expression and paclitaxel resistance (also part of the CROSS 
regimen) [21, 22, 42, 43]. The precise mechanism of SOX2 in the context of 
EAC and response to nCRT is unknown but serves to be investigated.
Aberrant p53 expression was seen in the majority of the pretreatment tumor 
biopsies (85%) and was significantly associated with major response in the 
primary cohort, while in the validation cohort only a trend of increased 
probability was detected. In fact, overall, conflicting data are reported. Kitamura 
et al. showed that p53 was significantly associated with increased sensitivity 
to nCRT, whereas other studies could not confirm this correlation [44, 45, 
46]. The majority of immunohistochemical studies have been performed in 
patients with ESCC or mixed population of EAC and ESCC patients, therefore 
to be interpreted with caution. In addition, in contrast to our study, others 
scored strong nuclear p53 as aberrant only [39]. Truncating TP53 mutations 
or epigenetic silencing may result in p53 inactivation by complete absence. 
Based on our experience, both patterns could be classified as aberrant [35, 
38]. Zhang et al. showed in a meta-analysis of in total 28 studies with 1497 
patients a significant association between major response to chemotherapy-
based treatment in EC with low p53 protein expression or wild-type TP53 [39]. 
Again, this hampers by tremendous heterogeneity across studies regarding 
histology, p53 scoring, therapy response, and therapy regimens. A more 
recent study showed that EC patients with a normal TP53 status may benefit 
from nCRT with cisplatin/fluorouracil compared to mutant TP53 status (no 
immunohistochemical analysis performed) [47]. Patients in our study were 
treated according to the CROSS regimen, consisting of carboplatin plus 
paclitaxel and radiotherapy. Carboplatin and radiotherapy are likely to act via 
a p53-controlled pathway, but docetaxel acts differently and it is not clear if 
and how it interacts with TP53 [48, 49]. Therefore, no general conclusion can 
be drawn.
SOX2 as a single biomarker may has more power to predict therapy response 
than p53, but the predictive value slightly increased by the combination of 
aberrant p53 expression with concurrent absence of SOX2 expression. These 
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findings might have important and clinically relevant implications. Assessment 
of p53 and particularly SOX2 immunohistochemistry offers an additional 
tool, in combination with other diagnostic modalities, to select those patients 
who are likely to benefit most from this multimodality treatment. Recent data 
from the CROSS study group showed that a prolonged time to surgery after 
completion of nCRT up to at least 12 weeks was associated with an increased 
pathological response, without a significant rise in postoperative complications 
which supports a more conservative wait-and-see strategy in a selection of 
patients [9, 50]. However, additional studies are needed to investigate the 
prognostic value of p53 and SOX2, which is beyond the scope of this study.
Patients in our study were subdivided into TRG major and TRG minor response 
group based on previous publications [33, 34]. Furthermore, different aspects 
of tumor response were measured. Besides TRG also pathological TN-
downstaging was evaluated and compared with p53 and SOX2 expression. 
Absence of SOX2 expression was significantly more common in patients with 
T-downstaging than in patients without T-downstaging, strengthening the 
association between SOX2 expression and response to nCRT. However, this 
was only identified in the validation cohort and may be explained by the fact 
that in the primary cohort several patients showed a TRG 2 response without 
T-downstaging, so the few residual tumor cells were still present in the initially 
involved layers of the esophagus. The same was true for p53, where only a 
trend between p53 expression and T-downstaging was observed in the primary 
cohort. Our single institution CROSS regimen study has several strengths. 
Importantly, we identified two biomarkers for predicting therapy response in 
a primary cohort, used for the determination of the most optimal cut-off value 
for biomarker expression, and validated these results in a second independent 
cohort of EAC patients. Additionally, all stained slides were reviewed by at 
least two experienced observers to obtain a final diagnosis based on consensus. 
Our study also has some limitations. We evaluated the predictive value of 
biomarker expression retrospectively, however all parameters were collected 
prospectively. Although immunohistochemistry is a standardized method 
within clinical pathological laboratories, the scoring of the expression can be 
subjective. However, our study showed a good interobserver agreement for 
both markers [35, 38]. In conclusion, Expression of p53 and particularly SOX2 
in pretreatment tumor biopsies predicts response to nCRT in patients with 
potentially curable EAC. These biomarkers may contribute, in combination 
with other modalities, to accurate evaluation of response to nCRT and thereby 
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help to individualize treatment decision in patients with potentially curable 
EAC.
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Abstract
Introduction: Esophageal adenocarcinoma (EAC) is a highly aggressive 
malignancy with poor survival, which is highly variable amongst patients with 
comparable conventional prognosticators. Therefore molecular biomarkers 
are urgently needed to improve survival prediction in these patients. SRY (sex 
determining region Y)-box 2, also known as SOX2, is a transcription factor 
involved in embryonal development of the gastrointestinal tract as well as in 
carcinogenesis. Here we aimed to test whether SOX2 expression is associated 
with survival in patients with EAC.
Methods: SOX2 was studied by immunohistochemistry in patients who had 
undergone potentially curative esophagectomy for adenocarcinoma. Protein 
expression of SOX2 was evaluated using tissue micro arrays from resection 
specimens and the results were analyzed in relation to the clinical data by 
Cox regression analysis. SOX2 was evaluated in two independent EAC cohorts 
(Rotterdam cohort and multicenter UK cohort).
Results: Loss of SOX2 expression was independently predictive for adverse 
overall survival (OS) in the multivariate analysis adjusted for known factors 
influencing survival, in Rotterdam as well as in the UK cohort (Rotterdam 
cohort: HR=1.42, 95% CI 1.07-1.89, p=0.016; UK cohort: HR=1.54, 95% CI 
1.08-2.19, p=0.017). When combined with clinico-pathological staging, SOX2 
segregated patients into prognostic groups in pT1/2 tumors (p=0.01) and 
nodal-negative EAC (p=0.038), with incremental adverse effect on OS for 
stage I EAC with SOX2 loss (HR=3.18, 95% CI 1.18-8.56, p=0.022).
Conclusions: We identified SOX2 as an independent prognostic factor for 
long-term survival in EAC, in particular in patients with stage I EAC.
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Introduction
Esophageal adenocarcinoma (EAC) is an aggressive cancer with steadily 
increasing incidence [1, 2]. The major risk factors for EAC are gastroesophageal 
reflux [3], abdominal obesity [4] and Barrett esophagus (BE) [5, 6]. While 
patients with non-dysplastic BE show a low rate of progression to EAC during 
surveillance (<1% per year) [7], most patients with EAC exhibit underlying 
BE at the time of EAC diagnosis and are typically diagnosed at an advanced, 
frequently incurable stage [8]. 
Although the addition of (neo-)adjuvant therapy to primary surgical resection 
improves overall survival (OS) and disease-specific survival in locally advanced 
tumors, the prognosis of most patients with advanced EAC including those 
treated with curative intent is dismal, with a 5-year survival of 47% at most 
[9, 10, 11]. Postsurgical prognostication is currently based on tumor staging 
according to the American Joint Committee on Cancer staging system, 
supplemented by pathological criteria [12]. However, even after considering 
all known parameters including resection margin, nodal status, presence of 
vascular invasion, tumor grade, and differentiation grade, the course of the 
disease remains variable [13, 14, 15]. Improving clinical decision making 
is essential, especially in early EAC. In these patients numerous treatment 
modalities are available, depending on tumor characteristics, and the best 
treatment modality for the individual patient is under discussion. One method 
for a better prognostication in early EAC is the use of biomarkers, which can 
improve the decision on the optimal treatment strategy. 
Various signaling pathways essential for embryonal development are involved 
in cancer initiation and progression, including the sex determining region 
Y-box2 (also known as SOX2). SOX2 is a highly conserved gene coded on 
a single exon which plays a pivotal role in the maintenance of embryonic 
stem cells [16]. In the gastrointestinal tract it determines the formation and 
differentiation of esophageal and gastric epithelium during embryogenesis 
[17, 18]. Besides its role in embryogenesis, SOX2 is involved in various 
malignancies including squamous cell carcinoma of the esophagus [19], 
gastric adenocarcinoma [20], prostate cancer [21] and colorectal cancer [22]. 
SOX2 functions differ depending on the cell of origin and oncogenic as well as 
tumor suppressive mechanisms have been described. The SOX2 gene can be 
amplified in squamous cell carcinoma of the esophagus and trachea and acts as 
a lineage survival oncogene by promoting cell migration and proliferation [23, 
24]. Accordingly, upregulation of SOX2 is strongly associated with adverse 
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outcome in these patients [19]. In contrast, the opposite functions of SOX2 
were shown in gastric adenocarcinoma, in which loss of SOX2 expression 
was correlated with worse prognosis and PTEN has been proposed as a direct 
target of SOX2 [20]. 
It is noteworthy that little is known about the role of SOX2 in EAC. Previously, 
we evaluated SOX2 expression in BE and showed that SOX2 downregulation 
is highly associated with progression of BE to high grade dysplasia and EAC 
[25]. Furthermore, SOX2 status was indicative for the pattern of response to 
neoadjuvant chemoradiotherapy in patients with EAC [26, 27]. Another Dutch 
group had previously shown that SOX2 may have prognostic effect for disease 
free survival (DFS) in a small cohort of surgically treated EAC patients [28]. In 
light of the emerging data on SOX2, the aim of the present study was to assess 
the role of SOX2 in prognostication of patients with surgically treated EAC 
with particular emphasis on patients with stage I disease.
Methods
Patient selection
Both, the Rotterdam (N=336) and the UK multicenter cohort (OCCAMS, 
Oesophageal Cancer Clinical and Molecular Stratification Study cohort, 
N=420) consisted of patients who underwent esophagectomy with curative 
intent for pathologically confirmed adenocarcinoma of the esophagus or 
gastroesophageal junction. Follow-up of all patients was performed in the 
respective clinical centers and only patients who were alive one month after 
surgery were included in the analysis. The Rotterdam cohort consisted of 
patients treated at the Department of Surgery at Erasmus Medical Center, 
Rotterdam, the Netherlands during the time period between 1995 and 
2006. The UK cohort consisted of patients form six tertiary hospitals treated 
between 1992 and 2000. Within the Rotterdam cohort, 68 (20.2 %) of patients 
received neoadjuvant chemoradiotherapy (29 patients) or chemotherapy (39 
patients). In the OCCAMS cohort, 146 (42.1%) patients received neoadjuvant 
chemotherapy according to UK guidelines. 
The clinical and pathological data of both cohorts were collected and included 
tumor grade, pathological stage, chemotherapy treatment, age at surgery, 
comorbidities and OS, amongst others. The TNM system according to the 
UICC (Union Internationale Contre le Cancer, 2009, 7th edition) was used 
for pathologic grading and staging [12]. To insure reliable classification, all 
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tumors were revised by an expert gastrointestinal pathologist.
Tissue micro array
For the construction of a tissue micro array (TMA), formalin-fixed paraffin-
embedded tissue from the resection specimens were retrieved from the 
archives at the Departments of Pathology of the participating institutions. 
For each tumor, 3 to 6 cores from multiple representative areas of EAC, as 
identified by a pathologist on H&E slides, were taken from the original paraffin 
blocks, including the central part and invasive front of the tumor [29, 30].
SOX2 Immunohistochemistry
The SOX2 immunohistochemical staining technique has been described 
extensively in previous publications [25, 26]. In short, 5μm sections were 
cut from the TMA and were de-paraffinized and rehydrated. Tissue of 
squamous cell carcinoma with clear positive staining for SOX2 was placed 
on each immunohistochemal slide of the TMAs as a positive control. Antigen 
retrieval was enhanced by heating in a Tris buffer. Endogenous peroxidase 
activity was blocked by incubating the slides in a solution of 0.3% hydrogen 
peroxide in phosphate-buffered saline. Primary SOX2 antibody (AF2018, 
dilution 1:800, R&D systems, Abington, UK: goat, polyclonal) was applied 
for 22 hours at 4°C. The secondary antibody was a biotinylated horse anti-
goat IgG antibody (1:150; BA-4000, Vector, Peterborough, UK). Visualization 
was achieved using the horseradish peroxidase avidin-biotin complex (HRP- 
ABC) method and diaminobenzidine (DAB). The slides were counterstained 
with hematoxylin. The immunohistochemically stained TMA slides from both 
cohorts were digitalized and scored independently by two investigators (SO 
and KB), who were blinded to the clinical and pathological outcome. In case of 
disagreement, the cores were reviewed by both investigators simultaneously 
and a consensus was achieved. 
SOX2 was scored as positive or negative in each of the stained cores. As 
described previously, weak or strong nuclear expression of at least 50% of the 
tumor cells was defined as positive, while nuclear expression in less than 50% 
of the tumor cells as well as cytoplasmatic SOX2 expression were defined as 
negative [26]. Because SOX2 expression might be heterogeneous in EAC, the 
overall expression in each tumor was calculated from all corresponding cores. 
Patients with less than 3 cores containing cells representative for the original 
EAC were excluded from analysis. 
The most optimal cut-off value of immunohistochemistry with SOX2 to predict 
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survival was calculated by Receiver Operating Characteristics (ROC) curve 
analysis in the Rotterdam cohort, using the Area Under the Curve (AUC) as the 
performance measure. Based on this evaluation, absence of SOX2 expression 
was defined by negative staining of SOX2 in >75% of the cores, and otherwise 
SOX2 was considered to be present.
Ethics
The investigational protocols of both cohorts were approved by the relevant 
institutional review boards (MEC-12-469 and LREC 04/Q2006/2).
Statistical analysis
The primary endpoint in this study was 5–year OS, defined as time from surgery 
until death. The differences between the Rotterdam and the UK cohorts were 
analyzed using a Students t-test for normal distribution and Mann-Whitney 
test for non-normal distribution for continuous variables and a χ2 test for 
categorical variables. The equality of distribution was tested using a Levene’s 
test. The interobserver variation between the two investigators for scoring of
SOX2 (SO, KB) was calculated using Cohen’s kappa. Strength of agreement 
was categorized as follows: 0.00–0.20, poor; 0.21–0.40, fair; 0.41–0.60, 
moderate; 0.61–0.80, good; and 0.81–1.00, excellent. 
Kaplan-Meier curves were used to plot the 5-year survival by SOX2 status. After 
imputation of missing variables using a linear regression model, univariate 
and multivariate Cox proportional hazard model was applied to estimate the 
independent association between the SOX2 immunohistochemical expression 
and survival. In the multivariate analysis adjustments were made for those 
clinical and pathological factors which were independently predictive in 
the univariate analysis. Also, sensitivity analysis using multivariate Cox 
proportional hazard model excluding all patients with (neo-)adjuvant 
treatment and adjusting for the clinical and pathological factors was performed 
to test the SOX2 role in chemoradiotherapy-naïve patients. The pN-stage was 
dichotomized in a pN0 and a pN+ (pN1-3) group for the multivariate analysis. 
All analysis were performed using SPSS-software (version 22, SPSS IBM inc, 
Armonk, NY, USA). A P-value of <0.05 was considered to be statistically 
significant.
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Results
Patient characteristics
The EAC cohort from Rotterdam consisted of 336 patients, while the cohort 
from the OCCAMS study consisted of 420 patients. Clinical characteristics of 
the patients from Rotterdam and OCCAMS cohorts as well as for the entire 
group are listed in Table 1. Patients from the OCCAMS cohort were older 
compared with those from the Rotterdam cohort (age 66.0 years versus 64.7 
years, p=0.01) and had a shorter median follow-up time (18.0 months versus 
25.0 months, p<0.01). There was a male predominance in both cohorts as 
expected. Patients from the Rotterdam cohort more often had a tumor at the 
esophageal-gastric junction (Siewert type II), a higher degree of differentiation, 
an earlier T-stage as well as less frequent lymph node metastases (p<0.01). 
There were fewer patients with (neo)adjuvant treatment in the Rotterdam 
cohort. Furthermore, loss of SOX2 expression was more common in the 
OCCAMS cohort compared to the Rotterdam cohort.
Table 1. Clinico-pathological characteristics, combined cohort and specified by 
Rotterdam and OCCAMS cohort.
Combined (N=756) Rotterdam (N=336) OCCAMS (N=420) P-value
Variable
Age at surgery
  Median 65.4 64.7 66.0 0.01
  Range (33-90) (33-90) (33-88)
Follow-up time, months
  Median 20.9 25.0 18.0 <0.01
  Range (1-199) (1-199) (1-193)
Sex
  Male 602 82.0% 293 87.2% 309 77.6% <0.01
  Female 132 18.0% 43 12.8% 89 22.4%
Siewert classification
  Type 1 460 69.7% 190 57.1% 270 82.6% <0.01
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Combined (N=756) Rotterdam (N=336) OCCAMS (N=420) P-value
Variable
  Type 2 168 25.5% 126 37.8% 42 12.8%
  Type 3 32 4.8% 17 5.1% 15 4.6%
Recurrence 182 54.2% 182 54.2% NA
Resection margin status
  pR0 396 71.0% 245 72.9% 151 68.0% 0.21
  pR1 162 29.0% 91 27.1% 71 32.0%
Histology grade
  Well 52 7.5% 26 7.7% 26 7.3% 0.01
  Moderate 248 35.7% 139 41.4% 109 30.4%
  Poor 394 56.8% 171 50.9% 223 62.3%
Pathologic T-stage
  pT1 79 11.2% 48 14.7% 31 8.2% <0.01
  pT2 132 18.8% 59 18.0% 73 19.4%
  pT3 474 67.3% 218 66.7% 256 67.9%
  pT4 19 2.7% 2 0.6% 17 4.5%
Pathologic N-stage
  pN0 245 35.9% 142 42.4% 103 29.6% <0.01
  pN1 or more 438 64.1% 193 57.6% 245 70.4%
(Neo-)adjuvant 
treatment
  Yes 214 31.3% 68 20.2% 146 42.1% <0.01
  No 469 68.7% 268 79.8% 201 57.9%
Alive after 60 months
  Yes 234 31.0% 106 31.5% 128 30.5% 0.75
  No 522 69.0% 230 68.5% 292 69.5%
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Combined (N=756) Rotterdam (N=336) OCCAMS (N=420) P-value
Variable
SOX2
  Negative 436 66.1% 181 57.1% 255 74.3% <0.01
  Positive 224 33.9% 136 42.9% 88 25.7%
Association between SOX2 expression and survival
The interobserver agreement for the assessment of SOX2 immunohistochemistry 
between the two observers was excellent (kappa-value= 0.92; p<0.001). After 
exclusion of patients with less than 3 representative cores available for the 
SOX2 evaluation, 539 patients remained from the total of 756 patients for the 
final analysis of SOX2 immunohistochemistry (288 in Rotterdam cohort and 
251 in the OCCAMS cohort). In total, SOX2 was positive in 186 EAC while 351 
EAC were SOX2 negative. 
In the Rotterdam cohort, negative SOX2 was associated with a shorter 
median OS compared to patients with positive SOX2: 19.5 versus 32.9 months 
(p<0.01). Survival in the OCCAMS cohort was similar to the Rotterdam cohort 
with a median survival of 15.0 months in SOX2 negative versus 26.0 months 
(p<0.01) in SOX2 positive tumors (supplemental Table 1). Corresponding 
Kaplan-Meier curves of both cohorts separately and the combined group are 
depicted in Figure 1.
Figure 1: Expression of SOX2 is prognostic for overall survival; Rotterdam cohort 
(A), OCCAMS cohort (B) and combined cohort (C) (p-values are indicated in the left 
lower corner of each graph).
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Next, univariate analysis was performed according to the Cox proportional 
hazard ratio model which demonstrated HR for death in patients with SOX2 
loss of 1.54 (95% CI 1.16-2.04, p=0.003) for the Rotterdam cohort, HR of 1.58 
(95% CI 1.12-2.22, p=0.009) for the OCCAMS cohort and HR of 1.55 (95% CI 
1.25-1.93, p<0.001) for the combined cohort.
SOX2 is independent of conventional clinico-pathological 
parameters for patient prognosis
Multivariate Cox-regression analysis was performed in the Rotterdam, 
OCCAMS and combined cohort to test the independent value of SOX2 in 
relation to other clinical parameters. SOX2 remained significant for OS, as 
summarized in Table 2, in both cohorts separately as well as in the combined 
cohort (HR=1.42, 95% CI 1.14-1.77, p=0.002).
Information about the DFS was only available in the Rotterdam cohort. Here, 
SOX2 was independently predictive for recurrence of the disease with a HR 
of 1.37 (95% CI 1.01-1.86, p= 0.045) in a multivariate analysis (see Table 2). 
Chemotherapy-naïve patients were selected for further sub-analysis, in which 
SOX2 loss was confirmed as statistically significant prognostic indicator for 
worse OS (Table 3).
Table 2. Multivariate survival analysis, for all patients (specified in Rotterdam and 
OCCAMS cohort). Positive SOX2 expression was used as reference.
SOX2 (positive ref) HR 95% CI P-value N
Combined cohort OS 1.42 1.14-1.77 0.002 402
Rotterdam OS 1.42 1.07-1.89 0.016 287
DFS 1.37 1.01-1.86 0.045 287
OCCAMS OS 1.54 1.08-2.19 0.017 115
HR=Hazard ratio, CI=Confidence Interval. OS=Overall Survival, DFS=Disease Free Survival.
SOX2 loss predicts worse outcome in chemotherapy-naïve patients 
with stage I EAC
Next, we evaluated the prognostic value of SOX2 in chemotherapy naïve 
patients in relation to the clinic-pathological staging. SOX2 showed segregation 
in prognostic groups in pT1/pT2 tumors (HR=2.36, 95% CI 1.23-4.51, p=0.01) 
but not in pT3/pT4 tumors (Figure 2a, Table 3). When combining SOX2 with 
the nodal status, patients with pT1 EAC and loss of SOX2 had a trend for pN+ 
(p=0.070). For pT2-pT4 tumors no correlation of SOX2 and nodal status was 
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found (data not shown). When combining SOX2 and pN-stage, a significant 
segregation into prognostic groups was detected in pN0-patients (HR=1.71, 
95% CI 1.03-2.85, p=0.038) while in pN1-pN3 patients no effect of SOX2 was 
visible (Table 3 and Figure 2b).
Figure 2. SOX2 expression in combination to clinico-pathological staging (a: pT-
stage, b: pN-stage and c: stage groupings) segregates chemotherapy naïve patients, 
into prognostic groups in early EAC (pT1/pT2 tumors, pN-tumors and stage I 
tumors, p<0.05).
Based on the findings on the pT- and pN-stage, Kaplan-Meier curve was 
constructed for the differentiating effects of SOX2 for each of the stage 
groupings as mentioned in the TNM classification, in which the sub-stages 
were combined in stage I, stage II and stage III. Here a differentiating effect 
for stage I was found only, with HR a for death of 3.18 (95% CI 1.18-8.56, 
p=0.022) (Table 3 and Figure 2c).
Table 3. Multivariate survival analysis for SOX2-expression in chemotherapy naïve 
patient, for all patients and specified for pT1/pT2-tumors, pN0-tumors and stage 
I-tumors. Positive SOX2 expression is used as reference.
SOX2 (positive ref) HR 95% CI P-value N
Overall 1.35 1.04-1.75 0.026 297
pT1/2 2.36 1.23-4.51 0.010 105
pN0 1.71 1.03-2.84 0.038 112
Stage I 3.18 1.18-8.56 0.022 64
HR=Hazard ratio, CI=Confidence Interval.
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Discussion
In the present study we demonstrated that SOX2 immunohistochemistry 
adds to the prognostication of patients with EAC. SOX2 loss was predictive 
for adverse outcome in both of the independent cohorts (Rotterdam and 
OCCAMS) with significant incremental adverse effect for OS, especially in 
pN0 and stage I EAC. 
Besides prediction of response to neoadjuvant treatment, improved early 
detection and individualized targeted treatment, prognostication is an 
important current challenge in the clinical management of patients with 
EAC. Earlier studies attempted to identify clinically applicable predictive 
biomarkers for treatment response and overall prognosis, but most studies 
were underpowered [31] or included heterogeneous patient populations 
with squamous cell carcinoma and adenocarcinoma which have different 
biology [32]. Furthermore, biomarker analysis might be hampered by 
different neoadjuvant regimens used for treatment of advanced EAC making 
the comparison between relevant studies difficult [33]. Large collaborative 
projects using standardized methodology are required to generate a clinically 
useful approach. Using this strategy, a three-gene immunohistochemical 
panel was previously shown to be useful in a large multicenter study [34]. 
Hereby, combining TNM staging with this immunohistochemical panel of 
EGFR, TRIM44 and SIRT2 allowed segregation of patients with stages II 
and III disease into distinct prognostic groups, while the effect in stage I was 
minimal [34]. This is different from the SOX2 findings reported here.
The transcription factor SOX2 not only plays an essential role in the 
embryological formation of the stomach and esophagus [18], but is also 
involved in pathogenesis of gastric [35, 36] and esophageal (squamous cell) 
carcinoma [19]. Little is known so far about the role of SOX2 in EAC and BE. 
We previously detected gradually decreased SOX2 expression in low- and 
high grade dysplasia of patients with BE which is possibly related to the loss 
of epithelial identity during neoplastic BE progression [25]. In advanced 
EAC, retained expression of SOX2 has previously been related to resistance 
to neoadjuvant chemo-radiation therapy in patients treated according to the 
CROSS-regime [26, 27]. Also, an earlier small Dutch study on 94 patients 
with surgically treated EAC suggested SOX2 loss to be a predictor of impaired 
DFS but was underpowered to establish incremental value of SOX2 for OS 
[28]. In the present study we focused on surgically treated EAC and analyzed 
immunohistochemical SOX2 expression in relation to the clinic-pathological 
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parameters and OS in two well-characterized and independent EAC cohorts. 
In fact, we could not only confirm prognostic value of SOX2 for the DFS (HR 
1.37, p=0.045) but also showed for the first time that SOX2 loss predicts 
adverse OS in patients with EAC. Importantly, SOX2 status was independent 
of all clinical and histological parameters known to influence survival including 
neoadjuvant treatment (HR 1.42, p=0.002). 
Among all patients with EAC, patients with stage I disease are in a prognostic 
favorable group with a 5-years survival of 87.7% and 73.3% for stage Ia 
and Ib respectively [37]. In these patients prediction of survival is difficult 
while numerous treatment modalities are available, including endomucosal 
resection and surgical treatment, with or without neoadjuvant treatment. 
At this moment the optimal treatment strategy for patients with stage I EAC 
is not known because of the increased but highly variable risk of lymph-
node metastasis [38]. Also, the beneficial effects of neoadjuvant therapy in 
these patients are not clear [39]. In the present study we showed an adverse 
incremental value for OS in chemotherapy-naive patients with stage I EAC 
with loss of SOX2 (HR 3.18, p=0.022). Furthermore, our results suggest that 
SOX2 might predict lymph node metastases in pT1 EAC, however, further 
studies, preferably in specific target group of patients with pT1b EAC would 
be valuable to confirm this finding. 
The role of SOX2 in the pathogenesis of EAC is still poorly understood. 
Significant association of retained SOX2 expression and favorable survival 
could be explained by SOX2 function as a tumor suppressor gene in parallel 
to the findings in gastric carcinoma. Lower mitotic rate, increased apoptosis 
and reduced invasion and dissemination were detected in gastric cancer with 
retained SOX2 expression compared to those with SOX2 loss [36, 40, 41]. In 
line with its tumor suppressive role, several downstream targets of SOX2 were 
identified in gastric cancer including CCND1, pRB1, CDKN1B as wells as PTEN 
and pAKT [36, 41, 42]. Given the lineage specific SOX2 function in formation 
of the stomach and esophagus during embryogenesis, the role of SOX2 in EAC 
might be similar to that in gastric cancer. 
The current study has some limitations including its retrospective design and 
the fact that since we included all patients with surgically resected EAC, the 
subgroup of stage I tumors was limited. Another limitation is that we tested the 
expression of SOX2 on TMAs constructed from resection specimens and not 
in preoperative biopsies of patients with EAC. Further validation of our results 
in the prospective setting and on preoperative tumor material would therefore 
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be valuable. Another potential bias is the SOX2 immunohistochemistry and 
interpretation of the results. SOX2 detection in this study was performed by 
standardized immunohistochemical technique which is easily reproducible 
in the pathology laboratory. However, because the interpretation might be 
subjective, all SOX2 stained TMAs were scored by two investigators, showing 
an excellent interobserver agreement (kappa 0.92), indicating that accurate 
classification of SOX2 pattern is possible in general practice. 
In conclusion, our study shows that immunohistochemical detection of 
SOX2 provides prognostic information in patients with EAC independently 
of clinical parameters. Using this marker in addition to the current staging 
systems could be of particular relevance in selected populations of nodal-
negative tumors and stage I EAC. Identification of patients with absent SOX2 
expression and hence a worse prognosis compared to tumors with retained 
SOX2 might prompt for a change in patient management. Since SOX2 loss 
is indicative for a more aggressive tumor biology, a more extensive therapy 
might be justified for patients with stage I EAC and loss of SOX2 expression. 
The precise biological role of SOX2 in EAC requires further elucidation.
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Introduction
In order to detect high-grade dysplasia (HGD) or esophageal adenocarcinoma 
(EAC) at an early stage when curative treatment is still feasible, endoscopic 
surveillance is recommended in patients with Barrett’s esophagus (BE). 
In the Netherlands, recommendations for BE surveillance are based on the 
guidelines of the American College of Gastroenterology, which recommend 
endoscopic surveillance with biopsy sampling every 3-5 years for BE without 
dysplasia, endoscopic surveillance every 6-12 months for BE with low-grade 
dysplasia (LGD), and (endoscopic) treatment for patients with established 
HGD or EAC [1, 2, 3, 4]. However, the value of endoscopic BE surveillance 
(based on histological diagnosis alone) has been under discussion given the 
overall low incidence of neoplastic progression, lack of discriminative tests 
for adequate risk stratification and limited evidence that surveillance prevent 
advanced EAC and improves survival. Initially, the estimated incidence of EAC 
in patients with BE was believed to be between 0.5 and 1% per year [5, 6, 7, 8]. 
However, more recently population-based studies and two meta-analyses have 
set this risk around 0.12% to 0.38% per year [9, 10, 11, 12]. These relatively 
low annual risk values reinforce the need for better risk stratification tools 
in BE patients to make BE surveillance truly cost-effective. The aim of this 
thesis was to investigate whether biomarkers can contribute to improved risk 
stratification in BE in order to optimize surveillance strategies and to evaluate 
the effectiveness of surveillance according to the current guidelines in terms 
of cost-effectiveness and survival. In addition, we investigated the value of 
biomarkers on prediction of prognosis and therapy response in EAC patients.
Biomarkers in Barrett’s esophagus surveillance
Nowadays, histological diagnosis of LGD is used for the risk assessment of 
neoplastic progression in BE surveillance and more intensive follow-up is 
recommended in LGD patients (yearly instead of every 3 years) [1, 2, 13]. 
However, the histological diagnosis of LGD has a low predictive value, owing 
to sample error and a considerable inter- and intraobserver variation [14, 15, 
16]. Curvers et al. demonstrated that when LGD diagnosed by community 
hospital pathologist was reviewed by a panel of expert gastro-intestinal 
pathologists, 85% was downstaged. Patients with a confirmed diagnosis 
of LGD had a markedly increased annual progression risk of 9% versus the 
patients whose diagnosis of LGD was downstaged (0.9%). So in our opinion 
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all patients diagnosed with LGD should undergo revision of the histological 
diagnosis by an expert panel [14]. The use of (a panel of) objective biomarkers 
(in addition to histology) may improve risk stratification in all BE patients. 
Many immunohistochemical (IHC) biomarkers have been studied in BE 
progression mainly because the ability to directly visualize stains as applied 
to intact histological morphology. Besides, IHC is relatively cheap and easy 
applicable to clinical practice compared to other techniques. Currently, p53 
IHC staining is only recommended in the guideline of the British Society of 
Gastroenterology to improve the diagnostic reproducibility of the histological 
diagnosis of dysplasia [1]. However, thus far in routine clinical care, neither 
p53 nor other IHC biomarkers are used as predictors of neoplastic progression. 
We conducted a systematic review and meta-analyses to investigate the value 
of different IHC biomarkers for predicting neoplastic progression in BE, it 
showed that only four IHC biomarkers have been investigated more than 
once. The biomarker investigated most frequently is p53 which was assessed 
in 12 studies, totaling 2023 patients. The meta-analysis showed that aberrant 
p53 expression is associated with neoplastic progression with an OR of 4.15 
(95% CI 1.96 to 8.81) and is predictive of progression in patients with both 
non-dysplastic BE and BE with LGD. IHC p53 staining in addition to the 
histological diagnosis can be implemented to improve risk stratification in 
BE surveillance, but consensus formation amongst pathologists concerning 
the appropriate staining method and cut-off value is necessary. Our research 
group previously reported in a large case-control study that aberrant p53 
expression was significantly associated with an increased risk of neoplastic 
progression in BE. However, only 40% of the BE patients with progression to 
HGD or EAC showed an aberrant p53 protein expression during surveillance, 
indicating that additional biomarkers are needed [17]. 
A potential biomarker for BE progression is the transcription factor SOX2 (sex 
determining region Y-box2), a highly conserved single exon gene which plays 
a pivotal role in the maintenance of embryonic stem cells and also determines 
formation and differentiation of esophageal and gastric epithelium during 
embryogenesis [18, 19, 20]. SOX2 is involved in various malignancies including 
squamous cell carcinoma of the esophagus, gastric adenocarcinoma, as well as 
colorectal cancer [21, 22, 23]. In cancer, SOX2 functions are cell-dependent 
and oncogenic as well as tumor suppressive mechanisms have been described. 
Using IHC, SOX2 protein was shown to be progressively downregulated in 
intestinal metaplasia and adjacent gastric cancer [24, 25]. Recent studies 
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in gastric cancer cells revealed a role of SOX2 in growth inhibition through 
cell-cycle arrest and induction of apoptosis, indicating cancer-suppressive 
functions [26]. However, the predictive value of SOX2 in BE and its expression 
during the metaplasia-dysplasia-adenocarcinoma sequence is largely 
unknown. Another promising biomarker is cyclin A, a protein that plays an 
important role in the G1-S transition of the cell cycle. The results of previous 
studies evaluating the value of cyclin A expression for predicting neoplastic 
progression in BE are conflicting. A relative small case-control study (48 
patients) showed that cyclin A surface expression was significantly associated 
with an increased risk of neoplastic progression (OR 7.6; 95% CI 1.6 to 37.0), 
whereas a more recent larger population-based study (380 patients) could not 
confirm this correlation and only found a trend towards an increased risk of 
progression (OR 1.32; 95% CI 0.66 to 2.66) [27, 28]. The value of cyclin A has 
not yet been investigated in large prospective studies. In addition, there is a 
lack of studies testing performance of multiple biomarker simultaneously in 
the same cohort of BE patient. To investigate the predictive value of SOX2 
and cyclin A we performed a case-control study within a large multicenter 
prospective cohort of 720 BE patients (Probar cohort) and combined these 
results with our previously reported p53 and AMACR immunohistological 
data in the same cohort, to identify an informative panel of biomarkers for 
predicting neoplastic progression in BE. SOX2 and cyclin A protein expression 
was evaluated in more than 12.000 biopsies from 625 patients. 
SOX2 expression was progressively lost in dysplastic BE and was seen in only 2% 
of biopsy series without dysplasia, in contrast to 28% in LGD and 67% in HGD 
or EAC. Loss of SOX2 expression was significantly associated with an almost 
5-fold increased risk of neoplastic progression, independent of age, gender, BE 
length and esophagitis. Also Cyclin A surface positivity significantly increased 
throughout the metaplasia-dysplasia-carcinoma progression steps and was 
associated with a 2-fold increased risk of neoplastic progression. However, in 
a fully adjusted model (including histological diagnosis and the biomarkers 
p53, SOX2, cyclin A and AMACR), aberrant p53 expression showed the 
highest change in AUC (0.05) after exclusion, to a lesser extent aberrant SOX2 
expression (0.014) and histological diagnosis of LGD (0.005). The biomarkers 
cyclin A only showed a minimal drop in AUC after exclusion (0.003). The 
highest predictive value was achieved by concurrent loss of SOX2 expression 
and aberrant p53 expression in BE patients with LGD. The incremental value 
of cyclin A was limited. We have also shown good interobserver agreement 
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for the assessment of SOX2 expression and p53 expression, which indicates 
that both markers are clinically suitable markers to predict progression in BE. 
Use of these markers could significantly improve risk stratification and has 
the potential to improve cost-effectiveness of BE surveillance. In daily routine 
practice, these biomarkers would not necessarily replace current clinical and 
histological variables, but it is envisaged that a panel of biomarker, combined 
with relevant clinical and histological factors may improve our ability to 
objectively assess a patient’s individual risk. Although routine p53 and SOX2 
staining incur higher costs than histology alone, application of this panel of 
biomarkers has the potential to reduce the overall costs of Barrett surveillance. 
Patients at low-risk of neoplastic progression, i.e. the majority of the patients 
with LGD, might be follow-up less intensively with the potential to eventually 
discharge them. However, a more detailed cost-effectiveness analysis should 
be performed to evaluate the economic value of p53 and SOX2 IHC.
Cost-effectiveness Barrett surveillance
BE patients have a higher risk of developing EAC compared to the general 
population, but the absolute risk of neoplastic progression is relatively low. 
One of the key questions in the discussion about BE surveillance is whether 
is it cost-effective. Previous studies investigating the cost-effectiveness of 
BE surveillance have shown variable results. Surveillance was reported to be 
cost-effective in four studies with surveillance intervals ranging from two to 
five years [29, 30, 31, 32]. However, in four other studies surveillance was 
not cost-effective with sometimes even higher costs and less quality of life 
than without surveillance [33, 34, 35, 36]. These highly variable results were 
mainly due to different assumptions about progression rates and quality of 
life associated with different health states. In most studies, the incidence of 
EAC was estimated based on pooled literature data and esophagectomy was 
performed in case of both HGD and EAC. Importantly, over the past years there 
has been a major shift in the treatment of BE patients with the introduction 
of endoscopic treatment modalities such as endoscopic mucosal resection 
(EMR) and radiofrequency ablation (RFA) for patients with HGD or early EAC. 
Esophagectomy is still the cornerstone for curative treatment of advanced 
EAC, but is nowadays combined with neoadjuvant chemoradiotherapy (nCRT) 
[37, 38]. To investigate the cost-effectiveness of BE surveillance according 
to the current guidelines, we performed a cost-effectiveness analysis within 
a large multicenter prospective cohort of 714 patients with BE. A multi-
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state-Markov model was used to calculate progression rates based on the 
prospective follow-up data. These progression rates were incorporated in a 
decision-analytic model, including costs and quality of life data. We evaluated 
different surveillance intervals and different therapeutic modalities for BE 
without dysplasia and LGD. The incremental cost-effectiveness ratio (ICER) 
was calculated in costs per quality-adjusted life year (QALY) gained. Assuming 
a willingness-to-pay threshold of €35.000 per QALY, surveillance with EMR 
and RFA for HGD or early EAC, and esophagectomy for advanced EAC is 
cost-effective every 5-years for no dysplasia and every 3-years for LGD. For 
patients with ND, the results of our study correspond to recommendations 
made in current guidelines [39, 40]. For patients with LGD, surveillance is
recommended with intervals of six to twelve months, while according to our 
study intervals should be at least three years in order to be cost-effective. 
Identification and incorporation of additional biomarkers/risk factors besides 
histological diagnosis of LGD may improve risk stratification and eventually 
cost-effectiveness of Barrett surveillance with shorter intervals.
Survival
Another key element in the discussion of Barrett surveillance is whether 
surveillance is able to reduce the occurrence of advanced EAC and improves 
survival. These key questions have been investigated in case-control studies, 
population-based studies and small prospective cohort studies with conflicting 
results [41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56]. Most studies 
have shown that patients diagnosed with EAC in BE surveillance programs 
have earlier-stage tumors and better survival rates than those diagnosed with 
EAC after the onset of symptoms. In contrast, some other studies reported no 
effect on mortality [56]. However, in these studies BE patients were not under 
strict surveillance, which is crucial for the detection of early EAC. For this 
purpose, we evaluated the impact of endoscopic surveillance on tumor stage 
and survival, of patients with BE of at least two centimeters according to current 
guidelines and incorporating of the new (endoscopic) treatment modalities in 
case of HGD or EAC, within a large prospective cohort of 783 BE patients. 
During surveillance incident cases of HGD or EAC were identified. Survival 
data were collected and cross-checked using death and municipal registries 
and compared to data of patients with EAC in the general Dutch population. 
Thirty-three BE patients developed HGD or EAC during surveillance, which 
was diagnosed at a significantly earlier stage than in the general population 
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(P<0.001). Survival of BE patients with neoplastic progression diagnosed 
during surveillance was not significantly worse than those of patients without 
progression (HR 1.8, 95% CI 0.9-3.3), and was similar to those of patients with 
stage 0 or stage 1 EAC in the general population (HR 0.8, 95% CI 0.3-1.8 and HR 
0.7, 95% CI 0.4-1.2). This study suggests that regular endoscopic surveillance 
of BE patients enables the detection of EAC at an early and curable stage when 
endoscopic treatment is still feasible and leads to good survival. The results 
of this study therefore support current guidelines recommending endoscopic 
surveillance in patients with BE. Although a randomized controlled trial 
would be the ideal way to investigate the effect of endoscopic BE surveillance 
on survival, but ethically impossible.
Biomarker in Esophageal adenocarcinoma (EAC)
Prediction of response to neoadjuvant treatment, improved early detection 
and prognostication, as well as individualized targeted treatment are the 
current challenges in the clinical management of EAC patients. Earlier studies 
attempted to identify clinically applicable prognostic biomarkers for treatment 
response and overall prognosis in EAC but most of the performed studies 
were underpowered or consisted of highly heterogeneous patient population 
with squamous carcinoma and adenocarcinoma, and lacked standardized 
interpretation of immunohistochemical staining [57, 58, 59, 60, 61, 62]. 
Furthermore, biomarker analysis in EAC patients might be obscured by 
various neoadjuvant regimens used for advanced EAC making the comparison 
between studies difficult[63]. Large (collaborative) projects using standardized 
methodology are required to generate clinically useful approaches. Therefore, 
we investigate the association between p53, SOX2 and CD44 protein expression 
in pretreatment tumor biopsies and tumor response in a primary cohort (77 
patients), and validated these result in a second independent cohort of EAC 
patients (70 patients). In a subsequent study, we evaluated the prognostic 
value of SOX2 in two independent cohorts after assessment of tissue micro 
arrays from resected EAC specimens of in total 756 patients. Expression of 
p53 but in particularly SOX2 was significantly associated with response to 
neo-adjuvant chemo-radiotherapy (nCRT). Loss of SOX2 expression indicates 
a high probability of a major response to nCRT with an adjusted OR of 4.1 
(95%CI 1.4–12.4) in the primary cohort and an adjusted of OR 6.1 (95%CI 
1.6-23.4) in the validation cohort, respectively. SOX2 expression was not only 
predictive for therapy response but also improved prognostication in patients 
proefschrift_def.indd   175 20/04/2017   20:02
176
Chapter 9
undergoing resection of EAC. We showed that loss of SOX2 is an independent 
predictor of adverse outcome with median survival of 19.7 months after 5 
years in contrast to 31.7 months in patients with retained SOX2 expression. 
Importantly, most significant effects of SOX2 for predicting prognosis were 
detected in pT1 (HR of 3.53, p=0.018) and pN0 (HR of 1.61, p<0.001) tumors 
in our study. 
These finding might have clinical impact and could be of particular relevance 
in selected populations of patients with pT1pN0 tumors. Identification of poor 
prognostic group among these otherwise good-prognosis patients could lead 
to a choice of more intensive surveillance or adjustment of (neo)adjuvant 
treatment. Hence, SOX2 could identify pT1b patients who have a high risk of 
disease recurrence, and at the same time could profit the most from nCRT. 
Since the prediction of prognosis is very limited in pT1b EAC, SOX2 may assist 
in clinical decision-making in this group of patients. 
On the molecular level, our clinical findings might be explained by the 
differentially regulated SOX2 targets [26, 64, 65, 66]. SOX2 loss might lead 
to loss of PTEN and upregulation of pAKT, with decrease of sensitivity to 
apoptosis of the tumor cells, while the mitotic activity, invasive growth and 
metastatic capability are increased, a mechanism previously identified in 
gastric cancer cells. Given the lineage specific SOX2 function in formation of 
stomach and esophagus during embryogenesis, the SOX2 role in EAC might be 
similar to that observed in gastric adenocarcinoma. However, further clinical 
and fundamental studies would be valuable to confirm our findings and to 
establish cellular SOX2 functions in EAC.
Conclusions
BE surveillance might enable the detection of EAC at an early and curable 
stage when endoscopic treatment with EMR and RFA is still feasible, and 
which eventually leads to improves survival. Although surveillance according 
to the current guidelines is cost-effective for patients without dysplasia, 
for patients with LGD, surveillance is recommended with intervals of six 
to twelve months, while according to our study intervals should be at least 
three years in order to be cost-effective. Identification and incorporation of 
additional biomarkers may improve risk stratification and eventually cost-
effectiveness of BE surveillance. A panel of biomarkers with p53 and SOX2 
immunohistochemistry appears to be more predictive than the histological 
diagnosis of LGD alone. P53 and SOX2 IHC have a good interobserver 
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agreement, are relatively cheap and easy applicable to clinical practice 
compared to other techniques, which makes them clinically suitable markers. 
SOX2 expression is not only predictive for neoplastic progression in BE but 
also might improve prognostication in patients undergoing resection for EAC 
and is significantly associated with therapy response in potential curable EAC 
patients. SOX2 may help to individualize (treatment) decision-making in EAC 
patients.
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Barrett’s surveillance
Barrett’s esophagus (BE) is a premalignant condition in which patients have an 
increased risk to develop esophageal adenocarcinoma (EAC) with an estimated 
incidence of 0.1 to 0.4% per year. The transition from BE to EAC is a gradual 
process, in which intestinal metaplasia evolves via low-grade dysplasia (LGD), 
to high-grade dysplasia (HGD) and finally to EAC. Endoscopic surveillance is 
recommended for BE patients to detect HGD or EAC at an early and potentially 
curable stage. Histological diagnosis of LGD is used for the risk assessment 
of neoplastic progression in BE surveillance and more intensive follow-up is 
recommended in LGD patients (yearly instead of every 3 years). However, 
diagnosis of LGD has a low predictive value, owing to sample error and a 
considerable inter- and intraobserver variation. Identification of additional 
predictors could improve risk stratification and hence cost-effectiveness of BE 
surveillance. 
The aim of part I of this thesis was to evaluate whether use of biomarkers can 
improve risk stratification in BE in order to optimize surveillance. In addition, 
the cost-effectiveness of BE surveillance according to the current guidelines 
and impact on survival was assessed. 
Many immunohistochemical (IHC) biomarkers have been studied in BE 
progression mainly because it’s relatively easy applicable for daily practice but 
so far none have progressed to the stage of routine clinical use. In chapter 
2 the existing literature is systematically reviewed regarding to the value of 
IHC biomarkers for predicting neoplastic progression in BE patients and 
meta-analysis was performed. The biomarker investigated most frequently is 
p53 and the performed meta-analysis showed that aberrant p53 expression 
is significantly associated with neoplastic progression in both non-dysplastic 
BE and LGD. P53 staining in addition to the histological diagnosis, can be 
implemented to improve risk stratification in BE surveillance. However, our 
group previously reported that only 40% of the BE patients with progression to 
HGD or EAC showed an aberrant p53 protein expression during surveillance, 
suggesting that additional biomarkers are needed. Another potential 
biomarker is the transcription factor SOX2. In chapter 3 the value of SOX2 
IHC is investigated to predict neoplastic progression in BE. A case-control 
study was conducted with a large multicenter prospective cohort of 720 BE 
patients. Patients with neoplastic progression, defined as development of HGD 
or EAC, were classified as cases and patients without neoplastic progression 
as controls. SOX2 expression was determined in more than 12,000 biopsies. 
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SOX2 expression was progressively lost in dysplastic BE and was significantly 
associated with an almost 5-fold increased risk of neoplastic progression, 
independent of age, gender, BE length and esophagitis. The use of this 
marker, in combination with p53, has the potential to significantly improve 
risk stratification by selecting truly high risk BE patients for neoplastic 
progression, and hence the cost-effectiveness of Barrett surveillance. 
Another potential biomarker for predicting neoplastic progression in BE is 
cyclin A. In chapter 4 the value of cyclin A to predict neoplastic progression 
in BE is investigated. Because there is a lack of studies testing performance 
of multiple biomarkers simultaneously in the same cohort of BE patients, we 
combined these results with our previously reported p53, AMACR and SOX2 
IHC data. Cyclin A surface positivity was associated with a 2-fold increased 
risk of neoplastic progression. However, in a fully adjusted model, aberrant 
p53 expression showed the highest change in area under the curve (AUC) 
after exclusion (0.050 specified), to a lesser extent aberrant SOX2 expression 
(0.014) and histological diagnosis of LGD (0.005). The biomarkers cyclin A 
only showed a minimal change in AUC after exclusion (0.003). The highest 
predictive value was achieved by concurrent loss of SOX2 expression and 
aberrant p53 expression in BE patients with LGD (being AUC 0.72; 95% CI 
0.67 to 0.77). The incremental value of cyclin A was limited. 
As indicated, BE patients have a higher risk of developing EAC compared 
to the general population, but the absolute risk of neoplastic progression is 
relative low. One of the key questions in the discussion about BE surveillance 
is whether it is cost-effective. In chapter 5 the cost-effectiveness of BE 
surveillance according to the current guidelines is investigated. A cost-
effectiveness analysis was preformed within a large multicenter prospective 
cohort of 714 patients with BE. A multi-state-Markov model was used to 
calculate progression rates based on the prospective follow-up data, which 
were incorporated in a decision-analytic model, including costs and quality of 
life data. Different surveillance intervals and different therapeutic modalities 
for BE without dysplasia and LGD were evaluated. Assuming a willingness-to-
pay threshold of €35.000 per quality-adjusted life year gained, surveillance 
with endoscopic mucosal resection (EMR) and radiofrequency ablation (RFA) 
for HGD or early EAC, and esophagectomy for advanced EAC is cost-effective 
every 5-years for no-dysplasia and every 3-years for LGD. 
Other key elements in the discussion of Barrett surveillance are whether 
surveillance is able to reduce the risk of advanced EAC and improve survival. 
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In Chapter 6 the impact of BE surveillance according to the current guidelines 
is investigated on tumor stage and survival of EAC patients, within a large 
prospective cohort of 783 BE patients. During surveillance incident cases of 
HGD or EAC were identified. Survival data were collected and cross-checked 
using death and municipal registries and compared to data of patients with 
EAC in the general Dutch population. EAC was diagnosed at a significantly 
earlier stage during BE surveillance than in general population. Survival of 
BE patients with neoplastic progression diagnosed during surveillance was 
not significantly worse than those of patients without and similar to those of 
patients with stage 0 or stage 1 EAC in the general population. This suggests 
that BE surveillance enables the detection of EAC at an early stage with good 
survival rates. The results of this study therefore support current guidelines 
recommending endoscopic surveillance in patients with BE.
Esophageal adenocarcinoma (EAC) and biomarkers
Neoadjuvant chemoradiotherapy (nCRT) followed by surgery has recently 
become standard of care for locally advanced esophageal cancers and achieves 
survival benefit. Still, the overall prognosis for most patients including those 
treated with curative intent is dismal with a 5-year survival of 47% at most. 
However, response to nCRT and overall prognosis is highly variable in EAC 
patients. Prediction of response to neoadjuvant treatment, improved pre-
operative prognostication, as well as individualized targeted treatment are the 
current challenges in the clinical management of EAC patients. The aim of 
part II of this thesis was to evaluate the value of biomarkers on prediction 
of prognosis and therapy response in EAC patients. In chapter 7 the 
association between p53, SOX2 and CD44 protein expression in pretreatment 
tumor biopsies for tumor response is investigated. Expression of p53 but 
in particularly SOX2 was significantly associated with response to nCRT in 
primary and validation cohort. Loss of SOX2 expression indicated a high 
probability of a major response to nCRT. In chapter 8 the prognostic value 
of SOX2 is investigated in two independent cohorts after assessment of TMAs 
from resected EAC specimens of in total 756 patients. Loss of SOX2 expression 
was an independent predictor of adverse outcome with median survival of 
19.7 months after 5 years in contrast to 31.7 months in patients with retained 
SOX2. Importantly, most significant effects of SOX2 for predicting prognosis 
were detected in pT1N0 tumors. Assessment of SOX2 may help to individualize 
(treatment) decision-making in EAC patients. 
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In conclusion, BE surveillance might enable the detection of EAC at an 
early and curable stage when endoscopic treatment with EMR and RFA is 
still feasible, and which eventually leads to improves survival. Although 
surveillance according to the current guidelines is cost-effective for patients 
without dysplasia, for patients with LGD, surveillance is recommended with 
intervals of six to twelve months, while according to our study intervals 
should be at least three years in order to be cost-effective. Identification and 
incorporation of additional biomarkers may improve risk stratification and 
eventually cost-effectiveness of BE surveillance. A panel of biomarkers with 
p53 and SOX2 immunohistochemistry appears to be more predictive than 
the histological diagnosis of LGD alone. P53 and SOX2 IHC have a good 
interobserver agreement, are relatively cheap and easy applicable to clinical 
practice compared to other techniques, which makes them clinically suitable 
markers. SOX2 expression is not only predictive for neoplastic progression in 
BE but also might improve prognostication in patients undergoing resection 
for EAC and is significantly associated with therapy response in potential 
curable EAC patients.
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Barrett slokdarm is een premaligne aandoening waarbij patiënten een verhoogd 
risico hebben op het ontwikkelen van een adenocarcinoom van de slokdarm 
met een geschatte incidentie van 0.1 tot 0.4% per jaar. De ontwikkeling 
van een adenocarcinoom in Barrett slokdarm is een stapsgewijs proces 
waarbij metaplastisch cilinder epitheel veranderd in laaggradige dysplasie, 
hooggradige dysplasie en uiteindelijk adenocarcinoom. Endoscopische 
surveillance is geadviseerd in patiënten met een Barrett slokdarm in de hoop 
zo hooggradige dysplasie of slokdarm adenocarcinoom in een vroegtijdig 
stadium op te sporen wanneer curatieve behandeling nog mogelijk is. De 
histologische diagnose van laaggradige dysplasie wordt gebruikt voor de 
risico inschatting voor maligne ontaarding in Barrett slokdarm surveillance 
en een meer intensieve follow-up is geadviseerd in patiënten met laaggradige 
dysplasie (jaarlijks in plaats van elke drie jaar). De diagnose van laaggradige 
dysplasie is echter onderhevig aan steekproeffouten en inter- en intraobserver 
variatie wat de voorspellende waarde beperkt. Identificeren van andere 
voorspellers voor maligne ontaarding zou risicostratificatie van patiënten met 
een Barrett slokdarm kunnen verbeteren en daarmee de kosteneffectiviteit 
van Barrett slokdarm surveillance. 
Het doel van deel I van dit proefschrift was om te onderzoeken of het gebruik 
van biomarkers kan bijdragen aan een verbeterde risicostratificatie van 
patiënten met een Barrett slokdarm om zo surveillance te optimaliseren. 
Daarnaast evalueerde we het effect van surveillance volgens de huidige 
richtlijnen op kosteneffectiviteit en overleving. Vele immunohistochemische 
(IHC) biomarkers zijn onderzocht in Barrett slokdarm surveillance omdat 
de techniek van immunohistochemie relatief makkelijke en toepasbaar 
is in de dagelijkse praktijk, maar tot op heden wordt nog geen biomarker 
routinematig gebruikt in de kliniek. In hoofdstuk 2 wordt de volledige 
literatuur systematisch geëvalueerd met betrekking tot de waarde van IHC 
biomarkers voor het voorspellen van maligne ontaarding in Barrett slokdarm 
patiënten en is een meta-analyse verricht. De biomarker p53 is het meest 
frequent onderzocht en de verrichte meta-analyse toont dat een afwijkende 
p53 expressie significant geassocieerd is met maligne ontaarding in zowel niet 
dysplastisch Barrett epitheel als in laaggradige dysplasie. P53 IHC kleuring in 
toevoeging op de histologische diagnose van dysplasie, kan geïmplementeerd 
worden om zo risico stratificatie binnen Barrett surveillance te verbeteren. 
Echter, onze onderzoeksgroep heeft eerder laten zien dat maar in 40% van 
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de Barrett patiënten met maligne ontaarding tot hooggradige dysplasie of 
slokdarm adenocarcinoom er sprake is van een afwijkende p53 expressie bij 
de voorafgaande surveillance, dit suggereert dat er aanvullende biomarkers 
nodig zijn. Een andere potentiële biomarker is de transcriptie factor SOX2. 
In hoofdstuk 3 is de waarde van SOX IHC onderzocht voor het voorspellen 
van maligne ontaarding in Barrett slokdarm. Hiervoor is een case-control 
studie verricht binnen een groot multicenter prospectieve cohort studie 
van 720 Barrett patiënten. Patiënten met maligne ontaarding, gedefinieerd 
als hooggradige dysplasie of adenocarcinoom, werden geclassificeerd als 
cases en overige patiënten zonder maligne ontaarding als controles. SOX2 
expressie werd bepaald in meer dan 12.000 biopten. SOX2 expressie was 
toenemend afwezig in dysplastisch Barrett epitheel en was geassocieerd met 
een bijna 5 keer verhoogd risico op maligne ontaarding, onafhankelijk van 
leeftijd, geslacht, Barrett lengte en aanwezigheid van oesofagitis. Het gebruik 
van deze biomarker, in combinatie met de biomarker p53, heeft de potentie 
om risicostratificatie significant te verbeteren door het selecteren van de 
daadwerkelijk hoog risico Barrett patiënten voor het ontwikkelen van maligne 
ontaarding, en daarmee ook de kosteneffectiviteit van Barrett surveillance. 
Een andere potentiële biomarker voor het voorspellen van maligne ontaarding 
in Barrett slokdarm is cyclin A. In hoofdstuk 4 is de waarde van cyclin A voor 
het voorspellen van maligne ontaarding in Barrett slokdarm onderzocht. Omdat 
er een gebrek is aan studies die de waarden van verschillende biomarkers in 
eenzelfde cohort van Barrett patiënten onderzoekt, zijn de resultaten van de 
biomarker cyclin A gecombineerd met de eerder gepubliceerde p53, AMACR 
en SOX2 IHC gegevens. Cyclin A positiviteit was geassocieerd met een 2 keer 
verhoogd risico op maligne ontaarding. Echter, in een volledig gecorrigeerd 
model toonde een afwijkende p53 de grootste verandering in ‘gebied onder 
de curve’ na uitsluiting (0.050 specifiek), in mindere mate was dit het geval 
voor een afwijkende SOX2 expressie (0.014) en de histologische diagnose 
van laaggradige dysplasie (0.005). De biomark cyclin A toonde alleen een 
minimaal verandering in ‘gebied onder de curve’ na uitsluiting (0.003). De 
hoogste voorspellende waarde werd gezien bij gelijktijdig verlies van SOX2 
expressie en een afwijkende p53 expressie in Barrett patiënten met laaggradige 
dysplasie (AUC 0.72; 95% CI 0.67 to 0.77). De toegevoegde waarde van cyclin 
A was gelimiteerd. 
Zoals aangegeven, hebben patiënten met een Barrett slokdarm een verhoogd 
risico op het ontwikkelen van slokdarm adenocarcinoom in vergelijking 
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met de algemene populatie, maar het absolute risico op maligne ontaarding 
is relatief laag. Een van de kernvragen binnen de discussie van Barrett 
surveillance is of Barrett surveillance kosteneffectief is. In hoofdstuk 5 werd 
de kosteneffectiviteit van Barrett surveillance volgend de huidige richtlijnen 
onderzocht. Een kosteneffectiviteitsanalyse werd verricht binnen een groot 
multicenter prospectieve cohort studie met daarin 714 Barrett patiënten. 
Een Multi-state-Markov model werd gebruikt om progressie kansen te 
berekenen op basis van prospectieve follow-up gegevens, welke vervolgens 
werden opgenomen in een beslismodel met daarin gegevens over kosten en 
kwaliteit van leven. We evalueerde verschillende surveillance intervallen voor 
patiënten zonder dysplasie of met laaggradige dysplasie en verschillende 
behandelmogelijkheden voor patiënten met hooggradige dysplasie of 
adenocarcinoom. Uitgaande van een drempel van €35.000 per gewonnen 
levensjaar, lijkt surveillance elke 5 jaar, met endoscopische behandeling voor 
zowel hooggradige dysplasie als vroegcarcinomen, en een slokdarmresectie 
met neoadjuvante chemoradiotherapie voor een gevorderd adenocarcinoom 
kosteneffectief te zijn in patiënten zonder dysplasie en surveillance elke 3 jaar 
in patiënten met laaggradige dysplasie. 
Een ander kernonderwerp binnen de discussie van Barrett surveillance is of 
surveillance daadwerkelijk het risico op het ontwikkelen van een gevorderd 
adenocarcinoom verminderd en de overleving verbeterd. In hoofdstuk 6 
hebben we onderzocht wat de invloed is van Barrett surveillance volgends 
de huidige richtlijnen op tumor stadium en overleving van patiënten met 
een adenocarcinoom van de slokdarm, binnen een groot prospectieve cohort 
van 783 Barrett patiënten. Overlevingsdata werden verzameld en vergeleken 
met overlevingsdata van patiënten met een adenocarcinoom van de slokdarm 
in de algemene Nederlandse bevolking. Slokdarm adenocarcinoom werd in 
een significant vroeger stadium gevonden tijdens Barrett surveillance dan 
in de algemene bevolking. De overleving van Barrett patiënten met maligne 
ontaarding tijdens surveillance was overeenkomstig met de overleving van 
patiënten met een stadium 0 of 1 adenocarcinoom in de algemene bevolking. Dit 
suggereert dat Barrett surveillance detectie van adenocarcinoom in een vroeg 
stadium mogelijk maakt met daarbij goede overlevingskansen. De resultaten 
van deze studie ondersteunen de huidige richtlijnen de endoscopische 
surveillance in patiënten met een Barrett slokdarm adviseren.
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Slokdarm adenocarcinoom en biomarkers
Neoadjuante chemoradiotherapie (nCRT) gevolgd door een operatie is sinds 
recent de standaard behandeling voor lokaal gevorderd slokdarmkanker 
en zorgt voor een betere overleving. Toch is de prognose voor de meeste 
patiënten, inclusief de patiënten die met curatieve intenties behandeld worden 
somber met een 5-jaars overleving van 47% maximaal. Echter, de response 
op nCRT en overall prognose is zeer variabel in patiënten met een slokdarm 
adenocarcinoom. Het voorspellen van response op neoadjuvante behandeling, 
het beter bepalen van de prognose voor de operatie, als geïndividualiseerde 
gerichte behandeling zijn de huidige uitdagingen binnen de management van 
slokdarm adenocarcinoom patiënten. 
Het doel van deel II van dit proefschrift was om de waarde van biomarkers 
voor het voorspellen van prognose en therapie response in patiënten met 
een slokdarm adenocarinoom te onderzoeken. In hoofdstuk 7 wordt de 
associatie tussen de biomarkers p53, SOX2 en CD44 expressie in biopten 
en tumorresponse onderzocht. Expressie van p53, maar in het bijzonder 
expressie van SOX2 was significant geassocieerd met response op nCRT in 
twee onafhankelijk cohorten. Verlies van SOX2 expressie geeft een grotere 
kans op een goede response op nCRT. In hoofdstuk 8 wordt de prognostische 
waarden van SOX2 onderzocht in twee onafhankelijke cohorten na 
beoordeling van slokdarm adenocarcinoom resectiepreparaten van in totaal 
756 patiënten. Verlies van SOX2 was een onafhankelijke voorspeller voor een 
ongunstige overleving met een gemiddelde overleving van 19.7 maanden na 5 
jaar in tegenstelling tot 31.7 maanden bij patiënten met een behouden SOX2 
expressie. Belangrijker, het meest uitgesproken effect van SOX2 expressie voor 
het voorspellen van prognose werd gezien in pT1N0 tumoren. Dus het bepalen 
van SOX2 eiwitexpressie kan helpen bij de besluitvorming voor behandeling 
in patiënten met een slokdarm adenocarcinoom. 
Concluderend, Barrett surveillance maakt het opsporen van slokdarm 
adenocarcinoom in een vroeg stadium mogelijk wanneer endoscopische 
behandeling nog tot de mogelijkheden behoord, en uiteindelijk leidt tot 
de verbetering van de overleving. Hoewel follow-up volgends de huidige 
richtlijnen kosteffectief is voor patiënten zonder dysplasie, voor patiënten 
met laaggradige dysplasie, is surveillance met een interval van 6 maanden tot 
1 jaar geadviseerd, terwijl volgens onze studie het interval tenminste 3 jaar 
moet zijn om kosteffectief te zijn. Identificeren van aanvullende biomarkers 
kan risicostratificatie en daarmee uiteindelijk kosteneffectiviteit van Barrett 
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surveillance verbeteren. Een panel van biomarkers met p53 en SOX2 lijkt 
meer voorspellend dan de histologische diagnose van laaggradige alleen. P53 
en SOX2 hebben een goede interobserver overeenkomst, zijn relatief goedkoop 
en makkelijk toepasbaar in de kliniek vergeleken met andere technieken, 
wat er voor zorgt dat beide klinisch geschikte markers zijn. SOX2 expressie 
is niet alleen voorspellend voor maligne ontaarding in Barrett surveillance 
maar verbeterd ook het voorspellen van de prognose in patiënten die een 
slokdarmresectie ondergaan en is significant geassocieerd met therapie 
response in patiënten met een potentieel te genezen adenocarcinoom van de 
slokdarm.
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Appendix: Deelnemende centra CYBAR en ProBar studies
Erasmus MC
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
Ijsselland ziekenhuis
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
Ikazia ziekenhuis
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
VUMC
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
Albert Schweitzer ziekenhuis
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
Deventer ziekenhuis
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
ZGT Hengelo
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
M.Kerkhof, M. Sikkema,  
F. Kastelein, S. van Olphen,  
C. Roumans, P. Siersema,  
E. Kuipers, M. Bruno, M. Spaander
H. van dekken, K. Biermann, F. ten Kate, 
M. Doukas
W. Bode, H.Geldof, T. Tang
H. van der Valk
R. Ouwendijk, C. Leunis,  
P. ter Borg
R. Giard, M. Bakker
E. Klinkenberg, R. Felt
G. Meijer, M. Broeckaert
W. Lesterhuis, R. Beukers,  
J. Alderliesten, J. Meijer,  
S. Hollaar
R. Heinhuis
F. ter Borg, I. van Zon,  
Y. Dieterman
J. Arends, R. Smits, M. Louwen
C. Wielens, G. tan
J. van Baarlen
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Rijnstate ziekenhuis
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
Sint Franciscus gasthuis
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
Medisch spectrum Twente
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
Orbis MC Sittard
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
UMC Groningen
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
Zaans MC
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
Franciscus ziekenhuis Roosendaal
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
Isala ziekenhuis Zwolle
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
R. de Vries, P. van Embden, B. den hartog, 
J. Burger, P. Poort
A. Mulder, M. Rijnders, J. Meijer
A. van Tilburg, E. Luthart,  
B. Ferreira, S. Mulder
H. van der Valk
J. Kolkman
J. van Baarlen
L. Engels, G. Remeeus,  
M. Romberg- Camps
W. Vos
F. Peters
A. Karrenbeld
R. Loffeld
M. Flens
H. van Roermund
F. Lockefeer
J. Kastermans, B. Schenk
F. Moll
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Maasstad ziekenhuis
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie 
Reinier de Graaf
Afdeling Maag-, Darm- en Leverziekten
Afdeling Patholgie
M. Hadithi
M. Bakker
R. Quispel, M. Goudzwaard en  
P. Van der Kraaij- Mertens
C. Meijers
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Molmed Day Erasmus MC, Rotterdam, the 
Netherlands
0.6
Attended seminars and workshops
Workload
(ECTS)
2012 The introduction Course on statistics & survival 
analysis for research
Molecular Medicine school, Rotterdam, the 
Netherlands
0.5
2012 Basic introduction course on SPSS
Molecular Medicine school, Rotterdam, the 
Netherlands
0.5
2012 Cursus Endnote
Medische bibliotheek Erasmus MC, Rotterdam, the 
Netherlands
0.2
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2012 Cursus Pubmed
Medische bibliotheek Erasmus MC, Rotterdam, the 
Netherlands
0.2
2013 Photoshop & Illustrator CS6 workshop 0.3
Molecular Medicine school, Rotterdam, the 
Netherlands
0.3
2013 Course biomedical research techniques
Molecular Medicine school, Rotterdam, the 
Netherlands
1.5
2013 Basiscursus Regelgeving en Organisatie voor Klinisch 
onderzoekers (BROK),
Erasmus University Medical Center, Rotterdam, the 
Netherlands.
2.5
2013 Post-DDW symposium 
Society of Gastroenterology, Utrecht, the 
Netherlands
0.3
2014 The 100th anniversary of the Daniel den Hoed 
Oncology Centre, Rotterdam, the Netherlands
0.3
2013 - 2016 Seminars at the department of Pathology, 
Erasmus Medical Center, Rotterdam
4.0
2013 - 2016 Seminars at the department of 
Gastroenterology and Hepatology, Erasmus 
Medical Center, Rotterdam
4.0
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Educational activities
Workload
(ECTS)
2013 Supervising graduation project Vezna de Maare, 
student Biomedical laboratory research, Avans, 
Breda, the Netherlands
2.0
2014 Supervising training project Marloes de Wijngaert, 
student laboratory technology, ROC, Utrecht, the 
Netherlands
2.0
2014 Supervising training project Quincy van den Bosch, 
student laboratory technology, ROC, Leiden, the 
Netherlands
2.0
2015 Supervising graduation project Yadira, student 
Biomedical laboratory research, Leiden, the 
Netherlands
2.0
(Inter)national conferences
2012 United European Gastroenterology week, Amsterdam, the 
Netherlands
2013 Congress of the European society for diseases of the 
esopahgus, Rotterdam, the Netherlands
2013 Dutch Society of gastroenterology (spring), Veldhoven, the 
Netherlands
2014 Digestive Diseases Week, Chicago, United States
2014 United European Gastroenterology week, Vienna, Austria
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2014 Dutch Society of gastroenterology (spring and autumn), 
Veldhoven, the Netherlands
2015 Dutch Society of gastroenterology (spring), Veldhoven, the 
Netherlands
Membership
2012  - current Dutch society of gastroenterology
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